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vAbstract
Introducing a new drug to market is a lengthy and expensive process (typically
10-15 years and $1.7 billion). Better understanding of how and why a drug
molecule binds to a target and what changes in the atomistic structure and
chemistry could improve the binding affinity and shorten the process. In
addition to structure-based approaches, the role of thermodynamics and
molecular motions in binding selectivity and efficiency have attracted
increasing attention. Whilst calorimetric methods can quantify total free energy
and entropy change, it is difficult to estimate contributions from the different
components of entropy, one of the largest unknowns being the magnitude of
the configurational entropy. Molecular dynamics (MD) simulations of the drug
and target protein can provide more details of the different atomistic
movements contributing to the total entropy change, thus potentially providing
valuable clues for lead optimisation.
In this study we use the well characterised N-terminal domain of the Hsp90
chaperone protein as a model system to study the changes in conformational
flexibility (configurational entropy) upon binding of small molecule inhibitors
using MD simulations, NMR and ITC. We show that the two inhibitors studied
cause different changes in the protein dynamics. These effects were seen with
NMR relaxation dispersion methods and with MD but the dynamic changes
however are not reflected in the global ITC parameters. Here the water is
assumed to have a dominating effect in the overall entropy change.
However, as some Hsp90 clients have been shown to preferentially interact
with only one conformation of the protein, we propose that the changes seen
with NMR and MD could be of interest for drug design. Manipulating the
dynamics by small molecules could favour interaction with a subset of client
proteins, without affecting the interaction of others, all together providing
specificity and potentially allowing to design an ‘ideal’ drug that only prevents
the folding of ‘bad’ cancer related proteins without affecting Hsp90 functions
in the normal cells. As the MD simulations also reflect these dynamic changes,
we propose that simulations could be also used as a screening tool for
selecting which inhibitors could be taken for further development in the lab.
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1Chapter 1
Introduction
1.1 Background
Molecular recognition is key to all cellular processes, from signal transduction
to DNA replication, and it has been studied widely over the last few decades.
Thanks to advances in X-ray crystallography, Nuclear Magnetic Resonance
spectroscopy (NMR), and electron microscopy techniques, we have a wealth
information on different biomolecular structures, accompanied by functional
details. However, proteins are not simply static objects within a cell, but are in
constant motion and, as a result, they can adopt and populate ensembles of
different conformations. It is accepted that these conformational dynamics do
not just present minor fluctuations around an average native structure.
Instead, the changes to the structure, and also to the equilibrium population
of conformations that a protein adopts, can affect the function and choice of
binding partners [1-3]. Understanding these “wiggles and jiggles” is the key to
both understanding life at the molecular level and how it could be manipulated
by pharmaceuticals. Here, the ability to fine tune the equilibrium population by
designing small molecule inhibitors that only interact with a particular subset
would clearly be of much interest.
In this work, we set out to explore the dynamic landscape of proteins further
and to specifically investigate how small molecules may change protein
dynamics. Below, we describe the underlying thermodynamics that is vital for
understanding molecular recognition. This is followed by a review of the
methods used to access the thermodynamic information, as well as a
description of the model system used for this study.
1.2 Thermodynamics and drug binding
The process of a drug binding to a protein has traditionally been described by
lock and key mechanisms, where the shape and chemical composition of a
2ligand determines whether interaction with the protein will take place. Whilst it
is true that both shape and bonds do have an effect to binding, changes in the
structure of binding partners also play a role. Although the connection
between thermodynamics and structure is not well understood, it is better to
use thermodynamics to describe the binding interaction, since this also takes
into account the flexibility of the system [4, 5].
If thermodynamic parameters are used to describe the binding interaction, the
change in the free energy (ΔG) dictates whether an interaction will take place, 
i.e. whether a drug will bind to the protein target or not. Here, the more
negative the free energy change, more readily the reaction will happen. The
overall free energy change is made up from contributions from chemical
interactions that arise from for example hydrogen bonding, and ionic
interactions between the drug and the target. These changes are described
by the enthalpy (H) term. The second contributor to the total free energy
change is the entropy (S) term, which describes changes in the dynamics of
the system. Both the enthalpy and entropy terms include contributions from
water, the target protein and the drug molecule, as shown in Figure 1.1 [6].
Figure 1.1: Thermodynamics plays a key role when the ligand binds to the
target protein. To determine the overall binding free energy,
contributions from water molecules (interface desolvation) need to be
taken into account, as well as the chemical interactions between the
protein and the drug, that are encompassed in the enthalphy (ΔH) term. 
Changes in the shape of both the protein and the drug also play a role
in the overall binding free energy change, and these are described by
the entropy (ΔS) term.  
3The free energy change (ΔG°) upon drug binding can thus be described by 
Gibb’s free energy formula, where ΔH° is enthalpy, ΔS° entropy and T 
temperature:
∆ܩ° = ∆ܪ° − ܶ∆ܵ (eq.1)
Alternatively, free energy can also be calculated in the following way if the
association constant (Ka) is known:
∆ܩ° = −ܴܶ lnܭ௔ (eq.2)
where R is the gas constant and T temperature.
It should be noted that in both cases, the changes in free energy (as well as
and enthalpy and entropy) calculated by equation 1 are relative to standard
conditions, as shown by the ° superscript. This means that any changes
observed are relative to those measured using standard conditions, which are
1 atm pressure, a temperature of 298 K, and 1 M reactant (protein and ligand)
concentrations [7]. Thus, any positive or negative changes per se lack
physical significance, because if different conditions were chosen, the zero-
point would change.
Whilst the changes in free energy will determine the binding affinity, for drug
design, the thermodynamic descriptions that include the changes in the
enthalpy and entropy are of more interest. The entropy and enthalpy terms
help to understand why the ligand-protein interaction happens, and how the
ligand could be manipulated to make it a ‘better’ drug molecule. The enthalpy
term reflects the specificity and strength of the molecular interactions between
the ligand and target. These include hydrogen bonds, electrostatic and van
der Waals interactions. The change in enthalpy also includes contributions
from water, as the bonds between the solvent (water molecules) and the
solute (ligand and protein) may be broken or formed upon complex formation
[8]. The entropy term, which reflects the changes in dynamics, similarly
include contributions from the solvent, as well as from the protein and ligand.
The solvent reorganisation, where water molecules are released to bulk
solution from the ligand and protein surfaces upon binding, is often a major
contributor to the overall entropy change. The solute contribution to the
entropy change is a combined effect from changes to translational and
4rotational motions (i.e. the overall tumbling) of the molecules, as well as
changes in the intra-molecular structure resulting from bond stretching and
angle bending [9].
A lot of effort has been made to understand and assign values to the different
parameters that govern the thermodynamics of drug and ligand binding over
the years as well as assigning values to the parameters [10]. These include
attempts to isolate and estimate the individual contributions functional groups
and H-bonds make to the binding energy. For example, H-bonds have been
calculated to contribute between 2-10 kcal/mol to the binding energy,
depending on the functional groups involved in the binding and whether they
are buried or solvent exposed [11]. Functional group contributions to drug-
receptor interactions have similarly been estimated. In general the more
electronegative the group, the stronger the binding energy; for example an OH
group has been estimated to contribute between 2.5-4 kca/mol to the free
energy of binding compared to 3.2-4 kcal/mol for C=O group or 0.8-1.8
kcal/mol for nitrogen [12, 13]. Similarly, energetic penalties resulting in the
loss of the rotational and translational degrees of freedom have been
estimated [10, 14, 15]. These estimates have subsequently been used to build
models to estimate the overall free energy upon binding. For this, each
physical process, from restriction of rotations to burial of hydrophobic groups,
has been assigned a value and a factor by which they increase the binding
energy [16]. However, estimation of the free energy is not as simple as adding
up the various constituents. There are many examples, where attempts to
increase affinity by focusing on the the enthalpy component, for example by
addition of H-bond motif, carry an entropic loss due to structuring of both the
ligand and the binding site [17]. On the other hand, some binding interactions
have been demonstrated to be more than sum of their parts. For example,
studies with thrombin ligands found that addition of a H-bond (enthalpic effect)
and increasing the size of a hydrophobic group (thus affecting entropy), had
in fact a co-operative effect. Here the affinity gain from the two modifications
to the ligand was larger than either on its own [18]. This additive affect has
also been seen with fragment based drug design, where the affinity of a larger
molecule (where the individual fragments are linked) can be greater than the
combined affinity of either fragment. The additive affect in the case of thrombin
5was suggested to depend on changes in the dynamic properties of the
molecule [19].
Generally, the estimations of binding energy as described above do not take
into account any changes to the target protein. In the past, the enthalpy term
describing the chemical interactions has received more attention in drug
design efforts. However, in recent years the static ‘lock and key’ mechanism
used to describe drug and protein association has been adapted to include
the changes in the conformations of the target protein as well as yielding the
induced fit and conformational selection models. In the induced fit model a
ligand binds to an inactive form of the protein and the interactions between
ligand and protein upon binding induce the protein to change to an active form.
The conformational selection model assumes that the protein exists in active
and inactive forms and the ligand binding to the active form subsequently
shifts the existing equilibria [20]. To understand these protein dynamics, the
entropy term, which describes changes in the different conformational states
that a system can adopt, is the key [21]. This will be the main focus point for
this study.
1.3 Experimental approaches to probe the protein dynamics
It has been said that ‘Heat does not come in many colours’ [22]. Whilst all the
thermodynamic parameters (ΔG, ΔH and ΔS) can be determined analytically 
with techniques such isothermal titration calorimetry (ITC), the global entropy
value obtained by ITC includes contributions from both solvation and the
changes in the macromolecular structure. However, understanding what the
global value means, in terms of the dynamics of individual components of the
binding system that determine configurational entropy at the molecular level,
is not possible. This is due to the fact that it is not possible to distinguish what
percentage of the change is due to the protein, or due to the drug ligand, and
also what effects to the structure of the protein these changes may have.
Apart from ITC, many biophysical techniques can be used to get clues about
thermodynamics of binding and contributions from conformational re-
arrangements, but like ITC, most provide limited resolution either in terms of
6detail of dynamic timescales or lack of atomistic detail. Techniques, such as
surface plasmon resonance, allow the determination of the binding kinetics,
but lack in structural detail [23]. In principle, hydrogen-deuterium exchange
mass spectrometry allows the determination of both binding kinetics and some
details of the structure of the protein. However, the structural information
obtained from this technique is of very low resolution, and falls into the same
category of ‘rough shape and size’ as the structures obtained via neutron
scattering, or small angle X-ray scattering [24-26]. With correctly chosen
labelling, or with the aid of mutational studies, fluorescent microscopy
techniques can give information about structural re-arrangements that occur
upon binding. However, the structural detail is limited to those areas adjacent
to the fluorescent labels [27]. Cryo-electron microscopy (cryo-EM) and X-ray
crystallography on the other hand allow determination of atomic structures,
and can provide some detail of the dynamics. Cryo-EM structures have been
used to give details of the dynamics, even back when the structures were
‘fuzzy’. This is because the populations of the different conformations can be
extracted from large datasets of imaged particles. Also, given the recent major
advances in the resolution of cryo-EM structures, it has become possible to
get atomistic detail of the structures, although the technique is suitable only
for large protein systems [28]. X-ray crystal structures of proteins on the other
hand are by definition rigid, but dynamic regions can still be inferred by using
the per atom calculated B-factors that contain information about the thermal
fluctuation of the atom in question. A small value for the B-factor describes
rigid atoms, larger numbers suggest some fluctuations [29]. However, the
dynamic information, in terms of timescales, obtained via the cryo-EM and X-
ray crystallography techniques, is not very detailed. To fully understand the
ligand-drug interaction, detailed information of both the atomistic structures
and the dynamics including the timescales they occur are needed.
Protein motions are thought to occur in timescales spanning from picoseconds
to seconds. This is to account for the bond vibrations to protein domain
movements and for protein folding, as shown in Figure 1.2. To understand the
dynamics of proteins, techniques which can span these timescales and
provide atomic resolution are needed. Here one should look into nuclear
7magnetic resonance spectroscopy (NMR) and all atom molecular dynamic
simulations (MD).
Figure 1.2: Protein motions cover the local bond vibrations to larger scale
domain re-arrangements and these events take place in different
timescales from nanoseconds to seconds. The changes in structure
require different magnitudes of free energy change and can be imaged
as peaks and troughs in the free energy landscape. Local bond
vibrations can be thought to reside in single energy well, whereas for
larger domain movements or protein folding/unfolding events which
require larger energy changes similarly require more time to cross
energy barriers (modified from [30]).
Both NMR and MD can provide information on different timescales. For
classical MD simulations, the lower time limit is related to picosecond bond
vibrations and whilst using special computer infrastructure millisecond
simulation times have been achieved, normally the simulation times are
currently in realm of hundreds of nanoseconds [31]. Nevertheless, with longer
simulation times and use of replica simulations, the energy landscape can be
explored adequately to observe dynamics resulting from ligand-protein
interactions. NMR on the other hand is very powerful technique, as with the
right choice of isotope atom labelling and pulse sequence, the dynamics
ranging from the picosecond bond vibrations to protein folding that can be
measured in milliseconds can be observed, as seen in Figure 1.3 [30]. NMR
experiments can also measure slower processes from seconds to hours.
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8As both the atomistic structure and details of timescales are needed to further
the understanding of dynamics and configurational entropy of
macromolecules, we will use MD simulations and NMR techniques to study
the protein and ligand dynamics. The pharmaceutically interesting protein,
heat shock protein 90 (Hsp90), which is an active cancer drug target is used
as a model system to be studied by NMR and MD techniques. Further, ITC
measurements will be conducted to get an idea of global vs local entropy
effects.
Figure 1.3: Atomistic scale techniques for probing protein dynamics at
different timescales. Protein motions range from local bond vibrations
to global domain re-arrangements and folding events. These different
motions happen in various timescales, from nanoseconds to seconds.
To probe these motions, NMR is a very powerful technique as different
NMR techniques can examine the very fast, as well as the slow,
events. Whilst different computer simulation techniques can access
similar timescales, coarse graining approaches are required to
measure the slower time scales.
1.3.1 Dynamic Hsp90 is used as model system to probe the role
of protein dynamics in ligand and drug interactions
The molecular chaperone Hsp90 is one of the most abundant proteins in a
cell. It is involved in maturation of large number of client proteins during the
later stages of protein folding [32]. To date, hundreds of diverse clients of
Hsp90 have been identified, ranging from kinases to nuclear receptors. As
many of the clients are oncoproteins, Hsp90 is also an active cancer drug
target [33, 34].
9Given that Hsp90 is vital for cell function, it is perhaps slightly surprising to
find it as a drug target. The pharmaceutical industry took note of the
chaperone during the 1990s after a natural product geldanamycin was first
found to revert cancerous phenotype in cell screens. Follow up studies using
pull down assays with geldanamycin found that it interacted with a 90 kDa
protein, which turned out to be Hsp90 [35]. After nearly two decades, there is
a wealth of Hsp90 data, including over 200 structures deposited into the
protein data bank on human Hsp90. A recent review found 280 published
Hsp90 ligands, with thirteen inhibitors, that are undergoing clinical trials [36-
38].
Hsp90 is a highly dynamic multi-domain protein made up of a N-terminal
nucleotide binding domain (NTD), a middle domain, which has been implied
to play a role in substrate and co-chaperone interactions, and a C-terminal
domain (CTD) which is used for dimerisation. Hsp90 forms homo-dimers and
fluctuates between wide variety of structurally distinct states [39]. Some of the
early crystal structures defined the open and closed states of Hsp90, where
the conformation change was regulated by ATP binding and hydrolysis. Here,
in the apo-form, the Hsp90 adopts a V-shaped open conformation, where the
dimer connections are formed via the C-terminal domains (Figure 1.4) [39].
Upon ATP binding to the NTD, the lid segment closes the binding pocket and
this slowly leads to the whole chaperone changing from an open V-shape to
a twisted closed conformation, where the two N-terminals also make contact
upon strand exchange. The ATP binding also has an effect on the NTD and
middle domain interface. Here, a highly conserved arginine residue of the
catalytic loop of middle domain interacts with the ATP bound to the NTD and
thus the middle domain contributes to the ATP hydrolysis. After ATP
hydrolysis, and subsequent ADP release, the Hsp90 returns to the original
open conformation [39-42]. The open and closed forms as defined by early
crystal structures are not the only conformations the Hsp90 adopts. SAXS and
EM studies have demonstrated that ATP binding and hydrolysis only shift the
equilibria between a pre-existing set of conformational states, which range
from open to closed structures with various intermediates and open structure
where the subunits are much further apart [41, 43]. Interestingly, although the
dynamic cycle between the open and closed forms of Hsp90 has been well
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established, mutational studies of the full length protein with non-functional
nucleotide binding domain found that both open and closed forms were also
populated in the absence of the nucleotide. This suggests that the chaperone
population exists in a dynamic conformational equilibrium [44].
Figure 1.4: Hsp90 undergoes large conformational re-arrangements upon
ATP binding and hydrolysis from V-shaped open conformation (E.coli
Hsp90 structure – PDB:2IOQ) to tightly packed closed conformation
(Yeast Hsp90 – PDB:2CG9). The chaperone is made up of three
domains, the N-terminal domain (NTD), the middle domain (Middle)
and the C-terminal domain (CTD). The N-terminal domain, where the
inhibitors bind to, is depicted in blue on the right of the figure.
The highly dynamic cycle that Hsp90 undergoes has an effect on both the co-
chaperone interactions as well as client binding. The Hsp90 co-chaperones
have been shown to interact with, and stabilise, different conformational states
during the ATP driven open-closed cycle [45]. Recent studies have also
suggested that different pools of Hsp90 may be involved in different functions
or pathways. Here, pull down assays have shown that the Hsp90 inhibitors,
whilst binding to the same N-terminal pocket, only interact with a small portion
of the total cellular Hsp90. The inhibitors also cause different cellular
phenotypes to occur, suggesting that they have different biological effects [42,
46-48]. For client protein interactions, no common sequence or motif has been
identified responsible for the interaction with the Hsp90. The current belief is
that the different conformational states of Hsp90 are associated with different
co-chaperone complexes, and that these interact with different clients. The
chaperone conformation will have different effects on the client
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folding/misfolding [39, 42, 49]. This conformational equilibrium is interesting
for the pharmaceutical industry; if particular clients interact with only a certain
conformation of Hsp90, it may be possible to selectively inhibit only a certain
pool of cellular proteins. This could help with toxicity issues associated with
the Hsp90 inhibitors.
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Hsp90 has been a cancer drug target for over a decade, and most drugs target
the N-terminal nucleotide binding domain. Two early inhibitors that have been
the subject of many studies were geldanamycin and radicicol. A large number
of inhibitors from different chemical classes have been added to the growing
list of Hsp90 inhibitors [37]. Both computational and NMR studies have shown
that nucleotide (ADP/ATP) binding causes changes in the N-terminal domain
dynamics of the chaperone, which are likely to be linked to the open-closed
states of the full length protein [50, 51]. It has also been demonstrated that the
changes in the N-terminal domain observed upon ligand binding also affect
the conformation of the middle and C-terminal domains in the full length
protein [52]. To examine whether small inhibitors also cause differences to the
chaperone dynamics, rather than merely inhibit the function by blocking the
ATP hydrolysis step, we selected two different ligands from a panel of Hsp90
inhibitors to carry out biophysical characterisations using NMR and computer
simulations. The two ligands selected for the studies were a large 17-DMAG
molecule [37], which is a more soluble derivative of geldanamycin, and a small
nucleotide mimic GVK0153 (see Figure 2.1 in Chapter 2 for structures). The
N-terminal domain of the human Hsp90 was used for the studies, as its size
is still amenable to both NMR methods and longer timescale MD simulations.
For the inhibitors, both molecules studied have been removed from active
drug research due to issues with in vivo toxicity. Since the Hsp90 is used here
purely as a model system to study dynamics, rather than to develop new
inhibitors, these side effects do not matter for this study.
1.3.2 Isothermal titration calorimetry
NMR and molecular dynamic simulations are used in this study to estimate
configurational entropy change. We also carry out isothermal titration
calorimetry (ITC) experiments, that allow the direct measurement of the
changes in enthalpy (H), as well as stoichiometry (n) and affinity (Ka) for
biomolecular processes in aqueous solution [53] [22]. These parameters allow
the calculation of free energy, and entropy values, using equations 1 and 2
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(shown in Section 1.2 and below). Thus, all thermodynamic parameters can
be obtained from a single experiment.
∆ܩ = −ܴܶ lnܭ௔ = ∆ܪ − ܶ∆ܵ (eq. 1 & 2)
The ITC instrument has two cells, a reference cell filled with the assay buffer
and a sample cell containing the macromolecule of interest to which the ligand
is going to be titrated. A schematic of the instrument is shown in Figure 1.5.
The reference and sample cells are connected together with thermo-coupled
circuits that detect any temperature differences between the cells caused by
the binding reaction of sample cell upon ligand titration. Depending on whether
the reaction in the sample cell is endo- or exothermic, the resulting sample
cell heat change causes power to either be applied, or reduced, to maintain
identical temperature between the two cells [54]. The changes in the feedback
power applied to the sample cell is measured, and recorded. This gives the
total heat change per injection, which can be plotted as a power-vs-time plot
to obtain the values of ΔH° and Ka.
Figure 1.5: Schematic of Isothermal calorimetry instrument. The sample
cell, into which the ligand is titrated, is thermo-coupled to a reference
cell. Depending on the reaction, power is applied or withdrawn from the
sample cell to keep the temperature constant between the reference
and sample cells. Figure adapted from [53].
This image has been removed by the author of this
thesis for copyright reasons
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Figure 1.6: Example of data from an ITC experiment, where GVK0153
inhibitor was titrated into Hsp90. The top panel shows the power
applied to the sample cell to maintain constant temperature between
the reference and sample cells, thus reporting on heat changes. The
bottom panel shows the integrals of the peaks, together with a line of
best fit that is used to estimate ∆H, Kd and stoichiometry (n).
As seen on the top panel of Figure 1.6, the changes in power are generally
large during the first few injections due to the excess of macromolecules, and
these maximum peaks correspond to enthalpy of binding (ΔH°). The changes 
in the heat become smaller with further titrations as the binding sites are being
filled. Eventually, a proportion of the titrated ligand will remain free in the
solution. The slope of the middle section of the plot, between the initial large
changes and final small changes in heat, can be used to estimate Kd. This is
the dissociation constant, and the inverse of Ka. Finally, if the concentrations
of the macromolecule and the ligand are known accurately, the stoichiometry
(n) can be determined from the graph [53].
Whilst all the thermodynamic parameters of interest can be determined by
ITC, the values obtained are global values and conformational entropy
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contributions cannot be separated from the effects of water and rotational and
translational components of the macromolecules. Also, ITC experiments are
sensitive only to certain affinity windows. Very strong interactions between the
ligand and target produce too steep a curve without sufficiently many points
to determine the Ka (i.e. slope). Vice versa, very weak interactions produce
flat curves, which make slope determination similarly imprecise. Nevertheless,
ITC is a popular method, and the global entropy values can give guidance as
to whether the magnitude of the configurational entropy obtained from other
techniques is the overall driving force of the binding reaction.
1.3.3 Nuclear Magnetic Resonance Spectroscopy (NMR)
It is close to four decades since the first protein structures were determined
by NMR. The technique has since been developed with many other
applications in mind. This includes NMR being used as a tool to study
structural ensembles, to identify ligand binding and protein-protein interaction
sites and to probe conformational dynamics, as well as binding affinity to name
a few applications [55, 56]. Proteins are not rigid, but populate different
conformational states. What makes NMR a particularly powerful technique is
the possibility of obtaining not only information about the structures a
macromolecule adopts in solution, but also the possibility of examining the
dynamics that govern these structural fluctuations. This includes obtaining the
global parameters for µs-ms exchange processes, such as the exchange rate
constants (kex), chemical shift differences between different states, as well as
populations to characterise protein dynamics. NMR also allows the
characterisation of local (site or residue-specific) ps-ns dynamics. Here NMR
experiments provide information about rigidity (by using order parameters, S2)
of individual bonds in the protein and the time scale of these motions [55].
NMR techniques were thus used for this study to probe the dynamic behaviour
of the Hsp90-NTD, when it is in complex with different inhibitors. This included
obtaining the assignments for the ligand bound Hsp90-NTD, and using
chemical shift perturbation (CSP) analysis to look into changes in structure
and/or dynamics of the protein upon ligand binding. As CSP analysis only
indicates that some changes in protein structure or/and dynamics has
occurred, but we cannot say what exactly happened, we also used relaxation
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dispersion methods to look into protein dynamics. These methods are
described below.
1.3.3.1 NMR protein 2D and 3D experiments and assignments
Protein NMR relies on monitoring magnetically active nuclei (typically these
include 1H, 15N and 13C for biological macromolecules). After a labelled protein
has been produced for the study, the NMR experiments often start with
assignment of the protein backbone atoms.
Here, the 2D heteronuclear single quantum coherence (HSQC), or transverse
relaxation optimized spectroscopy (TROSY), on backbone amides is often the
first multidimensional experiment run, as it can inform on spectral quality [57].
The HSQC experiment is generally used for smaller proteins, while the
TROSY is used for larger systems (14-20+ kDa), and in higher magnetic fields.
Although some side chains can also be seen (Trp, Asn and Gln), NH TROSY
experiments mostly report on the backbone amides, and generally one peak
can be seen for each amino acid backbone residue, although there are
exceptions, such as Proline residues. If the assignments of the apo protein
are available, and the peak positions in the amide 2D spectra of the protein in
the presence and absence of different ligands are similar enough to transfer
the existing peak assignments between the spectra, NH TROSY is often used
as a sole experiment for finger printing the binding interactions using 15N
labelled protein [58].
For protein backbone assignments, 3D triple-resonance experiments
HNCACB and HNCOCACB are used [59]. These link the backbone atoms with
their neighbours. As apo Hsp90-NTD assignments were available, here we
used ‘an incomplete set’ of experiments - TROSY versions of triple-resonance
experiments such as HNCA, HNcaCO and HNCOca as well as HNCO, that
are often used to assign larger proteins. The HNCA/HNCOca and
HNCO/HNcaCO 3D experiments link the neighbouring carbons (Figure 1.7).
In the HNCA experiment, the magnetisation is passed from H to N and then
to Cα and Cα-1 via the heteronuclear one-bond or two-bond J-coupling between
the N and Cα or Cα-1. Then the magnetisation is passed back again to HN for
detection, as shown in Figure 1.7. In the resulting 3D HNCA spectra, each
backbone HN bond is represented by two peaks. These have the same
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chemical shifts in 1H and 15N dimensions, and different chemical shifts in the
13C dimension, one corresponding to Cα and the other to Cα-1, which is normally
the weaker of the two peaks. Similarly, for HNCOca, the magnetisation is
passed from H to N and to CO and to Cα and back again for detection. The
resulting 3D HNCOca is similar to the HNCA spectra, but a peak is only
observed from the Cα-1 residue in the carbon dimension. HNcaCO and HNCO
form a similar pairing to HNCA/HNCOca, where for HNCO, a single peak in
the CO dimension is seen from ‘i-1’ residue, and in the HNcaCO spectra the
carbon dimension has two peaks, one for the residue ‘i’ and the other from ‘i-
1’. For the HNCO experiment, the magnetisation is passed from H to N and
then to the CO, via N-CO J-coupling and on the carbon dimension on the
HNCO spectra, the CO from the ‘i-1’ residue is seen. For HNcaCO, the
magnetisation is transferred via H to N, then to Cα and finally to CO via Cα-CO
J-coupling, and back again for detection. As the amide nitrogen is coupled
both to its own Cα and that of the previous residue, for each backbone NH
bond, two carbonyl groups COi and COi-1 are seen, where the COi peak is
normally more intense.
The information from the HNCA/HNcaCO and HNCO/HNCOca experiments
can be used to connect a residue with its preceding neighbour (i.e. ‘i’ with the
previous ‘i-1’). Identification of the Ca or CO and preceding Ca-1 or COi-1 peaks
allows the building of strips of connected residues, as shown in the bottom
panel of Figure 1.7. As some residues, such as Glycine, have very typical Ca
chemical shifts, these can be used to ‘anchor’ the strips to a particular set of
amino acid sequence in the protein structure [60]. Whilst the HNcaCO and
HNCOca are needed to link the residues together to build strips of linked
residues for assignment, the HNCA and HNCO spectra are also useful,
especially for weaker peaks, as they are more sensitive experiments.
Even if protein assignments are available, triple resonance experiments are
often required to verify peak assignments and/or identify peaks for residues
affected by ligand binding, as discussed in the next section. Additionally, 3D
experiments (particularly HNCO) help to resolve overlapped peaks in the 2D
amide spectra. In this project, TROSY, HNCA, HNCO and HNcaCO
experiments are used to verify previously published assignments of Hsp90-
NTD (BMRB:7003), and assign the ligand bound Hsp90-NTD spectra [61].
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Figure 1.7: Schematic overview of the heteronuclear NMR experiments
HNCA, HNCO and HNcaCO commonly used for the assignments of
backbone resonances. Circles indicate the correlations that are
recorded in the given experiment. Red circles represent nuclei for
which chemical shift is recorded and blue circles are nuclei for which no
chemical shift is recorded, but that are used for coherence transfer. The
strips on the right of the figure show expected peaks and intensities in
the carbon dimension of the spectra. The bottom panel of the figure
shows an example of how the Cα carbon shifts can be used to link up
the residues in a protein structure.
1.3.3.2 Chemical shift perturbation analysis
Chemical shifts are resonance frequencies of a magnetically active nuclei
which are influenced by the nearby electrons. Thus in a protein molecule,
where atoms are connected through bonds and space, chemical shifts differ
even for residues with the same amino acid type. This results in differences in
peak positions in the spectra. As chemical shifts are very sensitive to the
electronic environment of a nucleus, even very small changes in the chemical
environment can be detected. Measurements of changes in chemical shifts
(i.e. chemical shift perturbations or CSPs) are commonly used to study
protein-ligand binding. CSP measurements provide a valuable tool to
characterise structural and dynamic changes in macromolecules, for example
due to interactions with small molecule ligands.
The CSP analysis is used to identify site-specific differences between two
protein states, for example, between the apo-protein and protein-ligand
complex. Depending on the protein size, and complexity of the system under
study, 2D or 3D NMR spectra are collected for the two states (apo and ligand
bound), and peak positions for individual residues are analysed. If a ligand
does not bind, no changes in chemical shifts are observed in NMR spectra.
Detecting changes in peak positions upon ligand binding allows localisation of
ligand-binding sites. This is because the protein residues involved in direct
binding are likely to have changes in their peak positions. If ligand binding
causes long-range structural and/or dynamic changes in the protein,
perturbations in the magnetic environment of nuclei result in changes in peak
positions of residues that are not directly involved in ligand interactions. If the
crystal structure of the protein is known, and its NMR spectra assigned, the
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observed chemical shift perturbations can be mapped onto the crystal
structure. This allows us to identify residues that are directly affected by
binding, as well as sites with ligand-induced long-range conformational
changes [57].
Usually for small ligand binding, 2D TROSY or HSQC spectra in the apo and
ligand bound form are recorded to detect chemical shift perturbations for the
protein backbone amides, i.e. 1H and 15N chemical shifts. For each residue (or
NH bond), the total chemical shift change (∆ߜ௧௢௧) is calculated using the
following equation [62]:
∆ߜ௧௢௧ = ඥ(∆ߜு)ଶ+ (0.154∆ߜே )ଶ (eq.3)
where ∆ߜு and ∆ߜே are the chemical shift differences for 1H and 15N.
For larger, more complex systems, 3D HNCO spectra, that provide 15N, 1HN
and 13CO chemical shifts are often used in CSP calculations instead of 2D
TROSY/HSQC to resolve peak overlap.
To analyse the chemical shift perturbations, the observed chemical shifts (∆ߜ)
are quantified to separate ‘genuine changes’ from experimental noise before
mapping the changes onto the protein structure. Here a commonly used
method is to calculate the standard deviation for all the observed chemical
shift changes. Next, all the residues that have a very large ∆ߜ (e.g. greater
than 2 or 3 standard deviations) are excluded from the dataset to avoid biasing
the distribution. Then the standard deviation is recalculated. The genuine
changes can then be defined as those residues whose observed chemical
shift is larger than the standard deviation [57].
1.3.3.3 NMR relaxation dispersion experiments to study µs-ms protein
dynamics
The micro- to millisecond timescale dynamics are often relevant for small
molecule binding events [63, 64]. The current view of proteins is that they exist
in an ensemble of different states. In turn, ligand binding can shift the
equilibrium of this conformational ensemble [65]. Thus, understanding the
dynamics that govern the exchange between the states, as well as the
structural information about the states, is needed to better understand the
underlying biomolecular recognition events.
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Provided that there is a difference in chemical shifts (∆ߜ) between the states
and exchange between states is on the micro- to millisecond timescale,
different peak patterns can be seen in the spectra, depending on the
exchange regime (kex) between the states (Figure 1.8).
௘݇௫ = ஺݇஻ + ஻݇஺ (eq. 4)
where kAB is the exchange rate constant from state A to B and kBA the
exchange rate constant from B to A.
A single peak is observed when the exchange rate constant between the
states is significantly faster than the chemical shift difference (∆ߜ) between
the peaks corresponding to individual states (kex>>∆ߜ) (Figure 1.8). In this
case, the observed peak position can be used to calculate the populations of
individual states using the following equation (provided here for state A):
݌஺ = (ߜ௢௕௦− ߜ஺)/(ߜ஻ − ߜ஺) (eq. 5)
Here pA is the population of state A, ߜobs the chemical shift for the observed
peak and ߜA, ߜB are the chemical shifts for states A and B respectively.
At the other end of spectrum, where the rate of exchange between two states
is a lot slower than the difference in chemical shifts (kex<<∆ߜ) between the
states, the spectra shows two peaks. For each peak, its height is proportional
to the population of the corresponding state (Figure 1.8). Between the fast and
slow exchange rates falls the intermediate range, where the exchange rate
constant is roughly equal to the difference in chemical shifts between the two
states (kex~∆ߜ). In this case, interconversion between state A and state B
‘interferes’ with the chemical shifts, resulting in ‘exchange broadening’ of the
observed NMR peak.
In general, these differences in the peak pattern and peak width can be
studied using line shape analysis. Line shape analysis can be used to
estimate exchange rate constants and the population of individual states.
However, for more careful quantitative analysis, relaxation dispersion
measurements using the Carr-Purcell-Meiboom-Gill (CPMG) method are
commonly used [30, 55].
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Figure 1.8: Overview of NMR dynamics experiments using the classic two-
site chemical exchange example. If the exchange between the two
states (A and B) is slow, two peaks are observed where the height
distribution reflects the population of each state. For fast exchange,
only a single peak is visible with its the position based on the
population. Intermediate exchange, where the exchange between the
two states is roughly equal to their chemical shift difference, results in a
broad peak. (Figure modified from [55]).
The CPMG approach allows re-focusing the broad peaks caused by
intermediate exchange. The basic idea behind these experiments is to
quantify the effective line width of peaks as a function of number of refocusing
pulses. Without refocusing, the line widths are broad due to dephasing of
magnetisation caused by stochastically changing between two states (states
A and B). In the absence of refocusing pulses, state A changes to state B
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randomly, resulting in defocusing magnetisation in the XY plane. This causes
a broadening of the resulting NMR peak (Figure 1.9, top). To re-focus
magnetisation in XY plane, a variable number of 180° re-focusing pulses in
the same delay period can be applied. As the refocusing pulses become more
frequent, i.e. there is less time between 180° pulses, there is less of a chance
for the state A to change to state B. The CPMG sequence can thus refocus
magnetisation, and lead to sharper peaks (Figure 1.9). An elegant analogy of
the CPMG experiment has also been suggested by Lewis Kay [66]. Here
runners and walkers are used to describe the spins of the two different states
(A and B), while differences in their speeds can be used to describe
differences in chemical shifts between A and B. As states A and B can
interchange, runners can start walking and walkers can start running. At the
beginning of experiment runners and walkers are set off to run a lap around a
field. In the absence of exchange (or if an exchange is very slow), there will
be two populations of finishers; one group crosses the finish line first (runners)
and another later (walkers). In this scenario, there will be two peaks in the
NMR spectrum (one for state A and one for state B). If, on the other hand, the
exchange rate constant is very fast (all runners became walkers many times
over and vice versa), all the runners and walkers will finish together as one
group, and here one peak is observed in the NMR spectrum. In the case of
the intermediate exchange rate, some runners slow down to a walk once or
twice, others five times and so on, during the lap of the field. As a result, all
the runners and walkers finish at different times, and this would lead to a broad
peak in the NMR spectrum. To refocus this group of runners and walkers, a
CPMG experiment can be used. Here, the runners and walkers are again set
off around the field, but this time, if a whistle is blown (representing the 180°
pulse), all the runners and walkers will turn around. If there is no exchange
(i.e. runners will keep running and walkers walking), two peaks are seen on
the spectrum. If runners start randomly walking and walkers running, as in the
case of intermediate exchange, if the whistle is blown, some of the runners
may start walking back to start line and thus will not cover the same distance
as they did on the way out. Here, not everyone will cross the start line at the
same time. This would again lead to a broader peak in the NMR spectrum.
However, if a larger number of whistles are blown to keep turning everyone
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around again and again, the group should stay much less dispersed. As the
period between whistles gets shorter, there is less time for runners to start
walking and then running again. The distances covered running or walking are
shorter and the participants are spread across a far smaller part of the field.
This means that they are more likely to cross the finish line at the same time,
equating to a sharper peak on the NMR spectra [66].
Figure 1.9: Schematic of a CPMG relaxation dispersion experiment peak re-
focusing. If the two states of the system, A (in blue) and B (in red),
interchange roughly at the same rate as their chemical shift difference,
a broad peak is seen in spectra. The exchange between states A and B
is shown as dashed red or blue line. The use of an increasing number
of refocusing pulses (grey boxes) results in peak refocusing, as a peak
from only one state is observed, as seen on the right panel. The bottom
panel shows simulated data from CPMG experiments, where the peak
is refocused when the CPMG frequency is increased. (Figure modified
from [67] and [66])
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Whilst CPMG experiments probe only µs-ms time scales, they have become
a valued tool in studying ligand-protein binding, folding pathways and enzyme
reactions [68-70]. To obtain exchange parameters such as the interconversion
rate (kex) and the population of each state, as well as the chemical shift
differences between two interconverting states, relaxation dispersion
experiments need to be recorded at multiple magnetic fields. These
parameters provide information on global and local dynamics and the
thermodynamics of the exchange process [66]. Moreover, this approach
allows characterisations of minor populations (smaller than 1%) [71]. In turn,
information about chemical shift differences between the major and minor
conformations can be used to obtain insights into structure and dynamics of
the minor (populated less than 1%) state, which is not possible by any other
experimental method.
From the CPMG data, the transverse relaxation rates (R2eff) at different CPMG
field strengths can be calculated from peak intensities using the following
equation [72, 73]:
ܴ2௘௙௙ = − ଵ்಴ುಾ ಸ ln ூூబ (eq. 6)
Here, TCPMG is the constant time used for the CPMG experiment, I the peak
intensity and I0 the reference peak intensity.
In this work the relaxation dispersion method is used to study the differences
in µs-ms dynamics between the different Hsp90:inhibitor systems, and to
allow comparison, and validation, of computer simulation data.
1.3.4 Molecular dynamics simulations
Molecular dynamics simulations (MD) are a tool to describe, and visualise, the
movement of atoms making up biomolecules using classical Newtonian
physics. MD has provided insight into molecular movements since the early
simulations were completed in the 1970s [74]. The early simulations, which
included work on the 58 amino acid long bovine pancreatic trypsin inhibitor,
were only a few picoseconds in length. With the advances in supercomputing,
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larger systems, and even millisecond simulations, using specifically designed
computer architecture have been achieved [74, 75].
As this study uses standard ‘flavour’ MD simulations, that have been widely
adopted as a tool in biological research, a brief overview of the underlying
principles for MD is provided. This is followed by a review of the different
methods of obtaining entropy values from simulation data.
1.3.4.1 MD simulations - main principles
To run a molecular dynamics simulation, a co-ordinate file (typically from X-
ray or NMR structures, but possibly also a homology model) for the system of
interest is used as a starting structure. Next, a set of parameters to describe
atom types, bond length and charges are applied to the structure. After this,
the forces acting on each atom are calculated, based on classical mechanics,
and subsequently each atom is moved based on the force acting upon it. A
snapshot of the new system is taken, and the process is repeated over and
over again to get a trajectory file of the molecular movements [76].
For MD simulations, the forces acting on the atoms are described by a force
field, which contains terms for bonded and non-bonded interactions between
the atoms, as shown in equation 7 [77]. The bonded interactions include terms
for bonds, angles and dihedrals, to describe bond stretching, bending and
twisting, as shown in the first three sums of the equation 7. The final term
sums up the non-bonded interactions arising from van der Waals and
electrostatic forces.
ܧ௧௢௧௔௟=෍ ௥݇(ݎ− ݎ௘௤)ଶ + ෍ ఏ݇ (ߠ− ߠ௘௤)ଶ + ෍ ௡ܸ2
ௗ௜௛௘ௗ௥௔௟௦
[1 + cos(݊∅ − ߛ)]
௔௡௚௟௘௦௕௢௡ௗ௦+෍ ቈܣ௜௝
ܴ௜௝
ଵଶ−
ܤ௜௝
ܴ௜௝
଺ + ݍ௜ݍ௝ܴ߳ ௜௝቉
௜ழ௝
(eq.7)
The energy term for the bonds is modelled using two spheres connected by a
spring, to which a different stiffness (k) is applied depending on the atoms
involved in the bond. The letter r denotes the distance between the two atoms
connected by the bond, and this term describes the bond stretch compared to
the equilibrium position (see Figure 1.10). For angles, k is the force constant
27
for the angle bending, whose value depends on the types of atoms. The force
constant depends on how large or small the angle (θ) between the atoms is in
comparison to the equilibrium position. The dihedrals represent a torsional
term describing the rotation about the chemical bond. This is described by a
sinusoidal function that shows the energy differences between staggered and
eclipsed conformations. This is the difference in energy of the atoms when
they are furthest from, or closest to, one another due to bond rotation. As the
bond could rotate around 360°, the same conformations can be reached at
multiple times during the cycle ( ∅݊). The γ term accounts for shifts in the
maxima and mimima positions. The dihedral term often includes terms for
improper torsions, to maintain a particular geometry.
Figure 1.10: Different force field parameters shown at the atomistic level.
The bond stretch, angle bend and dihedral terms describe interactions
between connected atoms, whereas van der Waals and electrostatic
terms are included in the non-bonded interactions.
The non-bonded terms, that are given in the last part of equation 7, are
calculated for Van der Waals (VdW) interactions using the Lennard Jones 6-
12 potential. When the atoms are sufficiently close to one another, there is an
attractive force ( ஻೔ೕ
ோ೔ೕ
ల). The attraction term becomes weaker as the distance
between the atoms increases. When the atoms are too close, there is an
additional repulsive force ( ஺೔ೕ
ோ೔ೕ
భమ). The electrostatic interactions are modelled by
Coulombic laws, using atom-centred point charges [78].
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Whilst the bonded terms are easy to handle in potential energy calculations,
issues can arise with how great a distance the non-bonded interactions stretch
to. In principle, all non-bonded atoms should be considered for the
calculations, but in practice, this slows down the computations too much. To
speed up the calculations, short range forces (i.e. VdW) are normally treated
with a cut off value. For long range forces, i.e. electrostatics, more
sophisticated algorithms, such as the particle mesh Ewald (PME) algorithm,
are normally adopted. Additionally, simulations are normally run in periodic
boundary conditions, where the simulation box is virtually surrounded by
identical boxes. Here, if the molecule drifts to the edge of the box during the
simulation, it does not simply disappear into space, but re-appears on the
opposite side of the box (see Figure 1.11).
Figure 1.11: Virtual Periodic Boundary box. Simulations are normally run
with ‘imaginary’ boxes surrounding the actual simulation box as shown
on the left (greyed out cats for the virtual box vs black and white cat for
the simulation box). This prevents the drifting of the molecules into
space when they end up at the edge of the simulation box. The
molecule that leaves the box on the right, simply re-appears on the left
of the box, as depicted in the figure on right.
For MD runs to produce realistic atomic movements, the energy terms
described above need to be parametrised based on the types of atoms.
Collectively, these parameters are called a force field. The parameters are
derived from ab initio calculations and from a range of experimental data to
reproduce peptide and dihedral angles and protein crystal structures. These
parameters include, for example, the radius of atoms, partial charges to
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calculate the non-bonded terms, bond lengths, stiffness of the bonds, angles,
and dihedral parameters [76]. There are few commonly used force fields,
including those from Amber and CHARMM, that have been heavily tested by
the simulation community. These force fields have subsequently improved
over the years, in an attempt to make sure that they produce realistic
movements [79] [80]. Whilst the commonly used force fields for biological
macromolecules work reasonably well for protein and nucleic acid simulations,
they have limited parameters for organic molecules. This is mainly due to
difficulties with the accurate parametrisation of the significantly larger
chemical space that small molecules cover, compared to the 20 standard
amino acids and 5 different bases for DNA and RNA molecules.
To partly get around this issue of small molecule parametrisations, Amber
developers have written a General Amber Force Field (GAFF) to enable more
realistic simulations of organic molecule (i.e. drug) and protein or nucleic acid
interactions [81]. The description of atomic charges is the key to
understanding the chemical reactivity and physical properties of the
molecules. The atomic charges are often calculated separately, using
quantum-chemical ab initio methods, to obtain more accurate charges. These
values are fed back into Amber to produce library files that make up specific
force field parameters for the small molecule in question [82, 83].
1.3.4.2 Running a MD simulation
To run a simulation, first the forces acting on a system are calculated using
classical mechanics formulas. Then the atoms are moved, proportional to the
force acting on them. This two-step process is repeated over and over again.
For the force calculations, each atom is considered as a single point and the
forces (F) acting upon the atom can thus be calculated by:
⃑ܨ௜= ݉ ௜ܽറ௜ (eq.8)
where mi is the mass of atom i and ai the acceleration. The force could
alternatively be described by the gradient of potential energy (Etotal from
equation 7):
⃑ܨ௜= −∇௜ܧ௧௢௧௔௟ (eq.9)
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where ∇௜ is the three dimensional derivative operator giving details of the x,y
and z positions. This describes the force acting on atom i.
Combining these two equations allows us to compute the acceleration of the
atom:
റܽ௜= −
ଵ
௠ ೔
∇௜ܧ௧௢௧௔௟ (eq. 10)
Equation 10 can be numerically integrated, via a choice of different algorithms,
to get the position and velocity of the atom. Thus with the initial input of the
position of the atoms, and known initial velocities and acceleration, the
calculation can be repeated as long as necessary, to obtain a trajectory [78].
Whilst there are several slightly different implementations of how to integrate
the above equation, this is not the crucial factor. Rather, what is important is
to decide the length of the time step, given that a balance must be struck
between the time taken to obtain a trajectory of sufficient length, and the
accuracy of the calculations. The time step for the integration cannot be longer
than the fastest motion in the system, which is the bond-stretching vibrations,
typically in the order of 10 fs, and thus a routinely used time step for
simulations is 2 fs [84].
Finally, as biological molecules in a cell are in an aqueous environment, to get
a realistic picture of what is happening to the molecules, the MD simulations
are normally carried out in water. Here there are several choices of water
model, which range from explicit solvent (i.e. the water is modelled as
individual water molecules) to implicit solvent model, where a force presenting
bulk solution is applied to the surface of the biological molecule. The explicit
water model is generally accepted to provide a more realistic description of
water, although there is a large computational cost due to the sheer number
of atoms required. Implicit models on the other hand, which describe the effect
of water by simply adding forces, are often used when simulating very big
systems (>10,000 atoms). Here, addition of explicit water molecules would
simply make the system too large [85]. The calculation times are similar to
explicit water simulations, but the motions of the molecules in simulation are
accelerated. This can be explained by analogy - it is faster to run along the
beach than in waist deep water. Improving the accuracy of the modelling of
water is an active field of research in its own right, and a topic for another
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thesis. For this study, the priority is to select the most suitable water model for
the force field used. The chosen water model should match the water model
which was used for the force field parametrisation and validation, for example,
Amber ff99SB force field was parametrised using the three point TIP3P water
model [77].
1.3.4.3 Configurational entropy calculations from molecular dynamics
trajectories
MD simulations provide information on the flexibility and structural
heterogeneity of macromolecules. When MD simulations are run for long
enough to adequately sample the conformational space, the trajectory can be
used to calculate the number of microstates (Ω) a system can adopt, together 
with the probability (pi) of finding the system in a particular microstate. This
information can be used to estimate entropy. Unsurprisingly, attempts to
estimate the conformational entropy of macromolecules using MD simulations
have been made for nearly as long as there has been simulation data
available [86, 87].
The entropy calculations are based on the Boltzmann’s formula, where the
knowledge of the number of microstates (Ω), together with their probabilities, 
enables the calculation of the system’s entropy (S) [88]:
ܵ= ݇ logΩ (where k is the Boltzmann constant ) (eq.11)
There are two commonly used methods to calculate configurational entropies
from simulation data; the quasi-harmonic approximation and the histogram
method. Both methods are based on the above Boltzmann’s formula, but they
differ in the way the shape of the underlying energy landscape is
approximated. The quasi-harmonic approach assumes that the fluctuations of
the shape of the molecule during a simulation fit into a single large energy
well. The macromolecule oscillates harmonically in this well, and a Gaussian-
like distribution can be fitted to describe the well to estimate the entropy
(Figure 1.12). In contrast, the histogram methods divide the conformations
observed from the trajectory into different microstates that reside in different
energy wells. Here, the size and steepness of the wells describes the
likelihood of the molecule been found in each state. This gives the probabilities
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that are needed for the entropy calculations [89]. In practice, the quasi-
harmonic analysis works well for molecules that do not undergo large
conformational fluctuations, whereas the histogram methods can be used for
flexible molecules as well. However, for the histogram methods, issues do
arise regarding how to define what are different microstates versus
fluctuations within one state. Often an internal bond angle torsion (BAT)
coordinate system is used for the histogram methods, rather than the
Cartesian co-ordinates used to run the simulation. This is because it is easier
to define limits using bond angle fluctuations. These two methods are further
described below.
Figure 1.12: The quasi harmonic approximation and histogram methods for
entropy calculations both assume different underlying potential energy
landscapes. The quasi harmonic approach assumes a single energy
well, as shown on left, in which the macromolecule oscillates. The
histogram methods’ energy landscape is depicted on right. Here the
macromolecule is assumed to occupy several energy wells and the
shape and steepness of the energy well gives the probability of it being
occupied.
For the quasi-harmonic approach, the configurational entropy is generally
assumed to originate only from the internal motions of the molecule, rather
Quasi harmonic
approximation energy
landscape
Histogram based method’s
energy landscape
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than the overall tumbling of the molecule (i.e. rotational and translational
motions). Moreover, the Cartesian co-ordinate system is normally used for the
entropy calculations, as this allows the bond rotations and vibrations to be
added together in a linear fashion. For the calculations, the fluctuations in
atomic positions are converted into a mass weighted co-variance matrix that
described the fluctuations of each Cartesian coordinate relative to its average
position during the simulation. The co-variance matrix can then be
diagonilised to obtain eigenvectors and eigenvalues, where the largest
eigenvectors describe the dominant movements of the system. The total
entropy (S) can then be calculated using the following formula [89, 90]:
ܵ= ଵ
ଶ
݇∑ ln(1 + ௞்௘మ
ℏమ
ଷேି଺
௜ ߛ௜) (eq.12)
Here the ߛ௜are the eigenvalues of the mass weighted co-variance matrix. The
last logarithmic form is a correction term suggested by Schlitter, to reduce
“numerical noise” from the very smallest eigenvalues that lie outside classical
regime [90].
Quasi-harmonic approximation for conformational entropy is widely used.
Although it has been found to overestimate entropy, due to the assumption
that the internal vibrations are not correlated, the method has been
demonstrated to give reasonable estimates of the relative entropies for both
DNA and protein-ligand systems [14, 91]. The method has also been added
as a ‘standard tool’ to many molecular dynamics software packages. The
advantage of QHA is that it can help to rationalise the underlying biological
movements that lead to entropy changes. This is because it is based on
principal component analysis (PCA) with its use of eigenvectors and
eigenvalues. The eigenvectors can be used to provide insights into the
underlying biological system; the largest eigenvectors show where the major
conformational changes are taking place and the eigenvalue describe the
amplitude of the movement [92, 93].
One issue with the quasi harmonic approximation is that it breaks down if the
underlying movements are anharmonic. The method works remarkably well
for DNA, which is more rigid due to the ordered hydrogen bonds linking the
bases [91, 92]. However, issues can arise with using the method to study more
flexible and intrinsically disordered systems, which can be very anharmonic.
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Also, due to the use of Cartesian co-ordinates, the trajectory needs to be first
re-imaged, (i.e. all the simulation frames are aligned with a reference
structure) to remove any rotational and translational movements. This again
may present issues for flexible molecules.
Next, we describe in greater detail the histogram method for estimating
configurational entropy from MD simulations. In this method, the microstates
that are sampled during the simulation are divided into different bins to obtain
a probability density function of the states. This can be used to calculate the
entropy. Here, the probability density in a bin (݌௜) is calculated first:
݌௜= ௡೔௡ ଵ∆ (eq.13)
Where the ∆ is the size of bin and ௜݊ is the number of times the macromolecule
is found in the particular microstate during the simulation, compared to the
total number of samples .݊ This information can then be added to the formula
below to get the entropy:
ܵ= −݇∆ ෍ ݌௜ln݌௜௕௜௡௦
௜ୀଵ
(eq.14)
As explained earlier, how to define a microstate is often an issue with the
histogram method. Often the trajectory data are converted to an internal co-
ordinate system, where the ‘bond-angle-torsion’ (BAT) angles are used to
define the bins. The problem is that the BAT co-ordinates only consider the
bond twisting motions and ignores the contributions from bond stretching.
Defining averages is also not easy with BAT co-ordinates, due to periodic
movements of the bond rotations.
The advantage of the histogram method compared to the quasi-harmonic
approximation is that it does not break down with anharmonic systems.
However, the entropy value is often either over or under estimated, due to the
difficulty of defining the bin sizes. It is not easy to estimate what constitutes a
different microstate (and thus a different bin) as opposed to minor fluctuations
within a state (and thus within the bin). There have been attempts to define
the optimum dihedral angle to be used when defining the microstates, but the
suggested values vary from 1° to 5° [94, 95]. In complex macromolecules,
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correlated motions can play a large role. The configurational entropies may
be overestimated, if this is not corrected by selecting only a subset of the
dihedral angles of the macromolecule to be included in the entropy
computations. Consequently, the histogram method tends to work relatively
well for smaller molecules, but issues often arise with larger and more
complex macromolecules, where correlated motion is an issue.
Whilst the quasi-harmonic and the histogram methods differ in how the
underlying energy landscape and the probability distribution of the microstates
is approximated, they can provide comparable entropy estimates, at least for
calculations done on small molecules. An example of this was a study by
Gilson’s group, who tested their histogram method based the Mining Minima
algorithm against the quasi-harmonic approximation on Ampenavir drug
binding. The computed configurational entropy values were less than 1
kcal/mol apart, (calculated as 11.6 kcal/mol with the Mining Minima histogram
method, compared to 12.3 kcal/mol by quasi-harmonic approximation) [14].
For larger molecules, comparative entropy values obtained using quasi-
harmonic analysis and the histogram method have also been demonstrated.
A general issues with all the currently used methods for computing entropy is
convergence. When further MD data are processed, the entropy value
increases. This highlights the issue with using finite simulation data to sample
the nearly infinite energy landscape of complex molecules [96].
More recently, new methods for obtaining entropies from MD simulations have
been suggested. One of these methods is using atomic forces instead of
atomic positions for the calculations. This circumvents anharmonicity issues,
but so far it has had only limited use in examining the entropy of water. It
remains to be seen if it will be adopted for biomolecules [97]. Attention has
also focused on accelerated MD techniques that improve the sampling of the
conformational space. A study using an accelerated MD run, followed by per
residue re-weighted dihedral entropy calculations, demonstrated that the
‘accelerated MD entropies’ corresponded better with the entropy values
calculated from NMR dihedral analysis, compared to those from conventional
MD simulations [98]. Despite recent developments, one of the main problems
that remains is comparing the calculated entropy values to actual
experimental data. Only NMR relaxation techniques allow the estimation of
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configurational entropy at the atomistic level, rather than having to make
comparisons with global entropy changes. Here, fast nanosecond methyl
sidechain and amide backbone bond vector motions as measured by NMR
have been used to calculate order parameters, which show how flexible or
rigid the particular bond vector is [55, 99]. These order parameters can also
be calculated from MD simulations and have been used as a proxy for global
changes in protein dynamics to calculate changes in entropy [100-102]. The
fast motions have been shown to be relevant to the overall entropy change,
as work with thermo- and mesophile enzymes showed that the fast time scale
motions can increase in some parts of a protein upon ‘rigidification’ of some
other distal part of the enzyme [103]. Despite these advances, the
configurational entropy calculations using NMR data also rely on similar
assumptions to computations based on MD simulation data, where for
example unharmonicity and correlated motions remain an issue. Indeed,
whilst a number of studies have used the nuclear relaxation rate derived order
parameters as a proxy for entropy, there are concerns on how well the limited
number of measurements of internal motions characterise the overall protein
dynamics, as often only amide bond vectors or methyl side chain motions are
used [104]. Further, the side chain order parameters require different fit
parameters depending on the residue type before they can be used for
entropy estimation. These parameters also seem to be somewhat system
specific. Issues arise also from correlated motions, as well as the effects on
global flexibility affecting the general rotational term. To date the best results
of configurational entropy values have been quoted to have been achieved
using a rigid CAP protein [105].
1.4 Aims of project
The main aim of the project is to gain further insight into how protein dynamics
is influenced by small molecule binding using the Hsp90 chaperone as a
model system.
The interaction between protein and ligand are guided by thermodynamics,
which can be examined by ITC and other methods that measure the overall
binding affinity. However, examining the changes in configurational entropy,
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which report on structural dynamics, could be of more interest. This is because
it could enable conformational selection of only a certain pool of Hsp90, and
consequently a particular downstream pathway. The binding of a ligand would
further shift the conformational ensemble towards a certain ligand stabilised
conformation. To examine the configurational entropy, the effect of small
inhibitor binding to the Hsp90 protein was examined by NMR and MD
techniques. These atomistic scale results were compared to the global values
obtained from ITC. The overall aim of the study is not method development,
but to gain further understanding what different thermodynamic signatures
mean in the atomic level for protein dynamics.
The first chapter provides background on thermodynamics, the model system
and the main techniques used to probe dynamics. The second chapter
focuses in detailed description of the materials and methods used as well as
describing method optimisation and validation experiments. Chapter 3
describes the results from experimental (NMR and ITC) and computational
studies (MD simulations) of the effect small molecule binding has on Hsp90
dynamics. The results from the different techniques are compared and we try
to rationalise the global entropy change in the light of protein conformational
fluctuations. Chapter 4 focuses on configurational entropy calculations using
MD simulation data. Here, both the quasi-harmonic analysis and the
histogram methods are used to calculate entropies, with emphasis on
highlighting issues with the methods. A further issue relating to the entropy
calculations using MD simulation data relates to whether sufficient
conformational space has been explored by the molecule during the
simulation. We also try to answer the question of when ‘enough’ space has
been explored by representing the analysis of a large number of replica
simulations. Finally, Chapter 5 contains the overall conclusions of the studies.
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Chapter 2
Materials, methods and method optimisation results
This ‘Materials and Methods’ chapter describes both the experimental and
computational methods and how the materials were prepared. Results from
validation studies and optimisation trials are also presented.
2.1 Materials and reagents
2.1.1 Small ligand inhibitors
The chemical structures of the initial panel of six Hsp90 small molecule
inhibitors are shown in Figure 2.1. The panel included three commercially
available inhibitors of Hsp90; geldanamycin and one of its derivatives 17-
(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) as well
as radicicol. These three compounds were obtained from Cayman Chemicals.
The other three compounds, CNF2024, GVK0153 and GVK0161 were
received from AstraZeneca. All ligands were dissolved in dimethyl sulfoxide
(DMSO) to make 100 mM stock solutions.
2.1.2 Hsp90-NTD DNA template
The pET28a-6His-TEV-Hsp90(D9-E246) plasmid encoding for the human
Hsp90-NTD was obtained from AstraZeneca. The plasmid has a kanamycin
resistance gene for selection. The size of the Hsp90-NTD including the His-
tag and thrombin cleavage site is around 26 kDa. The sequence of the Hsp90-
NTD(D9-E246) used is shown below.
DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYE
SLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTK
AFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSA
GGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPI
TLFVEKERDKEVSDDEAE
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2.1.3. Chemicals
Standard chemicals were obtained from Sigma Aldrich and Fisher Scientific
unless otherwise stated.
2.1.4 Heavy isotopes
Per-deuterated glucose, 13C glucose, 15N ammonium chloride, deuterium
oxide (D2O) and Celtone complete medium D as well as Celtone complete
medium 13C, 15N were purchased from Cambridge Isotope Laboratories.
Figure 2.1: Chemical structures of the small molecule inhibitors used in this
study. The inhibitors included three nucleotide mimic compounds,
GVK0153, GVK0161 and CNF2024, shown on the left and middle of
the second row. The other three compounds were geldanamycin and
its derivative 17-DMAG as well as radicicol, which are shown on the
right and middle of the top row.
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2.2 General analytical methods
2.2.1 Quantifying plasmid DNA concentration
The plasmid DNA concentration was measured by using absorbance at 260
nm with the NanoDrop using the standard manufacturer’s protocol [106].
2.2.2 Quantifying protein concentration
To measure protein concentration, the samples were diluted in 6 M guanidine
HCl in 1:100 dilution prior to measuring the absorbance at 280 nm (Abs280).
The protein concentration was calculated using the Beer-Lambert law (A=Ɛcl), 
where absorption (A) depends on the extinction co-efficient (Ɛ), concentration 
(c) and the length of the path that light travels through (l), which in this case is
1 cm. The value used for Ɛ for Hsp90-NTD was 15,930 of M-1 cm-1 which was
obtained from the Expasy server. The algorithm used by Expasy to obtain the
value for Ɛ calculates the molar extinction coefficients at 280 nm for tyrosine, 
tryptophan and cysteine residues, and afterwards sums these up [107].
2.2.3 SDS-polyacrylamide gel electrophoresis
To prepare samples for gel electrophoresis, 5 µl of 4XSB buffer (900 µl 4x
Laemmli sample buffer (BioRad) and 100 µl 2-mercaptoethanol) was added
to 10 µl of sample. After mixing, the samples were put on a heat block (99°C)
for 2 minutes before loading. The samples were loaded on to precast BioRad
MiniProtean TGX Precast Any kD gels. BioRad Precision Plus Protein
Unstained Standard was used as the molecular weight marker. The gels were
run at 200 V/400 mA for approximately thirty minutes. After this, the gels were
stained for half an hour with BioRad Bio-Safe Coomassie G250 stain and de-
stained with water. The His-tagged Hsp90-NTD band was expected to be
around 26 kDa.
For samples that came from un-lysed bacterial cultures, 0.3 OD/ml of culture
was taken. The cells were centrifuged after which the pellet was resuspended
in 30 µl 8 M urea and 15 µl 4XSB buffer, prior to heating the sample briefly
and loading the sample to gel as described above.
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2.2.4 Preparation of agar plates and culture media
2.2.4.1 LB-agar plates
To make LB-agar plates for bacterial cultures, 25 g/l of Luria-Bertani media
(10 g tryptone, 5 g yeast extract and 10 g NaCl for one litre) was mixed with
15 g/l of agar and dissolved in distilled H2O. The media was next sterilised by
autoclave (20 minutes at 121°C) and let to cool to 50°C before 25 µg/ml of
kanamycin was added. After this LB-agar solution was poured onto plates to
set. The plates were stored in 4°C.
2.2.4.2 M9 media
For M9 media preparation, 6.5 g Na2HPO4, 3.0 g KH2PO4, 0.5 g NaCl, 1 g
NH4Cl, 2 g D-glucose, 120 mg MgSO4, 11 mg CaCl2, 10 mg biotin and 10 mg
thiamine were weighed and dissolved into 1000 ml of H2O or D2O. If isotope
labelling was required, ammonia and glucose were replaced by labelled
ammonia or glucose (15NH4Cl and 13C-glucose or per-deuterated glucose) as
needed. Here, for the relaxation dispersion experiments, per-deuterated
glucose and 15NH4Cl were used in order to obtain protein with 100% 2H and
15N labelling. The M9 media for expression of Hsp90-NTD used for
assignments on the other hand were prepared using 13C glucose and 15NH4Cl
to get ca. 70-80% 2H, 13C, 15N protein. After this, the media was filter sterilised.
Finally, kanamycin and 10 ml of LB was added to make up the M9 culture
media. LB was replaced by 10 ml Celtone complete labelled medium if 2H,
13C, 15N isotope labelling was required.
2.3 Protein expression and purification
2.3.1 Transformation
To transform the plasmid into bacterial cells, 1 µl of pET28-Hsp90-NTD
plasmid was added to a 50 µl aliquot of competent E.coli BL21 (DE3) cells.
The tube containing the DNA and the bacterial cells was left to incubate on
ice for 30 minutes. Following the incubation, the tube was placed on a 42°C
heat block for 45 seconds, after which 500 µl of LB broth was added and the
cells were placed in a shaker (250 rpm) to grow for 1 hour at 37°C. The cells
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were centrifuged briefly and the cell pellet re-suspended to 100 µl of LB broth
before plating them onto LB-Agar plates containing kanamycin antibiotic for
selecting the plasmid containing cells.
2.3.2 Preparation of DNA stock
To prepare plasmid stock for Hsp90-NTD expression, the pET28a-6His-TEV-
Hsp90(D9-E246) was transfected into E.coli DH5α cells following the heat 
shock method described above. A colony from the plate was picked to grow
in 5 ml LB plus kanamycin overnight at 30°C. The following morning, the cells
were harvested by centrifugation and DNA extracted using the Invitrogen
Purelink Quick plasmid miniprep kit for plasmid DNA extraction according to
manufacturer’s instructions.
2.3.3 Protein expression trials
To optimise the expression protocol for the Hsp90-NTD using the M9 media,
a small scale protein expression trial was carried out. For the trial, the effects
of different expression temperatures (37°C, 30°C and 20°C) and IPTG
amounts (0.1 mM and 1 mM) were tested.
First, a transformed E.coli BL21 (DE3) colony containing the pET28a-Hsp90-
NTD plasmid was picked from the LB-Agar plates and added into 5 ml of
LB/kanamycin media. The bacteria were left to grow in an incubator for 4 hours
(37°C, 250 rpm). After this, 1 ml of the starter culture was taken to seed 25 ml
cultures. The cells were further grown as above, until the, optical density of
the culture measured at 600 nm (OD600) was around 1.00. After this, the
expression of the plasmid encoded Hsp90-NTD was induced with either 0.1
mM or 1 mM IPTG and the culture was left to grow at either at 37°C for 4 hours
or at 30°C or at 20°C overnight. Samples from the cultures were taken before
and after the induction and these were run in SDS-PAGE gel, as specified in
Section 2.2.3.
2.3.4 Large scale protein expression (un-labelled)
To express the Hsp90-NTD protein, a transformed E.coli BL21 (DE3) colony
containing the pET28a-Hsp90-NTD plasmid was picked from the LB-agar
plates and added into 5 ml of LB/kanamycin media. The bacteria were left to
43
grow in an incubator for four hours (37°C, 250 rpm). After this, about 2 ml of
the starter culture was taken to seed 50 ml of M9 media in a baffled flask. The
cells were further grown as above until the optical density of the culture
measured at 600 nm (OD600) was around 1.00. Next, the culture was
transferred to 500 ml M9 media to grow further until the OD600 again reached
1.00. After this, protein expression was induced by addition of 1 mM IPTG to
a final concentration and the culture was left to grow overnight at 20°C.
The following day, the cells were harvested by centrifugation (5000 rpm for 20
min at 4°C). After this the samples were kept on ice to prevent any proteolysis
and the pellet was re-suspended in 35 ml of Buffer A (40 mM HEPES pH 8,
300 mM NaCl and 5 mM DTT). The pellet was then flash frozen at -80°C until
purification.
2.3.5 Expression of labelled protein
The above protocol was used to produce labelled protein, except that the
starter culture was grown overnight at 30°C to allow for the slower bacterial
growth in deuterium oxide.
2.3.6 Protein purification
To purify the His-tagged Hsp90-NTD, the cell pellet was defrosted. After this
20 mg/ml lysozyme and a protease inhibitor P8849 tablet (Roche) were added
to the sample. The tube was briefly mixed, and the cells were left to incubate
on ice for thirty minutes. After incubation, the sample was sonicated using a
six seconds on, six seconds off cycle for ten cycles, after which the lysed cells
were then centrifuged for 20 minutes at 20,000 rpm.
After centrifugation, the soluble fraction containing the His-tagged Hsp90-NTD
was loaded onto a HisTrap HP column (GE Health Care) using the ÄKTA
FPLC purification system. The unbound fraction was collected after which the
column was washed first with five column volumes of Buffer A containing 10
mM imidazole followed by a second wash again with five column volumes of
Buffer A containing 20 mM imidazole. Finally, the His-tagged protein was
eluted with Buffer A containing 250 mM imidazole and the fractions containing
the Hsp90-NTD were collected.
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2.3.7 Buffer exchange
Following the purification, the fractions containing the purified Hsp90-NTD
were pooled and dialysed against 500 ml of 20 mM sodium phosphate, pH 7.5
buffer (20 mM Na2HPO4 and 20 mM NaH2PO4) (NaPi buffer) for around twenty
four hours at 4°C with two changes of the dialysis buffer.
If the protein sample required concentrating, this was done using a 10 K
Amicon centrifuge tube until the desired concentration (350 μM for NMR
samples) was reached.
2.3.8 NMR sample preparation
The samples for NMR measurements contained additionally 1% AEBSF
hydrochloride protease inhibitor (from Biochemica) and 5% D2O to allow the
lock signal setting that stabilizes the magnetic field strength of the NMR
instrument.
2.4 Isothermal titration calorimetry
The isothermal titration calorimetry (ITC) experiments were performed using
a MicroCal iTC-200 instrument at 25°C. For the measurements, 20 µM Hsp90-
NTD and 200 µM GVK0153 ligand, 400 µM 17-DMAG or 300 µM of CNF2024,
geldanamycin, GVK1061 or radicicol were prepared in 20 mM sodium
phosphate buffer (20 mM Na2HPO4, 20 mM NaH2PO4, pH 7.5) assay buffer
with matched 2% DMSO concentration in both the protein and ligand samples.
For the experiments, 200 µl of 20 µM Hsp90-NTD protein solution was placed
in the ITC instrument sample cell and the concentrated ligand solution in the
40 µl syringe. Nineteen injections of 2 µl of ligands were added into the protein
sample and the mixing/equilibration time between samples injections was set
to 150 seconds.
The ITC data were processed using an automated algorithm in Nitpic software
to correct the base line [108]. The titration data was fitted using one site model
and a non-linear least squares curve-fitting Levenberg and Marquardt
algorithm with the Origin 7 Software from MicroCal.
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2.5 Heat capacity measurements
ITC measurements were also used to determine the heat capacities (Cp) for
the GVK0153 and 17-DMAG Hsp90-NTD complexes. The ITC measurements
were conducted, as specified above, using the automatic MicroCal Auto-
iTC200, except for the ligand concentration which was set to 300 µM. The
measurements were repeated at 7°C, 14°C, 25°C, 32°C and 37°C for both
GVK0153 and 17-DMAG ligands. The data were analysed as described above
and the enthalpy values from the different measurements were plotted against
the temperature to obtain value for the heat capacity (Cp) from the slope of the
enthalpy versus temperature plot.
2.6 NMR methods
2.6.1 NMR experiments - general conditions
NMR experiments on the Hsp90 protein were carried out using 600 MHz, 750
MHz and 950 MHz Bruker spectrometers equipped with TCI-cryoprobes. All
spectra were recorded at 25°C using the spectrometers either in the NMR
facility in Leeds or the National Institute of Medical Research in Mill Hill,
London. For NMR experiments, we used 350 µM Hsp90-NTD protein and 700
µM inhibitors and the samples were prepared in 20 mM Sodium Phosphate,
pH 7.5 buffer (20 mM Na2HPO4 and 20 mM NaH2PO4) with 1% AEBSF
hydrochloride protease inhibitor (from Biochemica) and 5% D2O.
2.6.2 TROSY and HNCA, HNCO, HNcaCO
The backbone assignments of human Hsp90-NTD apo form have been
published previously [61]. To transfer these assignments we used a set of
triple resonance experiments: NH Transverse Relaxation Optimized
Spectroscopy (TROSY) and a TROSY version of HNCA [109, 110]. The
spectra were recorded with a Bruker 600 MHz for the GVK0153:Hsp90-NTD
and 17-DMAG:Hsp90 complexes; the Bruker Avance III HD 950 MHz was
used for the apo sample. For the TROSY version of HNCO and HNcaCO
[110], the Bruker 950 MHz magnet was used for the GVK0153:Hsp90-NTD
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complex and the 750 MHz magnet for the apo and 17-DMAG:Hsp90-NTD
samples.
2.6.3 NMR spectra processing
All spectra were processed with NMRPipe [111] and analysed using Cara
[112] and Analysis [113] software.
2.6.4 NMR - chemical shift perturbations
To identify the residues that experience perturbations between apo and
ligand-bound forms, pairwise comparison of chemical shifts was performed.
For each residue, the change in peak positions was calculated using the
formula:
∆ߜ௧௢௧ = ඥ(∆ߜு)ଶ+ (0.154∆ߜே)ଶ [62] (eq. 3)
Here the ΔߜH and ΔߜN are 1HN and 15N chemical shift differences between
apo and ligand bound forms and 0.154 is the weighting factor for 15N. The
changes in CSP were classified as: significant (>0.06 ppm and/or 0.6 ppm for
amide 1H and 15N atoms) or large (larger than 0.3 ppm for Δߜtot).
2.6.5 NMR relaxation dispersion experiments
The 15N relaxation dispersion experiments were acquired at 600 and 950 MHz
fields for inhibitor:Hsp90-NTD complexes and 950 MHz only for the apo
protein. The samples were 15N labelled and deuterated with saturated molar
excess of ligands. We used the NH TROSY version of the Carr-Purcell-
Meiboom-Gill pulse sequence [114] with the 180° refocusing pulses set at 2,
4, 6, 8, 12, 16, 20 and 24 repeats (corresponding with CPMG field strengths
of 50, 100, 150, 200, 300, 400, 500 and 600 Hz) with the CPMG pulses
implemented in a constant time which was set to 40 ms.
For data analysis, only unambiguous residues, i.e. peaks that were not
overlapped by any other, were included. Next, the transverse relaxation rate
(R2eff) at different CPMG field strengths was calculated from peak intensities
using the following equation [72, 73]:
ܴ2௘௙௙ = − ଵ்಴ುಾ ಸ ln ூூబ (eq. 15)
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Here, TCPMG is the constant time used for the CPMG experiment, I the peak
intensity and I0 the reference peak intensity. The relaxation rate (R2eff) was
next plotted as a function of the CPMG field strength to identify residues with
exchange broadening.
Uncertainties were estimated from duplicate or triplicate measurements. The
residues with observable micro- to millisecond dynamics were classified using
the criteria that overall standard deviation of the peak intensities had to be
0.02 or larger, demonstrating the refocusing of the peak width upon increased
CPMG field strength with error less than 5% between the repeat
measurements.
2.6.6 NMR experiments on ligands
NMR spectra of the ligands were recorded using a 500 MHz Varian Inova
spectrometer. For the ligands, 10, 50 and 200 µM concentrations were
prepared in aqueous buffer (10 mM KPi, 50 mM KCl, 0.02% NaN3, 5 mM
MgCl2 and 5 mM DTT in D2O). One dimensional (1D) hydrogen spectra were
obtained at 298 K and 318 K using the presat pulse sequence to suppress the
water signal.
2.7 Crystal structures of Hsp90-NTD and ligand complexes
We used the previously solved X-ray crystal structures of the Hsp90-NTD in
complex with 17-DMAG (PDB:1OSF) [115] and GVK0153 ligands
(unpublished data from AstraZeneca). Both structures are of reasonably high
refinement (1.75 Å for the 1OSF and 2.07 Å for the GVK0153 bound structure)
thus allowing the use of the co-ordinates for the molecular dynamics (MD)
simulations.
Ligand and protein contacts were analysed by the LigPlot programme using
the crystal structures [116]. The crystal structures (apo Hsp90-NTD and
Hsp90-NTD in complex with GVK0153 or 17-DMAG) were compared using
structural alignment algorithm in VMD software. Root mean square deviation
values between the structures were calculated, as well as the solvent
accessible and hydrophilic and hydrophobic surface areas with standard tools
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in VMD [117]. For surface area calculations, we used a standard 1.4 Å cut off
value.
2.8 Molecular dynamics simulations
2.8.1 Molecular dynamics packages used
The MD simulations on apo Hsp90-NTD, 17-DMAG:Hsp90-NTD and
GVK0153:Hsp90-NTD complexes were performed using GROMACS (v 4.6.5)
with the Amber ff99SB force field and TIP3P water model [118, 119]. The
ligand only simulations were run using Amber 14.
2.8.2 Supercomputing resources
The simulations were run on various supercomputers, including the ARC1,
ARC2 and Polaris machines in the Leeds High Performance Computing
facility. Computing time was also obtained from the national ARCHER
supercomputer as well as the BlueGene in the Hartree centre. Simulations of
the Hsp90-inhibitor system and of free ligands were run using graphical
processing units (GPUs) with Amber’s pmemd GPU optimised code [120].
2.8.3 Generating files for MD runs
Before the MD runs can take place, the co-ordinate files also need
accompanying parameters to describe the system. As the preparation of the
files can be complex especially when small molecules are also included in the
simulation, the workflow in Figure 2.4 shows an overview of the different steps
taken for MD file preparation and these different steps are described in more
detail below.
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Figure 2.2: Workflow for the production of the MD simulation files starting
from crystal structures, parametrisation to MD production runs.
2.8.4 Ligand parametrisation
Whilst the Amber force field contains the parameters for the protein, small
ligands need to be separately parametrised including assigning atom types
and partial charges before they can be used in the MD runs. For this, the initial
co-ordinates for the ligands were obtained from the X-ray structures
(1OSF.pdb and un-published GVK0153:Hsp90NTD structure file from
AstraZeneca). Hydrogen atoms were added to the crystal structures using the
Chimera software [121].
2.8.4.1 Generalised Amber force field
As the Amber ff99SB force field used for the protein does not contain all
parameters for small organic molecules, Amber tools package ‘Antechamber’
was used to generate the force field parameters for the ligands. The
Antechamber uses general Amber force field (GAFF), which contains extra
atom types and the corresponding parameters for bonds and angles to cover
small organic molecules. The parameters for the ligands were thus generated
Crystal
structures
• Xray structures used as starting structures to obtain co-ordinates for protein and
ligands for simulations
• Same 'protein' template for all simulations (1YET.pdb):
• VMD used to align Hsp90 backbone from 17-DMAG:Hsp90 and GVK0153:Hsp90
crystal structures & 'cut and paste' ligand co-ordinates to '1YET.pdb' file.
Parametrisation
• Prepare parameter files for protein and ligand
• Ligand: charges calculated with Gaussian-03, Amber Antechamber and Amber
Generalised Force Field (GAFF) for other parameters
• Protein: parameters generated using standard Amber force field (ff99SB)
• 'xleap' in Amber to combine ligand and protein topology files
• Generate simulation box, add water and ions with either Amber 'xleap' or
Gromacs 'grompp'
MD simulations
• Minimise structures
• Thermalise and equilibrate
• MD production runs
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by the Antechamber using the GAFF force field with extra input of files
containing partial charges for the ligands derived from Gaussian quantum
mechanical calculations as described below [81].
2.8.4.2 Calculating partial charges for the ligands
Whilst the Amber GAFF force field contains general parameters for bonds,
angles and dihedrals, the charges for atoms need to be calculated separately.
Here, the partial charges for the ligands were derived by using quantum
mechanical calculations using the Hartree Fock (HF) level of theory and the
6-31G* basis set, which allows the calculation of the electron densities around
the molecule. The restrained electrostatic potential (RESP) can be
constructed from these data and fed back into Amber to use in the
parametrisation. The HF/6-31G* has also been used to derive the ff99SB
Amber force field parameters and thus the ligand charges and rest of the force
field parameters will be compatible [119].
For the partial charge derivation, first the ligand (.pdb) files were converted to
xyz format that is compatible with the Gaussian-03 using Open Babel [122].
After this, the Gaussian-03 package was used to first optimise the geometry
of the ligands using B3LYP/6-31G*, which is a faster method to calculate
charges based on density functional theorem to calculate point energy of each
atom to allow finding a optimise geometry at local energy minimum [123]. The
geometry optimisation results were checked with tools in the Molden
programme after which the final configuration was entered back to Gaussian-
03 for calculation of partial charges using HF/6-31G* [124].
2.8.5 Preparing protein structure files
To ensure that the different simulations (i.e. apo, 17-DMAG:Hsp90-NTD and
GVK0153:Hsp90-NTD) could be compared, i.e. that any differences observed
were only due to ligand and not due to any differences in protein structures,
the protein co-ordinates from a single Hsp90-NTD crystal structure file were
used for all simulations. For this, the 1YET.pdb file was chosen to be used for
the protein co-ordinates. This structure is one of the first human Hsp90-NTD
structures in complex with geldanamycin [125]. For the apo protein, the
geldanamycin ligand co-ordinates were simply deleted from the file. For the
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two different ligands, a ‘docking’ approach was used. To ‘dock’ the ligands to
the Hsp90-NTD structure from the 1YET.pdb, the geldanamycin ligand was
removed by cutting out the co-ordinates corresponding to the small molecule.
Next, both the “apo-1YET” structure and the structures of 17-DMAG:Hsp90-
NTD (PDB:1OSF) [115] and GVK0153:Hsp90-NTD (unpublished data) were
opened with VMD and the protein structures were next aligned using the
structural alignment tool within the MultiSeq extension of VMD [117]. After
alignment, the new coordinates of the aligned structures were saved and the
ligand co-ordinates simply cut and pasted to the end of the 1YET-Hsp90-NTD
co-ordinate file and the atom numbers were corrected. The resulting structure
was visually inspected for correct location of the ligand.
2.8.6 Generating the starting structures for MD
Once the co-ordinate files were ready, the xleap tool in Amber was used to
generate the necessary files for the MD runs. Here the crystal structure co-
ordinates were read in together with the GAFF force field and library files for
the ligands as generated before and the ff99SB force field for protein to allow
the topology file generation for the complex. Next, the systems were
neutralised by addition of sodium counter ions and merged into periodic box
surrounded by ~45,000 water molecules. The systems were then minimised,
thermalised and equilibrated using standard protocol of initial 4 step structure
minimisation followed by 8 equilibration steps where the temperature is
increased in a step-wise fashion and non-water atoms are initially constrained
with the constraining forces slowly moved over number of steps [126]. The
final equilibrated structures were used to run 500 ns unrestrained MD
simulations with periodic boundary conditions at constant pressure (1 atm)
and temperature (298 K). Shake was used to constrain all bonds involving
hydrogen atoms with time step of 2 fs for integration of Newton’s equations
and a 12.0 Å cut off was used for non-bonded interactions. For replica
simulations, the same starting structures were used but the values for initial
velocity were assigned using the random seed generator in Gromacs. The
input files for the energy minimisation (em.mdp) and the equilibration steps
(md1.mdp, md2.mdp and md3.mdp) as well as the production MD input are
shown in Appendix.
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For ligand only simulations, the parametrisation and MD starting file
preparation was carried as above with the simulations run using Amber’s GPU
accelerated code.
2.8.7 Post-simulation trajectory file editing
After the simulation runs had completed, the solute (water and ions) were
stripped from the files and the protein was re-imaged (i.e. centre of mass
aligned to the centre of the simulation box) to remove the diffusion of the
complex around the simulation box. The frames for the first 15 ns
corresponding to the equilibration were removed using standard tools within
Gromacs and Amber. There were issues with Gromacs imaging commands
with the ligand-protein files as only the protein was centred and the ligand
seemed to ‘jump out’ of the protein binding pocket when the trajectory was
viewed. To get around these imaging issues, the trajectories were loaded into
the VMD programme and the ‘Align’ option in the ‘RMSD Trajectory Tool’
within VMD was used to re-image the Gromacs trajectories to centre both the
ligand and protein thus ‘get the ligand to stick in the protein pocket’. The re-
imaged trajectories were then saved to Amber file format with VMD [117].
2.8.8 Simulation data analysis
For the simulation data analysis, root mean square fluctuation (RMSF) of the
backbone Cα residues were calculated for each simulation. Next principal
component analysis was used to gain insight for the main motions of simulated
systems. For principal component analyses, which enables one to find out the
dominant molecular motions from the trajectory, we used the PCAzip
compression and analysis toolkit [93]. The PCAzip calculates the average
atom co-ordinates from the MD trajectory to get a co-variance matrix which is
diagonalised to get a set of eigenvectors with corresponding eigenvalues to
get the direction and amplitudes for the main motions in the simulation. These
files can also be converted to short animations to visualise the largest motions
and extreme structures of the simulated system.
We also calculated the entropies of the simulated systems using the Schlitter’s
quasi harmonic method [90]. For this, an in-house code ‘X2S’ to produce the
mass weighted co-variance matrix of atom positions that allows the calculation
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of maximum entropy was used. For the entropy calculations and the PCA
analysis the N- and C-terminal loops as well as the C-terminal part of flexible
helix 2 were removed to leave the globular core, to able the analysis of the
smaller amplitude movements of the protein.
2.9 Method optimisation and validation results
2.9.1 Protein production trials
Prior to any large-scale protein expression, expression protocol optimisation
trials were carried out. For this, small 25 ml cultures were grown as specified
in section 2.3.3, after which the expression of the plasmid encoded Hsp90-
NTD was induced with either 0.1 mM or 1 mM IPTG. The cultures were left to
grow at either 37°C for four hours or 30°C or 20°C overnight (see Table 2.1
for summary of the different conditions used). The protein yield from the
different temperatures and IPTG amounts was analysed by running a SDS-
PAGE gel and comparing the band intensities (Figure 2.3).
The 1 mM IPTG induction followed by 20°C overnight culture produced the
highest yield of the Hsp90-NTD, as seen in the induced band intensities in
SDS gels (Figure 2.3). This condition was thus adopted for the large scale
protein expression.
2.9.2 Protein expression yields
The yields of Hsp90-NTD from 500 ml culture in per-deuterated M9 media
were typically 1 ml of 300 μM (~7.2 mg) protein and about twice the amount
for bacteria grown in M9 media prepared in H2O. The protein was purified as
specified in Section 2.3.5. Figure 2.4 shows results of a typical purification
with the over expressed Hsp90-NTD on lane four, that contains fractions
eluted by 250 mM imidazole.
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Table 2.1 Protein optimisation trial conditions
Temperature after
induction (°C)
Amount of IPTG
(mM)
Growth time after
induction
37 1 4 h
30 1 Overnight
30 0.1 Overnight
20 1 Overnight
20 0.1 Overnight
Figure 2.3: Small scale expression trials using M9 media. 25 ml cultures of
E.coli containing the Hsp90-NTD containing plasmid were grown in M9
media until OD600 was 1.00. The expression of the protein was next
induced either with 1 mM or 0.1 mM IPTG (see Table 2.1) and the
culture were left to grow for 4 hours or overnight at different
temperatures as specified on the sample lane labels. The band around
26 kDa present in the induced cultures (labelled with ‘+ IPTG’),
corresponding to the Hsp90-NTD is indicated.
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Figure 2.4: Purification of the His-tagged Hps90-NTD using affinity
chromatography. The SDS-page gel shows results of a typical
purification using the HisTrap HP column. Lane 1 contains the total
cellular protein (i.e. sample that was loaded onto the column), lanes 2
and 3 show washes with increasing Imidazole concentration (10 mM
and 20 mM respectively). Lane 4 the eluted fractions (250 mM
Imidazole wash) which contains the majority of the over expressed
Hsp90 as indicated.
The Hsp90-NTD was stable in the presence of protease inhibitors at room
temperature for several days. This was tested by the 2D NMR NH TROSY
spectra that were recorded at the start and end of the several day long NMR
experiments. Both spectra were identical and did not show any sign of
presence of unfolded protein peaks (data not shown). The oligomerisation
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state of the Hsp90-NTD in the high concentration required for NMR (350 µM)
was not measured, we assumed that the protein was monomeric.
2.9.3 Inhibitor selection for in depth studies
We were interested in whether different inhibitors binding to Hsp90-NTD have
any effect on protein dynamics. As both in-depth NMR studies and MD
simulations require considerable time investment for each different protein-
ligand system, it was decided to concentrate on two different ligands. We
describe here how the two ligands were selected.
A panel of small molecules was used for initial studies. The main criteria for
selecting the compounds for the initial panel included the availability of crystal
structures of the human Hsp90 in complex with the ligand, to allow for
molecular dynamics studies. Additionally, we wanted to choose compounds
that have similar binding affinities but different entropic contributions to
binding. Finally, the compound of interest should be soluble enough in H2O
buffer in the absence of Hsp90. The initial set of six compounds (shown in
Figure 2.1) included geldanamycin [127], its derivative 17-DMAG [128],
radicicol [129] as well as three new nucleotide mimic compounds obtained
from AstraZeneca, named; CNF2024, GVK0153 and GVK0161.
Early studies on yeast Hsp90 demonstrated that the geldanamycin and
radicicol have very different entropic contributions to the Hsp90-ligand binding
signatures [130]. No prior thermodynamic data was available for the new
AstraZeneca compounds.
We conducted ITC experiments on all the compounds and recorded 2D
protein NH TROSY amide spectra of Hsp90-NTD in complex with the
inhibitors. Based on the initial biophysical characterisations using NMR and
ITC, 17-DMAG and GVK0153 were selected for detailed NMR and MD
analysis. The 17-DMAG molecule was chosen based on ITC studies, which
showed the binding to be entropically driven (results from ITC are shown in
Chapter 3). From the other ligands in the initial panel, GVK0153 and GVK0161
from the AstraZeneca compound library were shown to have a small entropic
penalty upon binding, thus differing from the 17-DMAG. The CNF2024 and
radicicol bound to Hsp90-NTD too tightly to be measured accurately with ITC,
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as the nanomolar affinities suggested by the data resulted in a slope that is
too steep for accurate Ka determination.
The 2D protein NH TROSY amide spectra of Hsp90-NTD in complex with the
different compounds were all well resolved. The spectra for the AstraZeneca
compounds were very similar, with only a few shifts in the protein backbone
peak. The GVK0153 ligand had a few different shifts in the peaks, compared
to GVK0161 and CNF2024 spectra, which could be of interest. This was the
reason for selecting the GVK0153 compound for further studies.
2.9.4 MD simulation benchmarking and optimisation
Long simulation times and multiple replica simulations are needed in order to
explore the conformational space adequately for entropy determination.
Therefore we optimised the molecular dynamics runs for trajectory data
generation speed. In the past, the Amber platform has been used by the Harris
group. However, since the Gromacs software has been coded to optimise the
data output, it was decided to conduct a benchmarking study to test the output
speed of Amber versus Gromacs platforms. For this, short simulations of the
apo-Hsp90 were prepared as specified in Section 2.8. These simulations were
run on both the Amber and Gromacs engines using the ARC2 computer with
a different number of central processing units (CPUs). The Hartree centre’s
BlueGene computer’s performance was also compared to the ARC2.
As the supercomputing resources are, in general, shared between different
users, there is a balance to be struck between requesting a large number of
computer cores and the queuing time for the simulations. Generally, less
cores equals shorter queue times. MD runs were thus submitted on ARC2
requesting 16, 32, 64 or 128 CPUs. These runs had queue times ranging from
few hours to few days, which was quite acceptable for our purposes. Both
Amber and Gromacs packages were used in the benchmarking study. From
this benchmarking, the best Amber run produced 4.5 ns/day on 32 CPUs
(Amber runs on a larger number of CPUs were slower). The best Gromacs
runs were obtained using 128 CPUs, achieving 30.4 ns/day. For production
runs, it was noticed that on ARC2, the best performance was achieved when
all the CPUs used for the calculation were on the same node, rather than using
any free CPUs in different nodes. When sole use of all CPUs in a node was
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requested, this dramatically reduced the time spent on communication
between the CPUs whilst performing parallel calculations. Here, the
performance increased from 30 ns/day to 100 ns/day when calculations were
carried out on a node. For Amber, a similar increase in simulation time was
achieved, when all the calculations were done in one node with the top
simulation speed around 20 ns/day. Table 2.2 shows a comparison of the
simulation data speed with optimised conditions. The BlueGene architecture
on the other hand was a lot slower with 50 ns/day obtained using four times
as many CPUs.
As the benchmarking study showed that Gromacs runs were nearly five times
faster than Amber, Gromacs use was adopted for the study. The simulation
speed gain, which is normally the bottle neck in computational studies, far out
weighted the time required for converting the Amber files to Gromacs format
and back to Amber for analysis.
Finally, we obtained some graphical processing units (GPUs) and tested these
with the GPU optimised Amber code. Here, the GPU speed was comparable
to the ARC2 supercomputer, where 2 GPUs produced the same speed as 128
CPUs on the ARC2. As the GPUs were for the sole use of the Harris group,
there was no queuing time. This makes the new GPU technology very
promising in terms of output speeds, whilst being very economical in
comparison to supercomputing.
Table 2.2: Optimised production MD simulation times
Computer MD engine Simulation speed (ns/day)
ARC2 Gromacs / CPU 100 ns/day (128 CPUs)
ARC2 Amber / CPU 20 ns/day (128 CPUs)
GPU Amber / GPU optimised 35 ns/day (2 GPUs)
BlueGene Gromacs / CPU 50 ns/day (512 CPUs)
2.9.5 Molecular dynamics simulations - replica data
In an attempt to cover as much conformational space as possible for entropy
calculations, around 80 replica simulations were run. The total amount of
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simulation time was 40 µs from these multiple replica simulations. Table 2.3
shows the number of replicas run for each different system.
Some of the simulations were sampled every 2 fs and these data were used
for in depth analysis of the dynamics of Hsp90-NTD. A larger number of replica
simulations were also ran with the aim of obtaining an estimate of how large
a conformational space a single simulation explores. This would enable us to
have some idea of the number of replicas, and length of simulations required
to get a realistic representation of the conformational space. Due to the large
number of simulations and thus data storage requirements, data from these
replica simulations were saved every 10 fs.
Table 2.3: Summary of simulation data and total trajectory time
Complex Simulation
length
Number of
replicas
Total simulation
time
apo Hsp90-NTD1 600 ns 3 ~1.5 µs
Hsp90-NTD:17-DMAG1 550 ns 3 ~1.5 µs
Hsp90-NTD:GVK01531 550 ns 3 ~1.5 µs
Hsp90-NTD:17-
DMAGs*
500 ns 50 25 µs
Hsp90-NTD:GVK0153* 200 ns 25 5 µs
Apo Hsp90-NTD* 75 ns 10 750 ns
1These simulations were sampled every 2 fs and were used for in depth
analysis of differences in Hsp90-NTD dynamics of different complexes
*These simulations were sampled with every 10 fs and used to estimate how
much conformational space is sampled with each replica
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Chapter 3
Characterisation of Hsp90 and inhibitor dynamics
The chaperone Hsp90 is a highly dynamic protein and it has been suggested
that the changes in the structure of the chaperone may influence the choice
of binding partners [48]. To investigate the role that dynamics play in Hsp90-
inhibitor interactions, we analysed experimental ITC and NMR data as well as
performing a computational analysis based on MD simulations.
ITC is often seen as the gold standard method for determining Gibb’s free
energy, enthalpy and entropy of binding, as well as the binding (and
dissociation) constant [53]. However, ITC only provides data on ‘global’
changes that include effects from protein, ligand and solvation. To understand
the structural mechanisms of binding, one needs to know the individual
contributions from the protein, the small molecule ligand and the solvent.
These need to be complemented with information about the atomistic changes
in protein and ligand structure and dynamics. We employed NMR and MD
data to obtain these atomistic details.
The results from different NMR techniques and MD simulations that report on
protein flexibility are presented and compared. These atomistic scale results
are also compared with the ITC data. The apparent discrepancy between the
overall entropy change upon binding (as reported by ITC) and the changes in
configurational entropy is discussed. The latter changes were indirectly
measured using changes in protein dynamics with NMR and MD techniques.
To attempt to rationalise this discrepancy, the effect of the possible changes
in the solvation structure is discussed.
3.1 Analysis of the inhibitor:Hsp90-NTD crystal structures
Crystal structures of both GVK0153 and 17-DMAG in complex with human
Hsp90-NTD have been solved and these show that both molecules bind to the
N-terminal ATP/ADP binding pocket ([115], unpublished data from
AstraZeneca). To better understand, and interpret, the thermodynamic data,
we performed a preliminary analysis of these protein structures by root mean
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square difference (RMSD) of the backbone atomic coordinates, by examining
the ligand-protein contacts, as well as by looking at the surface areas of the
protein molecules.
The general structure of the human Hsp90-NTD is globular, with a number of
alpha-helices surrounding a central cavity, where the ATP/ADP and inhibitors
bind (Figure 3.1). Beta-sheets make up the bottom of the binding pocket [125].
One of the edges of the binding pocket is a so called ‘lid region’, which is made
up of alpha helices 4 and 5. This region has been shown to be highly dynamic
and changes conformation upon ATP/ADP binding [50].
The backbone RMSD between the apo protein and the 17-DMAG and
GVK0153 Hsp90-NTD complexes was calculated by the VMD programme
[117]. The Hsp90-NTD:17-DMAG (PDB:1OSF) and :GVK1053 (unpublished)
complexes show very minor differences, with backbone RMSD of 0.75 Å
between the two structures. This RMSD difference is very similar to that
between the apo Hsp90-NTD (PDB:1YES) and the 17-DMAG:Hsp90-NTD
and GVK0153:Hsp90-NTD structures, which are 0.73 Å and 0.75 Å
respectively. The main difference between the 17-DMAG and GVK0153
bound proteins is the position of the loop 4 (L4), which connects the helices 4
and 5 within the lid region. The loop is orientated towards the binding pocket
in the GVK0153 bound structure and away from the pocket in the 17-
DMAG:Hsp90 complex (see Figure 3.1). As the 17-DMAG compound is about
twice the size of the GVK0153 compound (molecular weights of the two
compounds are 617 g/mol and 312 g/mol respectively). The orientation of the
loop is likely caused by the larger area the 17-DMAG occupies within the
binding pocket. Interestingly, this difference in the loop structure has also been
observed in the apo Hsp90-NTD ‘open’ and ‘closed’ structures (PDB: 1YES
and 1YER respectively). Here, the loop 4 orientation is either towards the
binding pocket for the ‘closed’ form or away from it for the ‘open’ form [125].
The loop orientation in the GVK0153 structure is similar to the apo ‘closed’
structure and the larger 17-DMAG protein is similar to the loop in the apo
‘open’ structure. In contrast, when Hsp90 is in complex with either ADP or
ATP, the loop is in the ‘open’ position (PDB: 1BYQ for the ADP bound
structure and 1TC0 for the Hsp90 ER paralogue in complex with ATP) [131,
132].
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The contacts between the ligands and protein were analysed using the LigPlot
software, which plots H-bonds and hydrophobic contacts [116]. Both ligands
interact with the same seven amino acids (Asn51, Ala55, Asp93, Met98,
Leu107, Phe138 and Thr184) within the binding pocket (Figure 3.2). The
ligands also make a number of ‘unique’ contacts with the protein. These are:
Ser52, Lys58, Asp54, Ile96, Asp 102, Asn106, Lys112, Gly135, Val136 and
Gly137 for the 17-DMAG ligand, and Leu103, Tyr139, Val150 and Trp162 for
the GVK0153 ligand. These unique contacts are located at the bottom of the
binding pocket for the GVK0153 ligand and around the top of the pocket for
the 17-DMAG inhibitor. Looking at the X-ray structures of the protein-ligand
complexes, it is evident that the GVK0153 ligand inserts deeply into the
pocket, whereas the larger 17-DMAG ligand sits closer to the top of the pocket.
The LigPlot analysis also suggests that for both ligands, most of the
interactions are via hydrophobic contacts. There is only one hydrogen bond
between the GVK0153 ligand and the Asp93 residue of the protein (Figure
3.3). The 17-DMAG ligand on the other hand makes four H-bonds; with
residues Lys58, Asp93, Phe138 and Thr184 (Figure 3.3.). The smaller
GVK0153 ligand has fewer contacts - to only 11 amino acids, compared to 17
different amino acid contacts made by the larger 17-DMAG ligand.
The contacts between Hsp90-NTD and its natural substrate ADP were also
analysed using LigPlot (PDB:1BYQ) [131] to allow comparisons. Here, the
nucleotide and the protein make the same contacts that were also shared
between both 17-DMAG and GVK0153 ligands; i.e. Asn51, Ala55, Asp93,
Met98, Leu107, Phe183 and Thr184, as shown in the Figure 3.2. There are
several additional interactions between ADP and Hsp90-NTD, that include the
residues Asn106, Val136 and Gly137. These are a subset of the contacts that
were unique to the 17-DMAG ligand. These residues are located on the top of
the binding pocket and indeed, ADP does not insert as deeply into the pocket
as the GVK0153 ligand. The ADP molecule forms three hydrogen bonds with
the protein; to Asn51, Phe138 and Asp93. There are no crystal structures of
human Hsp90 in complex with ATP, only of yeast Hsp90 or human
endoplasmic reticulum Hsp90 paralogue. These crystal structures, whilst
similar in terms of structure and sequence, are not identical to the human
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cytosolic protein. Thus the ligand-protein contact analysis, which would have
allowed direct comparison, could not be done.
The solvent accessible surface areas (SASA), which can been used to
estimate the solvation contribution to the global thermodynamics, were
calculated for the ligand:Hsp90-NTD complexes (PDB:1OSF and unpublished
AstraZeneca structure) as well as the apo protein ‘open’ and ‘closed’
structures (PDBs: 1YES and 1YER respectively) [133, 134]. As expected from
the RMSD analysis (which suggested high similarity between all the crystal
structures), the total surface areas are also similar, ranging from 10,197 Å2 to
10,868 Å2. The overall surface areas of the ligand bound structures are slightly
larger than that of the apo structures; a difference of 560-670 Å2 for the apo
and GVK0153 bound structures and 220-340 Å2 difference between the apo
and 17-DMAG:Hsp90-NTD complex. There is also a small difference between
the surface areas of the two ligand bound structures, where the GVK0153
bound structure is ~350 Å2 larger (see Table 3.1). The two apo Hsp90-NTD
crystal structures also differ slightly in their overall surface areas. Recall that
the two apo states are defined as ‘open’ and ‘closed’. The overall surface area
of the ‘closed’ structure is slightly larger. Similarly, the GVK0153 bound
structure surface area is larger than the 17-DMAG bound protein. As both
‘closed’ structures (apo Hsp90-NTD and GVK0153 bound protein) have
slightly larger surface areas, it is likely that the loop 4 orientation towards the
pocket increases the overall surface area.
The surface areas were divided further into hydrophobic and hydrophilic for
additional analysis. The nature of the surface area can affect the surrounding
water structure and thus play a role in entropy [135]. The hydrophobic surface
area of the GVK0153 bound protein is slightly larger than the 17-
DMAG:Hsp90-NTD structure (2,732 Å2 for 17-DMAG bound protein compared
to 3,010 Å2 for the GVK0153:Hsp90 complex). The hydrophilic surface areas
of the ligand bound structures are more similar (~60 Å2 difference). The
hydrophobic surface areas of the apo “open” and “closed” structures on the
other hand differ only by 10 Å2. The apo protein hydrophilic surface areas
follow a similar trend to the ligand bound protein, where the ‘closed’ loop 4
orientation results in a slightly larger hydrophilic surface area. Although there
are some differences in the overall, and hydrophobic, surface areas between
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the crystal structures, these are all very small (6-10%). They are unlikely to
have a large effect on the binding energy. However, the data from the surface
area analysis is used later in this chapter in an attempt to rationalise the role
that water plays in the overall binding reactions.
Figure 3.1: Crystal structures of Hsp90-NTD in complex with 17-DMAG and
GVK0153. Both inhibitors bind to the same nucleotide binding pocket,
that is located in the N-terminus of the protein, as can be seen in the
top panel. The residues that are involved in the binding interactions, as
predicted by LigPlot software, are coloured red in each protein structure
on top panel. It can be seen that the larger 17-DMAG ligand makes
more extensive contacts with the protein [116]. The loop 4 (L4), which
is coloured in blue in the top structures, also has different orientation in
the two different ligand bound complexes. When bound to the 17-
DMAG, the loop is away from the binding pocket (i.e. ‘open’) and in
contrast, the loop points towards the pocket in the GVK0153:Hsp90
structure (PDB: 1OSF for the 17-DMAG [115]; (structure from
AstraZeneca, data not published). The bottom panel shows a close up
of the amino acid contacts each ligand makes. It can be seen that the
amino acids involved in the binding of the smaller ligand, on the right,
are located towards the bottom of the binding pocket. The 17-DMAG
contacts are mostly on the top edge of the pocket.
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To summarise, the analysis of the crystal structures suggests that there are
very minor structural differences between the ligand bound complexes. The
crystal structure analysis data presented here is used later on in this chapter
to interpret MD simulation data and the solvent accessible surface area
estimations can help with interpretation of thermodynamic data from ITC.
Figure 3.2: Summary of the residues involved in binding interactions
between 17-DMAG and GVK0153 respectively, with the Hsp90-NTD,
as predicted by LigPlot [116].
Figure 3.3: Polar contacts shown as dashed green line between (A)
GVK0153 and Hsp90-NTD and (B) 17-DMAG and Hsp90-NTD as
predicted by LigPlot [116].
A
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Table 3.1: The protein surface areas (solvent accessible, hydrophobic and
hydrophilic) of the different crystal structures
Crystal structure Total surface
area (SASA)
(Å2)
Hydrophobic
surface area
(Å2)
Hydrophilic
surface area
(Å2)
apo Hsp90-NTD
“open” (PDB:1YES)
10,197 2,654 7,542
apo Hsp90-NTD
“closed”
(PDB:1YER)
10,311 2,644 7,667
17-DMAG:Hsp90-
NTD (PDB:1OSF)
10,532 2,732 7,800
GVK0153:Hsp90-
NTD (un-published)
10,868 3,010 7,859
B
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3.2 ITC experiments on 17-DMAG and GVK0153 binding to
Hsp90
Isothermal titration calorimetry (ITC) allows the determination of the
thermodynamic parameters for ligand binding (dissociation and association
constants as well as changes in Gibb’s free energy, enthalpy and entropy)
from a single experiment. ITC is a widely used technique in drug discovery
[53]. In this project, ITC was used to study the binding of 17-DMAG and
GVK0153 inhibitors to Hsp90-NTD. These measurements can be used to gain
insight into any differences between the ligands, and to obtain global
thermodynamic values. These values can be compared with those obtained
from computer simulations.
The ITC data showed that both ligands bind to Hsp90-NTD, as the isotherms
demonstrated that the Hsp90-NTD binding site became saturated upon
titration of a ligand (Figure 3.4). The dissociation constant for both ligands was
in the nanomolar range; 20 nM for the GVK0153 ligand and 54 nM for the 17-
DMAG ligand. The free energy change for the binding of the smaller GVK0153
ligand was -9.14 kcal/mol; the enthalpy change was -9.71 kcal/mol and the
TΔS° term was 0.625 kcal/mol (Table 3.2). The ΔG° for the 17-DMAG ligand 
on the other hand was -8.57 kcal/mol. The entropy term (TΔS°) was the larger 
of the two contributors to the overall free energy change with -5.66 kcal/mol,
compared to the enthalpy change of -2.91 kcal/mol for the 17-DMAG ligand
(Table 3.2).
Table 3.2: ITC binding data for 17-DMAG and GVK0153
ΔG° 
(kcal mol-1)
ΔH° 
(kcal mol-1)
-TΔS° 
(kcal mol-1)
N
17-DMAG:
Hsp90-NTD
-8.566±0.165 -2.906±0.110 -5.661±0.990 2.073±0.19
GVK0153:
Hsp90-NTD
-9.140±0.100 -9.766±0.160 0.625±0.180 0.759±0.04
(± errors are standard deviations between repeats)
68
Figure 3.4: Isotherms from the ITC experiments for the 17-DMAG and
GVK0153 ligands. Isothermal titration calorimetry experiments were
carried out to determine the thermodynamic parameters for the binding
of GVK0153 (left panel) and 17-DMAG (right panel) to Hsp90 N-
terminal domain.
The titrations of both inhibitors were carried out in triplicate. In general, the
ITC data were highly re-producible, as seen from Figure 3.5. The largest
standard deviation was 159 cal/mol in the enthalpy values between the
repeats, accounting for less than 2% of the total enthalpy value.
Whilst the ITC data were very reproducible, looking at the isotherms in Figure
3.4, it can be seen that the stoichiometry (n) is differs from the expected 1:1
binding constant for the 17-DMAG ligand. The stoichiometry value depends
on the accurate estimation of both the ligand and protein concentrations, as
well as the amount of active protein. However, the shape of the isotherm (‘flat
curve’ indicative of a small heat change) observed for the 17-DMAG is typical
for entropy driven binding. Additionally, crystal structures and other published
data suggest that there is only a single binding site for the 17-DMAG ligand.
Thus, we assume that the ligand and/or protein concentrations were
inaccurate, rather than the ligand interacting with two sites. This error in
stoichiometry does not change the thermodynamic parameters, and the
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overall binding signature where entropy contribution is the major component
to the overall binding free energy is still valid. This is because the heat change
upon titration of ligand is not affected by stoichiometry value. Similarly, a large
entropic contribution (~10 kcal/mol) to the binding affinity has also been
observed with 17-DMAG binding to the full-length Hsp90 [136].
Figure 3.5: The repeat ITC measurements gave very consistent enthalpy
(ΔH°) values, as seen from the graphs. The standard deviation for ΔH° 
values between the repeats was 110 cal/mol for the 17-DMAG and 159
cal/mol for GVK0153.
Now it is time to compare the two ligands. From the ITC data of Hsp90-
NTD:GVK0153 and Hsp90-NTD:17DMAG, it was apparent that whilst the
affinities are of a similar micromolar magnitude (dissociation constant Kd
values were 20±0.02 µM for GVK0153 and 54±0.09 µM for the 17-DMAG),
the two systems have different entropic contributions to the overall Gibb’s free
energy change (Figure 3.6 and Table 3.2). The binding of the smaller
GVK0153 ligand is entirely enthalpy driven. In contrast, for the larger 17-
DMAG ligand, the entropy term is the dominant contributor to the overall
binding energy.
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Figure 3.6: The binding signatures of GVK0153 and 17DMAG. Both
inhibitors bind to the Hsp90 chaperone with similar affinity. The Gibb’s
free energy change (ΔG) is around 9,100 cal/mol for the GVK0153 
ligand and 8,500 cal/mol for the 17-DMAG. However, the enthalpic and
entropic contributions to the binding affinity differ between the ligands.
The error bars show the standard deviations from repeat
measurements.
Our ITC data suggest that 17-DMAG and GVK0153 have different
thermodynamic binding signatures. This means that the ligands are likely to
have different binding mechanisms. However, it is not possible to obtain
mechanistic insights from these global ITC parameters. The affinity (Kd) and
Gibb’s free energy (ΔG) terms are straightforward to understand in terms of 
binding in drug design. Normally compounds with tighter binding are selected
for further development. The enthalpy and entropy terms on the other hand
are not as straight forward. Negative enthalpy values are caused by bond
formations resulting in the release of heat. The net ΔH° effect, as observed by 
ITC, is a result of a large number of bonds being formed and broken [135].
The entropy change is similarly complex. A negative value for the –TΔS° term 
(i.e. when ΔS° is positive) reflects an increase in the disorder of the system. 
This can arise from increase in the ligand and/or protein flexibility, or from the
release of water molecules to bulk solution. Thus, enthalpy and entropy terms
are difficult to interpret as it is not possible to separate the contributions from
the protein, the ligand and changes in solvation from the global ITC
-12000
-10000
-8000
-6000
-4000
-2000
0
2000
GVK0153+NTD 17DMAG+NTD
ca
l/
m
ol
dG
dH
-TdS
71
parameters. Indeed, the large difference of ~6,200 calories observed in
entropic binding signatures between 17-DMAG and GVK0153 (Figure 3.6,
Table 3.2), could arise from changes to the protein and ligand dynamics upon
complex formation, from solvent re-organisation due to the release of tightly
bound water to bulk solvent, or from changes to the burial of hydrophobic
residues [8].
In conclusion, the ITC data suggest that the binding of the larger 17-DMAG
and smaller GVK0153 ligands to Hsp90-NTD have different balance of driving
forces. 17-DMAG binding has larger entropic contribution, whereas GVK1053
binding is entirely enthalpy driven. These differences in the enthalpy and
entropy contributions to the overall binding signatures are not unique to Hsp90
ligands, but have been observed in many different systems [137, 138]. Whilst
the global values suggest differences in their binding mechanism, the
structural and molecular details cannot be obtained from the thermodynamic
data alone. To obtain mechanistic insights into the binding of these two
inhibitors, we used NMR and MD experiments, that allow the investigation of
the interactions in atomistic detail.
3.3 NMR experiments on Hsp90-NTD complexes
Chemical shift perturbation analysis was used to characterise conformational
changes in Hsp90-NTD, when in complex with the 17-DMAG and GVK0153
ligands. To characterise the changes in µs-ms dynamics upon ligand binding,
we employed CPMG relaxation dispersion experiments. As a preliminary step,
protein backbone assignments, in the presence and absence of inhibitors,
were obtained using previously published assignments for the apo Hsp90-
NTD as a starting point.
3.3.1 Hsp90-NTD backbone resonance assignments
The backbone assignments for apo and inhibitor bound Hsp90-NTD were
obtained using a TROSY versions of 3D triple resonance HNCA, HNCO and
HNcaCO experiments [109, 110]. These experiments were described in
Chapter 1.
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NMR backbone assignments of the apo state of the human Hsp90-NTD have
been obtained previously (BMRB code 7003) [61]. These assignments were
transferred to our apo Hsp90-NTD sample, which was prepared using similar
experimental conditions. We recorded a set of triple resonance spectra for the
apo Hsp90-NTD; all of them were well resolved. For the majority of the
residues, peak positions in our apo protein spectra matched the published
assignments. The original assignments included amide peaks for 152 out of
205 non-proline residues (there are total of 209 residues in the Hsp90-NTD
construct). Assignments were transferred for 145 residues. We could not
transfer assignments for seven residues (Ala27, Lys100, Leu103, Asn105,
Asn106, Met119, Asp157), most likely due to significant line-broadening
observed in the NMR spectra for these residues. Additionally, we identified
nine further residues (Thr65, Leu76, Ala166, Gly167, Thr176, Glu200, Gln212,
Phe213, Ile214). In total, we obtained assignments for 74% of the apo Hsp90-
NTD.
The sets of 2D HN TROSY, 3D HNCA, HNCO and HNcaCO experiments were
performed for the 17-DMAG:Hsp90-NTD and GVK0153:Hsp90-NTD
complexes. The 2D amide TROSY spectra of 17-DMAG and GVK0153 bound
Hsp90-NTD are overall similar to the spectrum of the apo protein (Figure 3.7).
Thus, the apo-protein assignments were used as a starting point to assign the
17-DMAG and GVK0153 bound Hsp90-NTDs. For the residues, which have
similar or identical peak positions in the spectra of the apo and the ligand
bound protein, backbone assignments were transferred from the apo protein.
These assignments were confirmed using HNCA spectra. Approximately 30%
of Hsp90-NTD residues experienced significant changes in peak positions
upon 17-DMAG or GVK0153 binding. The positions of the majority of the
shifted peaks differed between the two ligands (Figure 3.8). The majority of
shifted peaks were assigned using a set of 3D triple resonance experiments.
In total, we obtained assignments for 72% of the Hsp90-NTD:17-DMAG
complex and 64% for the Hsp90-NTD:GVK0153 complex. Figure 3.9 shows
the Hsp90-NTD structures, where the assigned versus un-assigned regions
for the two protein-inhibitor complexes, as well as for the apo-Hsp90-NTD are
highlighted.
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Figure 3.7: Superposition of the NH TROSY spectra of apo (black contours)
and 17-DMAG:Hsp90-NTD (red contours). Whilst the majority of the
peaks overlap between the apo and the 17-DMAG bound spectra, there
are also significant shifts in the peak positions for certain residues (see
Figure 3.7 below). This indicates structural changes. The cross peaks
are labelled for the apo state. The assignments for the crowded area in
the middle of spectra are shown in the insert underneath. Here, only
the apo peaks are shown for clarity. The 17-DMAG spectra was
recorded at 600 MHz magnet and 950 MHz magnet was used for the
apo sample.
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Figure 3.8: A zoomed in view of the NH TROSY spectra shown in Figure
3.6. The red contours correspond to 17-DMAG:Hsp90-NTD, blue
contours to GVK0153:Hsp90-NTD and black contours with labelled
peaks to apo Hsp90-NTD. The peaks, which shift their position upon
ligand binding, move differently in direction and in magnitude,
depending on the ligand. For example, the position of the blue and red
peaks next to residues G137 and T171 are different. The red peaks
corresponding to 17-DMAG bound protein move upwards and the blue
peaks corresponding to the GVK0153 bound protein move downwards.
The 17-DMAG and GVK0153 bound spectra was recorded at 600 MHz
magnet and 950 MHz magnet was used for the apo sample.
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Figure 3.9: The Hsp90-structures, showing the amino acids for which we
have obtained NMR assignments. The regions of the Hsp90-NTD that
were assigned are shown in blue. The grey colour indicates the
residues where no assignments were obtained.
3.3.2 Chemical shift perturbation analysis
To identify residues directly affected by ligand binding, we carried out
chemical shift perturbation analysis (CSP). This also identifies possible ligand-
induced long-range perturbations in the protein conformation [57]. The
chemical shift difference of Hsp90-NTD in the presence, and absence, of its
inhibitors enables the identification of residues involved in the binding
interaction. Additionally, long range perturbations may also be observed in the
residues that are located far from the binding site. For this study, the crystal
structures of Hsp90-NTD were used in combination with the CSP data to
identify the residues involved directly in the binding interactions. The crystal
structures also helped to identify the residues with long-range perturbations
located away from the binding site.
For the CSP analysis, the changes in peak positions upon ligand binding were
calculated as described in Chapter 1, using the following equation:
οߜ௧௢௧ = ඥሺοߜு )ଶ ൅ ሺͲǤͳͷͶοߜே )ଶ) (eq. 3)
To define statistically significant changes we used the following criteria:
residues with significant CSPs should have at least one of their amide
chemical shifts (i.e. ߜுor ߜே) larger than 0.06 or 0.6 ppm respectively. The
0.06 and 0.6 ppm values for proton and nitrogen chemical shifts correspond
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to two standard deviations, calculated from all CSPs observed upon ligand
binding [57, 139]. We also defined residues that had undergone large
changes as those with οߜݐ݋ݐ> 0.3 ppm. An example of the significant and non-
significant changes in the peak positions is shown in Figure 3.9.
Figure 3.10: Examples of the peaks, for a ‘non-significant CSP change’ (left
hand peaks) and significant CSP change (right hand peaks). The
significant changes were classified as either οߜ௧௢௧ of larger than 0.3
ppm, or ߜுor ߜேlarger than two corresponding standard deviations; i.e.
0.06 or 0.6 ppm respectively.
Using CSP analysis, significant and large changes were observed for 39 of
the 149 assigned residues upon binding of the 17-DMAG ligand. For the
GVK0153 ligand, this figure was changes in 50 of the 133 assigned residues
(Figure 3.10). As expected, most of the significant changes were observed in
the residues directly involved with the inhibitor binding (residues that are
coloured red the crystal structures in Figure 3.1). These residues were defined
as those that were within 5 Å of the ligand in the X-ray crystal structures [140].
About half of the residues that underwent significant chemical shift
perturbations were classified as long range perturbations, e.g. CSPs observed
for the residues located at least 5 Å away from the corresponding ligand.
These changes are coloured in blue in the crystal structures in Figure 3.11.
These CPSs indicate structural and/or dynamic changes in residues that are
not directly involved in the ligand interactions.
Similar long range chemical shift perturbations upon ADP/ATP binding to
Hsp90-NTD have also been observed in yeast Hsp90 [141] and also in human
Hsp90-NTD [50], as shown in the bottom panel of Figure 3.11. Interestingly,
H
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some of these changes occurred in the alpha helices that make up the ‘lid’
region of the protein (Ala111-Val136) (grey panel in Figure 3.11). This region
is known to be highly dynamic; no residues could be assigned in the apo
Hsp90-NTD spectra for the start of the lid region (residues 111-116). This is
often suggestive of flexible residues that are involved in microsecond to
millisecond motions, and thus too broad to be observed in NMR spectra. The
B-factors of the X-ray structures that can indicate atomic vibrations are also
higher for the two alpha helices making up the lid region [61, 125]. A previous
NMR study looking into Hsp90-NTD structure, when the chaperone is in
complex with ADP or ATP-mimic (non-hydrolysable AMPPNP), found that the
lid region structures differed in these complexes. The residues making up the
lid region were absent on the AMPPNP bound spectra, which the authors took
to be indicative of microsecond dynamics. These peaks were observed for the
ADP bound structure. This suggests that the ADP bound protein does not
undergo microsecond timescale dynamic changes [50]. From our data, this
seems to case for the 17-DMAG and GVK0153 complexes. As can be seen
from Figure 3.11, the smaller GVK0153 inhibitor causes more shifts within the
residues making up the lid region (highlighted with grey background in Figure
3.11), compared to the 17-DMAG inhibitor. For the GVK0153 ligand, seven
peaks disappeared upon binding, suggesting large changes in conformation
and dynamics. An additional two residues showed large perturbations. In
comparison, only three residues showed large perturbations in the 17-
DMAG:Hsp90-NTD complex within the same (Ala111-Val136) segment. This
suggests that the binding of the smaller inhibitor causes larger changes to the
protein structure, or dynamics, within the lid region.
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Figure 3.11: Amide backbone chemical shift perturbation analysis (CSP)
show changes in the peak positions both for residues making up the
binding pocket, as well as long range perturbations. (A) The histograms
of the CSP changes show per residue perturbations, where the red
bars are the residues with large (∆ߜ௧௢௧>0.3 ppm) or significant changes
(where at least one of the shifts, i.e. ߜுor ߜேis larger than two
corresponding chemical-shift errors; i.e. 0.06 or 0.6 ppm respectively).
The red circles indicate residues that disappeared upon ligand binding.
CSPs for individual residues were calculated using the differences in
the chemical shifts for backbone amide 1H (∆ߜு ) and 15N (∆ߜே ) using the
equation ∆ߜ௧௢௧ = ඥ(∆ߜு )ଶ+ (0.154∆ߜே )ଶ . The lid region (Ala111-Gly135)
is highlighted in grey in the histograms. This area is also circled in grey
in the 17-DMAG and GVK0153 bound structures. (B) The crystal
structures in panel A show the CSP changes upon GVK0153 and 17-
DMAG inhibitor binding. Here, the green colour indicates the residues
where significant CSP changes were observed and that are involved in
ligand contacts. The blue coloured regions are those were significant
CSP changes were observed in residues that are not involved directly
in the ligand interactions (further than 5 Å of the ligand). (C) In
comparison to small molecule inhibitor induced CSP changes, panel C
shows the CSP changes reported upon AMPPCP or ADP binding. Here
the changes are similarly observed both in the residues that are in
direct contact with the ligand (green colouring), as well as those not
involved in direct ligand interactions (blue coloured residues). The
bottom AMPPNP and ADP bound structures were adapted from [50].
3.3.3 Relaxation dispersion measurements
Are the differences in the CSP profiles caused by changes in protein
millisecond-microsecond dynamics? To further examine the differences in
CSP pattern observed in the ligand binding signatures, we used 15N relaxation
dispersion measurements (Carr-Purcell-Meiboom-Gill, CPMG [55]) on the apo
Hsp90-NTD and the protein in complex with the two ligands. This method can
report on protein dynamics (i.e. structural changes) in the micro- to milliseond
timescale as explained in Chapter 1. Intermediate or slow time scales were
thought to be relevant for the Hsp90, as broad peaks were observed in the
Hsp90-NTD spectra. Also, previous studies looking into the differences in ADP
or ATP complexed chaperone suggested that slower timescale motions,
rather than fast pico- to nanosecond ones, are relevant to the Hsp90-NTD
dynamics due to line broadening [50].
In our study, 15N CPMG relaxation dispersion profiles were measure for apo
Hsp90-NTD and the protein complexed with the two ligands. A total of 97
residues for the GVK0153 bound protein and 109 residues for the 17-DMAG
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bound and apo Hsp90 were used for our analysis. All these residues have
non-crowded peaks and thus, any change in peak intensities can be
unambiguously analysed. Relaxation dispersion profiles (Figure 3.12)
indicative of micro- to millisecond dynamics were observed for 17 residues,
located in multiple regions of the Hsp90 nucleotide binding domain. Examples
of the dispersion data plots are shown in Figure 3.13. The dispersion data
plots for all residues with micro- to millisecond dynamics are shown in
Appendix.
Micro- to millisecond timescale changes in structure were observed in both
apo and ligand bound proteins around the histidine 154, which is located in a
loop region in the N-terminal domain and middle domain interface of the
Hsp90 protein. Similarly, micro- to millisecond dynamics were observed for all
protein states for residues Glu158 and Asn155, which are close to the His154.
Additionally, for GVK0153-Hsp90-NTD complex, µs-ms dynamics was also
observed for Asp175 that is located close in space to His154 in the
GVK0153:Hsp90-NTD spectra. The peaks for this residue were located in
over-crowded regions of the 17-DMAG and apo spectra, so for these states
data are not available. These micro- to millisecond dynamics around His154
are likely to be reporting on the different protonation states of the His154
imidazole ring at pH 7.5, where depending on the orientation of the ring, the
H-bond pattern with surrounding residues is likely to differ.
Micro- to millisecond dynamics around His154 (His154, Asn155 and Glu153)
were observed for all the different protein states (apo and ligand-bound). This
suggests that the experimental conditions (including pH and temperature) in
the different samples were the same or very similar. Consequently, any
additional changes in µs-ms dynamics observed between apo and ligand-
bound states of Hsp90-NTD should report on ligand effects and are not
caused by small variations in pH, experimental temperature, protein
concentration, etc. between different samples.
In addition to His154 protonation, our analysis revealed several other regions
with micro- to millisecond dynamics (Figure 3.12). Moreover, we also
observed changes in the micro- to millisecond dynamics between different
ligand-bound states. One of these regions includes residues within and
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around the helices making up the lid region (Ala111-Gly135) (Figure 3.12,
residues around Ile34). These near-lid residues showing µs-ms dynamics in
the apo and GVK0153 bound state, but not in the 17-DMAG bound state.
These residues include Ile34, Ile43, Gly135, Val136, Ser164 and Ala166.
Residues Ile26, Ile128 and Ser129 were excluded from the analysis because
CPMG dispersion data were available only for the apo state, while no data
were available for either ligand complex (see Table 3.3).
Figure 3.12: Hsp90-NTD structures, where red spheres are highlighting the
residues for which relaxation dispersion profiles indicative of µs-ms
dynamics, were observed. All the complexes show µs-ms dynamics for
and around the His154 residue. The apo and GVK0153 bound proteins
additionally show dynamics around the lid region (residue Ile34 and
those surrounding it). These dynamics are absent from the 17-DMAG
bound structure. There are further two regions, where intermediate
timescale dynamics were observed; around Leu70 for the ligand bound
structures and the C-terminal residues (Ile206) for the 17-DMAG and
apo structures. No data were available for the Leu70 residue for the
apo structure and C-terminal residues for the GVK0153 bound protein.
These findings suggest that the lid became more rigid on the micro-to
millisecond timescale upon binding of the larger 17-DMAG ligand.
Interestingly, previous crystallographic data (Table 3.1) suggests that the
larger 17-DMAG ligand makes a contact with the glycine 135 and valine 136
[115]. No lid contacts with the smaller GVK0153 were observed (unpublished
X-ray structure data from AstraZeneca). Thus, we hypothesise that the Val136
interaction in the 17-DMAG:Hsp90-NTD complex stabilises the whole lid and
the surrounding region.
In addition to the residues located near His154 and the lid; residue Leu70
showed micro- to millisecond dynamics for both ligand bound forms (Figure
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3.12). Unfortunately, for the apo protein, the peak corresponding to Leu70 was
located in a crowded area and CPMG data for the apo state could not be
Figure 3.13: Examples of the CPMG relaxation dispersion profiles. The
His154 showed relaxation dispersion profiles indicative of µs-ms
dynamics for all complexes (left panel of graphs). In comparison, for the
Ile43 shown on the right, relaxation dispersion profiles indicative of µs-
ms dynamics were observed only for the apo and GVK0153 complex.
The 17-DMAG bound protein shows a flat profile for this residue. The
red data points correspond to data obtained from the 950MHz magnet
and the blue ones to data from the 600 MHz one.
analysed. Leu70 is located at the end of a long alpha helix (helix 2). The C-
terminal end of the helix 2 has no contacts with other parts of the Hsp90-NTD,
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and thus, enhanced flexibility is expected for Leu70. In line with these CPMG
results, our molecular dynamics simulations also show enhanced flexibility for
this region (see Section 3.6.2 below).
Dynamics on a µs-ms timescale were also observed for Ala101 in the absence
of ligands. No µs-ms dynamics were observed in the presence of 17-DMAG.
CPMG data were not available for the GVK0153 bound protein, as no Ala101
peak was found in NMR spectra for GVK0153 bound Hsp90-NTD. Ala101 is
located relatively close to His154 and the non-flat dispersion profile for Ala101
may be due to His154 protonation/deprotonation. Alternatively, Ala101
dynamics may be linked to micro- to millisecond dynamics around the lid area,
as Ala101 is located at the edge of the flexible region making up the lid [125].
Finally, residues Ile206 and Val222, located near the C-terminus, showed
non-flat relaxation dispersion for the apo and 17-DMAG bound proteins.
Unfortunately, these peaks overlap in the GVK0153 bound spectra and were
not included in the analysis. The observed micro- to millisecond dynamics for
these residues may be due to the fluctuation of the C-terminal part of the NTD.
In summary, the analysis of CPMG data revealed several regions in Hsp90-
NTD that are affected by micro- to millisecond dynamics. These include the
functionally important lid region. We found that for the smaller GVK0153 ligand
and apo protein there are lid fluctuations on the micro- to millisecond
timescale. In contrast, the larger 17-DMAG, which interacts directly with the
lid residues Gly135 and Val136, halts lid fluctuations.
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Table 3.3: Summary of the residues with observable relaxation dispersion
profiles.
Residue
number
apo Hsp90-
NTD
17-DMAG:Hsp90-
NTD
GVK0153:Hsp90-
NTD
Ile26 + no data no data
Ile34 + - +
Ile43 + - +
Leu70 no data + +
Ala101 + - no data
Ile128 + - no data
Ser129 + - no data
Gly135 - - +
Val136 + no data +
His154 + + +
Asn155 + + +
Glu158 + + +
Ser164 + - +
Ala166 + - +
Asp175 no data no data +
Ile206 + + no data
Val222 + + no data
(+) Relaxation dispersion observed (i.e. µs-ms dynamics) and (-) no relaxation dispersion
(i.e. no µs-ms dynamics)
3.4 Molecular dynamics simulations and flexibility
What kind of motions does the Hsp90 protein undergo? NMR is a powerful
technique, reporting on dynamic processes in atomistic detail. The results of
the NMR experiments tell us that something is happening, but not what. To
study the possible causes of the motions and changes in the structure
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observed by the NMR techniques, we ran 500 ns full atom molecular dynamics
simulations of the three systems (apo protein, and Hsp90-NTD in complex
with 17-DMAG or GVK0153) in triplicates.
3.4.1 Measuring flexibility using root mean square fluctuations
To start the MD data analysis, root mean square fluctuations (RMSF) of the
backbone Ca positions were calculated. The RMSF is used as a convenient
and quick method to quantify differences in protein flexibility between the apo
Hsp90 and the ligand bound protein. The calculation of RMSF of the protein
structures takes a matter of minutes, compared to a few days of computation
time for more complex principal component analysis. The fluctuations in the
Ca backbone atoms were calculated separately for each replica trajectory.
These data were combined to calculate the average fluctuation of a complex
with standard errors. The RMSF data were plotted as histograms, that show
per residue fluctuations for each system. These histograms are shown in
Figure 3.14. From the histograms it can be seen that the N-terminal and C-
terminal coil regions, as well as various loop regions within the protein, were
highly flexible, as expected for non-structured elements. Pairwise
comparisons of the RMSF values demonstrate that the apo structure is more
flexible than either of the Hsp90-ligand complexes studied. These data
suggest that the ligand-protein interactions stabilise the protein. Interestingly,
there were differences in the backbone flexibility when the protein was in
complex with the 17-DMAG compared to GVK0153 bound structure. Here, the
17-DMAG complex showed slightly higher fluctuations around two coil regions
(end of the long helix two and coil connecting helix 4 and 5). In comparison,
the residues making up the alpha helices in the lid region (around residues
110 to 135) were more flexible in the GVK0153 bound protein. These
differences are highlighted in the Hsp90-NTD crystal structure in Figure 3.15.
In the structure, the red coloured areas refer to the regions where the 17-
DMAG bound protein was more flexible. The blue coloured region correspond
to the areas of greater flexibility in the GVK0153 bound protein. The
differences observed in the lid region using the RMSF data agree with the
NMR relaxation dispersion measurements. In these, the 17-DMAG bound
protein did not have any µs-ms dynamics around this region but the
GVK0153:Hsp90-NTD complex did.
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Figure 3.14: RMSF of the Ca backbone atoms calculated from MD
simulations. The most flexible areas, seen as large bars in the graphs,
correspond to the N- and C-terminal residues as well as residues
making up loops and random coils.
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Figure 3.15: Hsp90-NTD structure coloured to highlight the regions of
greater flexibility, as observed in the pairwise comparison of the Ca
backbone of GVK0153 and 17-DMAG bound Hsp90-NTD by RMSF
analysis. The regions coloured as red correspond to the more flexible
parts observed in the 17-DMAG:Hsp90-NTD complex. The blue
coloured regions were more flexible in the GVK0153 bound protein.
3.4.2 Principal component analysis
The RMSF analysis showed that there were differences in the backbone Ca
flexibility between the apo and the ligand bound Hsp90-NTD complexes. To
analyse these movements further, we used principal component analysis
(PCA). For PCA, the Cartesian coordinates of atom positions from simulations
are converted into eigenvectors. The largest eigenvector corresponds to the
biggest movements. The power of the PCA method can be thought as “helping
to see the wood from the trees”. This is because the largest eigenvectors can
be used to analyse concerted motions, such as movements of alpha helices,
rather than attempting to make sense of the ‘wiggles and jiggles’ of individual
atom positions of unprocessed MD trajectory data. The PCAzip tool used in
this work also allows the generation of short animations illustrating the
movement of the molecule along the eigenvector of choice [93]. These movies
of the first few eigenvectors, that correspond to the motions with largest
amplitude, can be used to identify flexible regions of the protein, and to
visualise the motions.
As PCA reports on the largest fluctuations, removal of highly flexible regions,
such as the N- and C-terminal ‘tails’ may help the data analysis. This is
because the flexibility of these coils corresponds to thermal noise rather than
Helix 4
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functional movement. They may mask smaller, but potentially biologically
relevant motions. Therefore, both the N- and C-terminal ‘tails’ were removed
from the analysis, as the RMSF data showed that the flexibility of these
regions were several magnitudes larger than the rest of the protein. From
initial PCA visualisations, it was also apparent that the C-terminal end of the
long alpha helix 2 was very flexible. The bending of the helix 2 dominated the
first few eigenvectors and ‘hid’ other movements. As this helix was highly
flexible in all simulations, this region was also removed from data analysis.
This left a globular core for further in-depth analysis.
The PCA analysis carried out on the globular core of Hsp90-NTD showed that
the largest movement is that of helices 4 and 5, making up the lid region. We
used the PCA animations to view these motions. The PCA animations portray
the Brownian diffusive motions the protein undergoes during the simulations
as symmetrical motions. Viewing these animations, the helices 4 and 5 seem
to undergo concerted movements that are ‘seesaw’ like, i.e. periodical
fluctuations back and forth. These fluctuations are larger in the apo Hsp90-
NTD and in the smaller GVK0153 bound protein, compared to the 17-
DMAG:Hsp90-NTD complex. These movements are shown in Figure 3.16,
where the different frames of the Hsp90-NTD PCA animation have been
superimposed. The PCA data ranks the apo and GVK0153 bound HSP90 as
being more flexible than the 17-DMAG bound protein. Although the timescales
between the MD simulations and NMR CPMG analysis differ (500
nanoseconds of simulation data compared to micro- to millisecond dynamics),
this PCA data is in agreement with the NMR relaxation dispersion results.
Here, the 17-DMAG:Hsp90-NTD complex did not show any µs-ms dynamics
in the lid region. This is in stark contrast to the apo and the GVK0153 bound
protein.
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Figure 3.16: Hsp90-NTD structures showing the superimposed frames from
PCA animations of the largest eigenvector movements for the apo and
ligand bound Hsp90-NTD. The time steps are coloured from blue to
red, and wider lines indicate larger movements. It can be seen that the
apo protein movements are largest, and 17-DMAG:Hsp90-NTD
complex is the least flexible.
3.4.3 Can crystal structures help to explain why the 17-DMAG
bound protein is less flexible?
Both NMR and MD simulations suggested that the lid region of the 17-DMAG
bound Hsp90 is less flexible, compared to the apo and GVK0153:Hsp90-NTD
complex. To try to pinpoint the potential cause for the differences in flexibility,
we returned to the crystal structure analysis. The contacts between the two
ligands and protein were analysed using LigPlot, as explained in Section 3.1
and shown in Figure 3.2 and Figure 3.3 [116]. The LigPlot analysis shows
that the 17-DMAG ligand interacts with the lid residues Gly135, Val136 and
Gly137. On the other hand, the smaller GVK0153 ligand, which inserts deeper
in the binding pocket does not interact with these or any other lid residues. In
line with this observation, the NMR CSP data show that there are also large
CSPs for these residues in the 17-DMAG bound Hsp90-NTD compared to the
apo protein (Figure 3.11). As the helices around the lid region move as one, it
is likely that the contacts between the 17-DMAG and the protein residues 135
to 137 prevent the movement by providing a counter force against the
“seesaw” like motion that was seen in the apo and GVK0153 bound protein.
Helix 2
Helix 4
Helix 5
90
3.5 NMR experiments for characterisation of isolated ligands
As well as characterising the Hsp90-NTD protein dynamics, we had also
hoped to analyse the changes in the ligand dynamics upon binding to the
protein. This would have allowed a more comprehensive view of what is
happening to the configurational entropy of the whole system upon complex
formation. To initially examine ligand dynamics, we used NMR. One
dimensional hydrogen spectra of the ligands in in aqueous buffer (10 mM KPi,
50 mM KCl, 0.02% NaN3, 5 mM MgCl2 and 5 mM DTT in D2O) was recorded.
Our preliminary analysis of 1H experiments on small molecule ligands suggest
that the quality of NMR data is not enough for detailed dynamic analysis. For
the larger 17-DMAG spectra, very poor signal to noise ratio was observed
(Figure 3.17) because of line-broadening. This was most likely caused by
unspecific aggregation of the isolated ligand in water, even though no
aggregates were observed in sample tubes. The spectra quality did not
improve with use of different temperatures or ligand concentrations (data not
shown). Due to the poor ligand only spectra on the isolated 17-DMAG
inhibitor, no further NMR experiments on the 17-DMAG ligand were possible.
The smaller GVK053 ligand 1D spectra on the other hand looked promising
for further studies. However, data from both ligands in isolation and in complex
with the Hsp90-NTD would be required for the comparison of the two systems.
As the 17-DMAG ligand was not suitable for further experiments, no further
studies were conducted on either of the compounds.
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Figure 3.17: Example of NMR 1H spectra of ligands. The smaller GVK0153
compound spectra has sharp peaks as expected for small molecules
(above spectra). The larger and more hydrophobic 17-DMAG spectra
shown below has broad peaks. Thus this compound is not suitable for
further NMR studies on ligand dynamics.
3.6 Comparing the ITC data and results from NMR and MD
Both the NMR and MD data suggest that the binding of the larger 17-DMAG
ligand makes the Hsp90 protein less flexible compared to the apo and
GVK0153 bound chaperone. The ITC data on the other hand showed that the
17-DMAG ligand binding has large entropic contribution. As entropy gain is
normally associated with increased disorder, at a first glimpse, it seems that
ITC results do not agree with the atomistic scale investigations.
Thermodynamic values from ITC provide information on the combined effect
of changes in the protein, the ligand, as well as the water molecules. This
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means that any comparison of the ITC results with the atomistic details of
protein flexibility is not comparing ‘like with like’. The total entropy change from
ITC includes contribution from water, ligand and protein. Furthermore, the
global entropy changes arise from rotational and translational movements, as
well as internal changes reflected in the configurational entropy term, as
shown by equations 16 and 17 below.
∆ ௧ܵ௢௧௔௟= ∆ ௪ܵ ௔௧௘௥+ ∆ ௣ܵ௥௢௧௘௜௡ + ∆ ௟ܵ௜௚௔௡ௗ (eq. 16)
∆ (ܵ௪௔௧௘௥/௣௥௢௧௘௜௡/௟௜௚௔௡ௗ) = ∆ ௥ܵ௢௧+ ∆ ௧ܵ௥௔௡௦+ ∆ ௖ܵ௢௡௙ (eq. 17)
Whilst it is not possible to separate the contributions, or to assign a magnitude
that the protein, ligand or water make to the overall entropy change using ITC
data alone, we tried to measure the heat capacities of the complexes. The
structural information was also used to qualitatively assess the potential
causes for the apparent discrepancy between the atomistic and ITC data.
3.6.1 Can heat capacity measurements help to solve solvation?
The heat capacity (Cp) value, can be used to aid the understanding the role of
water in the binding reaction. To obtain heat capacities, ITC measurements
are performed for a range of temperatures, to obtain enthalpy values as a
function of temperature. These values can be plotted to obtain the heat
capacity from the slope of the plot. A popular model, derived from protein
folding and unfolding studies, links the changes in the heat capacity to
changes in the polar and non-polar surface areas [135, 142]. Here, the burial
of nonpolar residues during folding leads to a decrease in the ΔCp value due
to the displacement of water with the magnitude of heat capacity change being
proportional to the change in the surface area [143]. Although this surface
area model for explaining heat capacity data does not always work with the
small magnitude changes observed upon ligand binding, perhaps as the
model links the changes in thermodynamics exclusively to solvation effects,
the method is still in use [135, 144]. Another technique relating the role of
water contribution using ΔCp measurements, is to repeat the experiment in
“normal” (H2O) and heavy water (D2O). As the deuterium bonds are stronger
than the hydrogen bonds, the difference in the heat capacities in otherwise
identical systems should be solely linked to the change in the bond strengths.
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This difference can be used to work out the contribution of water to the
enthalpy change. Few studies have been completed using this method and it
has been suggested that the water re-organisation accounts for 25-100% of
the enthalpy change in binding reactions, depending on the system [145].
To obtain an experimental value that would allow comparisons with the
qualitative estimations of the effect of water to ligand binding to Hsp90-NTD,
ITC measurements at different temperatures were carried out to obtain the Cp
values for the two ligands. These measurements were done initially in ‘normal’
H2O buffer.
The ΔCp for the GVK0153 binding to NTD was negative (-173 cal K-1 mol-1),
as can be seen from Figure 3.18, which is typical for small ligand binding
reactions. Unfortunately, the change in heat capacity for the larger 17-DMAG
could not be determined. This was because the changes in enthalpy values
for the lower concentration of the 17-DMAG ligand used for the ΔCp
measurements (compared to the ITC measurements reported earlier) were
too small to be accurately measured at all but the highest temperatures. Due
to this, no comparisons could be carried out for potential magnitude of
solvation changes upon binding of the two different ligands using ITC.
Figure 3.18: Heat capacity change for GVK0153 binding to Hsp90-NTD
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3.6.2 Desolvation effect – general theory
As the heat capacity measurements did not manage to produce results to
compare the role of water in the binding of the two ligands, we attempted to
rationalise this from theoretical point of view.
The effect of water is often thought to be the dominating component in the
overall entropy change [146]. This is partly explained by the vastly larger
number of water molecules compared to atoms making up the protein and the
ligand. In the simulations of ligand bound Hsp90-NTD that were run as a part
of this study, the ligand-protein complex accounted for only ~4,400 atoms out
of a total 45,000 atoms. However, only the water molecules that change state
matter for the water entropy. These are the water molecules that were part of
hydration shell surrounding the molecule which get released to bulk water
upon binding, or vice versa bulk water molecules that becomes more ordered
hydration water. Again, given the sheer number of water molecules in a
simulation, the state of each individual water molecule is very difficult to
measure during the cause of the simulation.
The effect of water on the binding reactions can be thought of in terms of
surface areas. Here the size, the shape and polarity matter. The general
assumption is that a water molecule in bulk solution has larger entropy
compared to the hydration water, which is the water making up the solvation
shell around the solute. The hydration water that surrounds the solute also
interacts with the solute, and thus have reduced movement. With regards to
surface areas, generally speaking, the bigger the area of solute (here a ligand
and/or protein), the larger the entropic gain upon binding. This is because the
water molecules surrounding the solute are released to the bulk solvent [147].
The nature of the solvent groups also matters. Both NMR and MD studies
have demonstrated that water molecules around polar and nonpolar groups
have different decay times (i.e. how long a water molecule is ‘attached’ to one
place). This suggest that the solvation shell structures differ between the polar
and nonpolar groups [148]. This effect can be explained by changes in the
hydrogen bond network. Near to hydrophobic surfaces, water molecules form
hydrogen bonds with the neighbouring water molecules, rather than with the
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solute. This pulls water away from the surface of the solute. This model was
justified by a recent molecular dynamics simulation study, which showed that
the water molecules around a non-polar solute adopt more structured
tetrahedron structures with slightly larger number of hydrogen bonds [149].
This would lead to a decrease in the entropy of water. Polar groups on the
other hand participate in the hydrogen bonding with water and this causes
water to adopt a different structure. MD studies have suggested that the decay
times differ around polar and non-polar groups. The average decay time for a
water molecule up to 3.2 Å away from a polar group is 100 ps, compared to
50 ps decay time of water within 4.5 Å of a hydrophobic group. [150]. This is
because water around polar groups is bound into favoured positions, with
hydrogen bonds between water and the polar surface, resulting in a decrease
in entropy.
3.6.3 Desolvation of ligands upon binding
To enable the examination of the effect of desolvation of ligands upon binding,
the surface areas of the ligands were analysed. Recall that the size and
polarity of the solute surface areas can be related to the changes in the water
structure. These changes in the water is one of the contributors to the overall
entropy change upon binding.
The 17-DMAG ligand is nearly a third larger than the GVK0153 molecule; its
solvent accessible surface area is 845.6 Å2 compared to 508.5 Å2 of the
GVK0153 ligand. The larger 17-DMAG ligand is also more hydrophobic; the
computationally predicted logP (‘lipophilicity’) and logS (‘solubility’) values for
the 17-DMAG are 1.84 and -4.47, respectively, compared to logP of 1.00 and
logS of -3.00 for the GVK0153 inhibitor [151]. The larger surface area and the
greater hydrophobicity values suggest that there is a more favourable entropy
gain with the larger ligand binding to the Hsp90-NTD due to the release of
hydration water to bulk solution compared to smaller GVK0153 ligand. This
release of water would contribute to the overall binding entropy, and agree
with the entropically driven binding signature of the larger 17-DMAG ligand
(more water being released by 17-DMAG desolvation compared to the
desolvation of the smaller GVK0153 ligand).
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Looking at the polarity of the two ligands, the larger 17-DMAG, whilst being
more hydrophobic in general, has seven oxygen atoms that can act as
hydrogen bond acceptors, compared to only one in the GVK0153. Hydrogen
bonding between the water molecules and the solute, here the ligands, will
increase the structure of the water. A simple model for analysing the
magnitude of potential entropy change upon moving the ligand from solute to
a binding pocket was recently suggested (Richard Henchman, personal
communication). The release of a bonded water molecule to bulk solution
upon ligand binding is estimated to be around -1.7 J K-1 mol-1 [152]. Hydrogen
bond formation with the solute would have an effect of 5 surrounding water
molecules [152, 153] . Based on these numbers, the entropy change, due to
release of water, could be calculated using:
∆ ௪ܵ ௔௧௘௥ = −1.7( ௪݊ ௔௧௘௥− 5 ு݊௔) (eq. 18)
,where ௪݊ ௔௧௘௥ is the number of waters in the hydration shell and ு݊௔ the
number of H-bond acceptors. Using this method, the rough estimates for
ΔSwater upon binding of 17-DMAG (i.e. due to release of solvent) is -142.8 J K-
1 mol-1 and -108.8 J K-1 mol-1 for GVK0153 (109 water molecules, 5 acceptors
for the 17-DMAG and 69 water molecules, 1 acceptor for GVK0153). These
figures equate to ~10.2 kcal/mol ΔSwater for 17-DMAG and ~7.8 kcal/mol for
the GVK0153 ligand at 25°C. The larger 17-DMAG ligand desolvation has a
larger entropically favourable signature, agreeing with the ITC data.
In conclusion, looking at the surface areas and the hydrogen bonding, both
effects would result in gain in entropy from release of structured water upon
binding. This effect is larger for the 17-DMAG ligand, i.e. the desolvation of
ligand is enhancing the entropic contribution to binding signature. The
increase in entropy from desolvation of ligands is likely to counteract some of
the loss of entropy due to ‘stiffening’ of the protein when in complex with the
17-DMAG, thus helping to rationalise some of the ITC data.
3.6.4 Protein solvation
The change in the Hsp90-NTD shape upon ligand binding, as suggested by
NMR chemical shift perturbation analysis, will also have an effect on the
surrounding water structure. The surface areas of the Hsp90-NTD crystal
structures (apo protein and 17-DMAG and GVK0153 bound Hsp90) were
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analysed in Section 3.1. This analysis showed that binding of either ligand
increases the protein surface area, which would equate to entropic penalty,
as the solvation shell is slightly larger. However, the 17-DMAG bound Hsp90-
NTD structure is around 340 Å2 smaller compared to the GVK0153 bound
protein. This means that the entropic penalty is smaller for the 17-DMAG
binding interaction. To try to quantify this difference, a diameter of a water
molecule is approximately 2.75 Å2. The difference between the two ligand
bound structures would be maximum of 124 water molecules, assuming the
water molecules are tightly packed [154]. Based on the surface areas, the
entropic penalty due to increased protein solvent accessible surface area
upon ligand binding would be larger for the GVK0153 bound structure, as it
has larger surface area compared to the 17-DMAG bound protein. This implies
that the 17-DMAG binding to Hsp90-NTD has a smaller entropic penalty
compared to the binding of GVK0153. However, the estimations here do not
take into account of release of water from the binding pocket of the apo protein
upon ligand binding, which would counteract some of the entropic penalty of
increased surface areas. ‘Cavity water’ has been described as being ‘more
structured’ than hydration shell water, thus lead to larger entropic gain upon
release [155].
To summarise, the ligand desolvation should cause a favourable entropy
effect upon binding and the effect is larger for the 17-DMAG ligand. Similarly,
the changes in the protein surface area are smaller with the 17-DMAG
complex formation, compared to GVK01053 structure. It is also likely that
there will be some favourable contribution to overall entropy from release of
the water from the ligand binding pocket. Thus the combined effect of the
desolvation is likely to counterbalance the configurational entropic penalty of
the 17-DMAG binding that makes the protein less dynamic.
Finally, to get a feeling of the magnitude of the difference the water may play
to the overall entropy values from ITC, we performed the following ‘back of the
envelope’ calculation. The difference between the entropic signatures of the
GVK0153 and 17-DMAG binding as measured by ITC was ~6,300 cal/mol,
which seems quite large. The release of one solvent molecule to bulk solution
has been estimated to contribute between 2 to 7 cal mol-1 K-1 [156]. When the
entropic difference between the two ligands is converted to the same per
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degree of Kelvin units, the difference of the entropic values between the two
ligands is 21 cal mol-1 K-1 (6,286 cal/mol divided by 298.15 K). This difference
would convert to three to ten more water molecules released to bulk solvent
by the larger ligand. Additionally, a smaller increase in protein surface area for
the 17-DMAG:Hsp90 complex compared to the GVK0153:Hsp90 complex
should also contribute into the experimentally observed differences in the
entropic contributions between the two ligands. Altogether, the apparent
discrepancy in entropic signatures as measured by ITC compared to the
changes in protein flexibility does not seem as alarming. These data suggest
that for Hsp90-ligand binding, the solvation contributions into the entropy of
binding are significantly larger than the contributions from the changes in
protein dynamics. We believe that these results will help to develop better
small molecule inhibitors for the chaperone as we now have a better
understanding of the relationship between protein dynamics and the
thermodynamic binding signatures.
3.7 Conclusions
The Hsp90 chaperone is known to be a dynamic protein. We have shown that
the dynamics of the chaperone can be altered by small ligand inhibitors, but
the effect of water is still the dominating factor in binding of ligands. For the
protein dynamics, in particular the lid region dynamics were different when the
protein was in complex with the larger 17-DMAG inhibitor, compared to the
smaller GVK0153, with the larger inhibitor suppressing the dynamics of the lid
region. The differences in the dynamics were seen both by NMR relaxation
dispersion techniques and from simulation data, where molecular flexibility
was analysed using RMSF and PCA. This is promising, as it can mean that it
is possible to use simulations to predict dynamic behaviour of a drug target.
This could inform which compound should be taken for further testing and
development in the wet lab.
The global thermodynamic parameters, obtained from ITC experiments,
however, suggest that for Hsp90, protein dynamics provide only a minor
contribution to the binding free energy. On the contrary, effects from water
molecules (i.e. solvation and desolvation of the ligand and protein upon
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binding) overcome the protein dynamic contribution and drive the binding
reaction. Indeed, the global thermodynamic parameters did not reflect the
decreased dynamics (configurational entropy penalty) of the 17-DMAG bound
protein, as the total entropy change as measured by ITC was favourable for
the system. Thus, the overall effect was likely to be caused by changes in
solvation structure that masked the changes in protein flexibility. This
highlights the issue with the use of global entropy values, which include
configurational changes as well as rotation and translation of all molecules in
the system to validate the changes at the atomistic level in only one
constituent of the system (here the protein configurational entropy). The end
goal, whether it is to optimise the binding free energy, or to further understand
the changes in flexibility of the molecule under study, will dictate the choice of
methods.
The Hsp90 chaperone has been a notoriously difficult target for
pharmaceutical development due to various toxic effects. This is presumably
due to its role in helping the maturation of over a hundred different clients. Our
results suggest that manipulating the configurational dynamics of the
chaperone by small molecules could help to select only a certain subset of
targets. However, the results presented here are preliminary and further
studies are needed to see if the changes seen in NTD dynamics do have an
effect in the context of full length protein. Further, it should be checked
whether the dynamic changes caused by the inhibitors have any effect for co-
chaperone recruitment. However, understanding the differences in dynamics
caused by the different inhibitors may lead to a more targeted drug design
approach.
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Chapter 4
Multiple replica MD simulations and configurational entropy
The results presented in the previous chapter showed that the NTD of Hsp90
has different dynamics when it is in complex with different ligands. To
understand what the differences in the dynamics mean, in terms of
configurational entropies, this chapter focuses on configurational entropy
calculations, and exploration of the conformational space, using molecular
dynamics simulation data. For this, data from multiple replica simulations were
used (50 replicas of 17-DMAG:Hsp90-NTD complex and 25 replicas for the
GVK0153:Hsp90-NTD complex, totalling 25 µs and 5 µs of trajectory data
respectively).
The configurational entropies can be used to quantify the changes in flexibility.
We compute the configurational entropies from the different simulations using
the quasi-harmonic approximation (QHA) approach to check on the
robustness and suitability of this approach for the NTD of Hsp90 protein. The
entropies are calculated using both the more frequently sampled simulation
data of apo, 17-DMAG: and GVK0153:Hsp90-NTD systems (that were used
in the data analysis in Chapter 3), and the large, not so frequently sampled,
replica dataset. This allows us to explore one of the issues with configurational
entropy calculations - the more data, the larger the entropy. We also attempt
to answer the question “How much simulation data are needed to adequately
sample the conformational space?”.
4.1 Issues with configurational entropy calculations
Molecular dynamics simulations provide information on the flexibility and
structural heterogeneity of macromolecules. When MD simulations are run for
long enough to adequately sample the conformational space, the trajectory
can be used to find the number of microstates (Ω) a system can adopt with 
the probability (pi) of finding it in a particular microstate. This information can
be used to estimate entropy [88]. Configurational entropy computations using
simulation data have been attempted nearly as long as molecular dynamics
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simulations of macromolecules have been run. However, there are still major
issues relating to the entropy estimations from simulation data, some of which
will be explored in this chapter.
One of the main issues in obtaining configurational entropy from simulations
relates to sampling, where finite simulation data is used in an attempt to obtain
an entropy for nearly infinite phase space. For this we use replica simulation
data to try to answer the question of how much sampling is enough, even if
full convergence cannot be achieved.
Secondly, whilst the molecular dynamics force fields have improved over the
years, and shown to produce comparable data to experimental NMR results,
the methods in use to calculate entropies have not undergone similar
development [81, 89]. The two main methods currently in use for calculating
configurational entropies from simulations are the quasi-harmonic approach
(QHA) and the histogram based method, which were introduced in Chapter 1
[89]. Both of these methods have limitations. The histogram method, where
the dihedral bond rotations are normally used to define different states, has
been successfully applied to small molecules and more recently also to
peptides and proteins [96, 157]. However, this approach tends to have
convergence issues with complex systems. Furthermore, the choice of bin
sizes, where the bins are used to define what constitutes a different state,
rather than fluctuations within a state, remain problematic. Moreover, in the
histogram method, traditionally only internal bond rotations are used as co-
ordinates. This means that only rotational movements are considered, and
any vibrational movements from bond stretching are ignored. As a result, the
entropy values from the histogram method can be significantly underestimated
[89].
On the other hand, the quasi-harmonic approach (QHA) uses Cartesian
coordinates to calculate the fluctuations of the macromolecule in order to
obtain the probability distribution required for entropy computations [89]. This
approach takes into account both bond rotations and vibrations. However, the
QHA method often overestimates entropies, as it is assumed that the different
motions are independent. The main assumption behind QHA is that the
molecule of interest resides in, and oscillates around, a single large energy
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well, which can be described by a Gaussian-like distribution. As a result, the
QHA does not work for flexible molecules, which have an energy landscape
with multiple energy minima. Nevertheless, this approach has been
extensively tested, and shown to work for larger systems such as proteins and
DNA [91, 158] [90].
To further examine some of these issues with configurational entropy
calculations using simulation data for relatively large dynamic protein systems,
we ran multiple replica simulations of the NTD of Hsp90 model system. The
overall aim is not to extensively test, and compare, the configurational entropy
values obtained by the QHA method with other methods. Instead we want to
test its suitability for Hsp90. The effect of simulation time and sampling of
conformational space is also explored to see how it affects the convergence
of entropy calculations.
4.2 Can the quasi-harmonic approach be used for Hsp90-
NTD?
One of the key assumptions for the configurational entropy calculations using
the quasi-harmonic approach is that the system resides in a single energy
well, where it oscillates around the average structure. Whilst the harmonic
oscillator model describes well the movements of more rigid molecules such
as DNA, proteins are expected to have a rougher energy landscape containing
multiple minima, and any larger structural re-arrangements will break the
applicability of the model [159]. To test the suitability of the QHA entropy
computation for the Hsp90-NTD system, configurational entropies of the 500
nanosecond long replica trajectories of apo Hsp90-NTD and 17-DMAG or
GVK0153 complexed protein were computed. These data are the more
frequently sampled set of trajectories, which was used for the analysis of
protein flexibility in Chapter 3 (i.e. three ~500 ns long trajectories of each apo,
17-DMAG and GVK0153 bound Hsp90-NTD, see also Table 2.3).
As shown in Chapter 3, PCA analysis of the MD data revealed differences in
the protein dynamics between the different Hsp90 conformations. Moreover,
these computational results are in good agreement with our NMR analysis.
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The differences in dynamics can be used to make a ranking of individual
Hsp90 states, where the apo state was found to be most dynamic, followed
by GVK0153 bound protein and finally, the most rigid 17-DMAG complex. As
increased flexibility means higher entropy, the same ranking was expected of
the configurational entropy values the different Hsp90 complexes. Next, we
calculated the configurational entropies using the same trajectory data (three
replica trajectories of each system), as used for the PCA analysis in Chapter
3.
The configurational entropies were calculated using the Schlitter’s quasi-
harmonic method, as described in Chapter 1, where the mass weighted co-
variance matrix of atomic positions is diagonalised [90]. For the analysis, to
allow direct comparison of the entropy values for the three systems, the
ligands were ‘cut out’ from the 17-DMAG:Hsp90-NTD and GVK0153:Hsp90-
NTD trajectories to match the atom numbers of apo Hsp90-NTD simulations.
The entropies for each separate trajectory were computed both for the total
500 ns trajectory length, as well as for smaller windows. This is because the
overall entropy has a hidden dependency on trajectory size; the longer the
simulation is run, the more conformational space is explored. Consequently,
the longer simulation times result in a larger entropy value, due to more
microstates being populated. This means that entropy is increasing over the
length of the simulation. However, for a smooth energy landscape (i.e. where
there is only one deep minimum), it is possible to get around this problem by
dividing the simulated data into smaller windows, from which the entropies are
calculated separately [91]. The entropy values are then plotted as a function
of the length of the sampling window to get the rate of increase over simulation
time. The resulting curve can be fitted, using the equation below, to estimate
the total configurational entropy value as it approaches a stable limit (S∞):
ܵ= ஶܵ + ஺௧೙ , (eq.19)
Here, A and n are fitting parameters and t is the size of the sampling window
[91].
The MD data from the apo and ligand bound Hsp90 simulations were
processed as described above (Figure 4.1). It can be seen that the entropy of
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the apo protein is converging to the largest value (Figure 4.1, green data
points). This is followed by the GVK0153 bound protein entropy (Figure 4.1,
blue data points). The configurational entropy for the 17-DMAG:Hsp90-NTD
complex is significantly less than the other two values (Figure 4.1, red data
points). Moreover, the 17-DMAG:Hsp90-NTD complex has significantly
smaller entropy values than that of the apo and GVK0153 bound Hsp90. This
matches the ranking expected from the NMR relaxation dispersion
experiments (Chapter 3.3.3) and from the MD trajectory PCA analysis
(Chapter 3.4.2). This suggests that the quasi-harmonic approximation is
suitable for entropy estimations for the Hsp90-NTD system.
Figure 4.1: Configurational entropy values as calculated by quasi-harmonic
analysis over the length of the sampling window, for the apo Hsp90-
NTD and the Hsp90-NTD and inhibitor complexes.
Whilst the entropies calculated via quasi-harmonic approximation produce the
expected ranking of configurational entropy values, as can be seen from the
curves in Figure 4.1, the entropy values have not yet reached a stable limit,
but are steadily increasing. Thus, to get a total entropy value, the data were
fitted, as described above, using equation 19. Figure 4.2 shows an example
of the fit of the 17-DMAG:Hsp90 trajectory data. The configurational entropies
values obtained for each system were: 4,165±20 kcal/mol/K for the apo
protein, 4,040±45 kcal/mol/K for the GVK0153 bound structure and 3,810±45
kcal/mol/K for the 17-DMAG:Hsp90-NTD complex. The entropies were
calculated separately for each of the three replicas of each protein complex,
and the errors in the entropy value were calculated as the standard deviation
105
between the different replicas. The ranking of the data from the graphs, and
the estimated configurational entropy values suggest that the apo Hsp90-NTD
and GVK0153 bound protein have similar entropies. This result is in
agreement with the similar dynamics of the apo and GVK0153 bound Hsp90,
as observed by the NMR relaxation dispersion methods. The more rigid 17-
DMAG bound protein has a smaller configurational entropy, as expected.
Finally, to check whether the underlying assumption of the smooth energy
landscape was true for Hsp90-NTD, the range of the entropy values computed
from different windows along the trajectory were examined. For a smooth
energy landscape, the QHA entropy should not vary based on the position of
the sampling window. Instead, the data points should be interspersed with
only a minor spread between the values calculated from different windows.
For example, the entropy should not vary much between the first quarter and
the last quarter of the simulation data. Figure 4.3 shows the configurational
entropies, calculated using different position of the sampling window, for the
apo protein. It can be seen that the entropy values are very similar, both within
the same simulation (Figure 4.3, same colour points), and between different
repeats (Figure 4.3, different colour points), as the points corresponding to
different sets of data overlap. The maximum difference in the data points for
ten nanosecond window size was 37.5 kcal/mol for the apo protein. This
corresponds to 1% variation in the entropy value. The spread of values for the
GVK0153 and 17-DMAG simulations were very similar to the apo Hsp90
entropies, 1% and 4% respectively. This relatively small spread of entropy
values, calculated over the different windows of the whole trajectory, supports
the assumption that the protein oscillates within one energy well, and does not
undergo large conformational re-arrangements, at least during the simulation
time (500 ns).
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Figure 4.2: A fit of the average Schlitter entropy (red line) against window
size (blue data points) for 17-DMAG:Hsp90-NTD.
Figure 4.3: The spread of entropy values for the apo Hsp90-NTD
simulations, as calculated for the short trajectory window sizes.
4.3 The size of conformational space
Hsp90-NTD configurational entropies calculated from 500 ns MD trajectories
agreed surprisingly well with the ranking predicted from NMR experiments that
characterise protein flexibility on µs-ms timescale. However, the entropy
values were still increasing over the 500 nanosecond simulations, suggesting
that the sampling of conformational space is not complete.
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Adequate sampling of protein conformational space is one of the main issues
of computing the configurational entropy from MD simulations. Indeed, the
configurational entropy is a measure of the volume of the conformational
space that the molecule can visit at a given temperature. The size of
conformational space can be given as 3N-6 dimensions, where the N is the
number of particles in the system [160]. To sample sufficient conformational
space for entropy values to converge, the Hsp90-NTD system should sample
at least 9660 dimensions. Each dimension has an undetermined number of
configurations the system can adopt. This estimate of the number of
dimensions is based on the assumption that each dimension is a perfect
smooth well, which is unlikely to be true given the general roughness the
energy landscape. Given the complexity of macromolecular landscape, even
with the recent advances in computer hardware and software, that have
enabled micro- and even millisecond simulation times to be reached, it is
probable that simulation data still presents only partial exploration of the
available space [31]. Indeed, a study conducted a few years ago suggested
that molecular dynamics simulations may never reach an equilibrium, as the
entropy from different replica simulations seemed to be increasing even after
70% of the conformational space was explored [96]. Similar conclusions have
also been reached by other groups [161]. Nevertheless, whilst simulations
may never produce a complete energy landscape, it is clear that the more
space visited, the better the entropy estimations. Thus we set out to explore
how much simulation data is required to sample the Hsp90 energy landscape.
4.3.1 Conformational space sampling by replica simulations
One of the issues with simulations is the time taken to collect sufficient data.
It is generally thought that data from multiple replica simulations can represent
the conformational landscape better than one long simulation, which can be
trapped in a local energy minimum for long periods of time [162]. Data
collection is also faster when simulations are run in replicate, as these can be
run in parallel. Whilst accelerated simulation methods, such conformational
flooding and meta-dynamics, have gained popularity over the last few years,
the question remains as to how accurate the energy landscape produced is.
This is due to the biases that are introduced to enhance the sampling [163].
The accuracy of sampling the relevant states that the system visits is vital for
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calculations of thermodynamic parameters. At the same time, the ‘standard’
force fields have recently been shown to re-produce the structures and
fluctuations of several molecules to the same accuracy as NMR data, as well
as reproducing transient states in protein folding pathways [164] [165]. Thus,
we ran fifty 500 nanosecond long replica simulations of the 17-DMAG:Hsp90-
NTD system using ‘standard’ MD methods, in an attempt to answer the
question “How many simulations should be run to get an adequate coverage
of the conformational space?”. Collecting this replica dataset took just under
two calendar months using the supercomputing resources in Leeds University.
In comparison, obtaining a single 25 µs long trajectory would take 250 days,
assuming that there was no time spent queuing for the supercomputing
resources.
The replica simulation data were converted to eigenvectors and eigenvalues
using principal component analysis. This conversion of the data from
Cartesian coordinates to eigenvector space considerably reduces the
complexity of the data, as each vector component can be thought to represent
one dimension in phase space. To further simplify the analysis of the volume
of space explored by different simulations, the projections of the two largest
eigenvectors (principal components 1 and 2, i.e. PC1 and PC2), which made
up 25% of the total dynamics, were chosen to represent the conformational
space. The projections of PC1 and PC2 produce a two dimensional volume to
which standard geometrical analysis can be applied. It also makes the data
easy to visualise. In contrast, to achieve eighty percent coverage of the
movements seen during the simulations, the analysis would need to include
the fifty largest eigenvectors.
To start the analysis into the conformational space exploration by the different
replica simulations, PC1 versus PC2 volumes were plotted for each individual
simulation. These plots were used to check that the different replicas indeed
did explore different parts of the conformational space. The data for the
individual PC1 vs PC2 plots were further broken into four separate time
windows, that were plotted using different colours, to view the path each
simulation processed along. A sample of the resulting graphs are shown in
Figure 4.4. From the plots it can be seen that the different replicas do explore
109
different areas of the conformational space, as both the shape and the volume
of the areas explored differ. Some replicas produced similar shaped areas, for
example ‘V-shaped’ graphs were quite common, as shown in the third row in
Figure 4.4. However, the path taken to produce the shape differs, as can be
seen from the coloration of the frames making up the trajectories. Only a few
trajectories produce a continuous area, the majority seemed to suddenly
‘jump’ from one conformation to another.
Figure 4.4: Volume plots of the first two eigenvector projections of the
replica simulations. The different colours correspond to different
hundred nanosecond windows of the trajectory. This shows the path
(from dark blue, light blue, dark purple to light purple) the molecule
explores the conformational space.
Whilst it was clear that each replica simulation visited slightly different areas
of conformational space, it is not possible to tell the size of the overall space
the simulations collectively explored. Although the largest movements making
up the PC1 and PC2 occurred in similar areas of the protein, as seen in Figure
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4.5, the dot products used to compare the similarities of the largest
eigenvectors demonstrated that the eigenvectors were not identical between
the replicas, even when the ‘shape’ of the area was similar. This is probably
caused by the complex nature of the underlying energy landscape and
‘softness’ of proteins. Helix movements for example are a combination of
many smaller twists that can take different directions. To get around this issue,
the trajectories from the different replica simulations were joined together to
form one long trajectory, for which the PCA analysis was completed. This
ensured the largest eigenvectors describe the same movements.
Figure 4.5: The animations of the largest eigenvectors for different replicas.
Whilst there are movements observed in the same three areas as
indicated by the circles, the magnitude and direction of the movement
differs.
The projections of the two largest eigenvectors of the concatenated trajectory
data produced a continuous 2D volume in the shape of an ellipse, as shown
in Figure 4.6 (top panel on the left). The ellipse shaped volume clearly differs
from the discontinuous areas the individual simulations explored, as shown in
Figure 4.4. This confirms that, collectively, the fifty replicas making up a twenty
five microseconds trajectory had explored a much larger part of the
conformational space. For the analysis here, it was also assumed that the
combined replica dataset had explored the total conformational space
available (at least for the two largest dimensions examined), as no new space
was visited after 22 microseconds.
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Although replica simulations can be run in parallel, routinely running fifty
replica simulations is computationally costly, at least from pharmaceutical
industry point of view. The key point is to make sure enough conformational
space is explored. Therefore, we wanted to estimate how many replicas need
to be run in order to achieve coverage of the majority of the conformational
space. For this, the dataset was divided into smaller parts (half, quarter, eight,
sixteenth) and these partial datasets were superimposed on top of the total
dataset, to see how much the explored space was reduced. From the plots in
Figure 4.6, it can be seen that half of the data (25 replicas/12.5 µs) covers
almost the same area as 50 replicas do (95%). Similarly, a quarter of the data
(12.5 replicas/6.25 µs) also explores 86% of the conformational space. On the
other hand, an eight of the data (6.25 replicas), whilst covering two thirds
(78%) of the total space, has some discontinuity in the area covered. Finally,
three replicas cover only 63% of the total space, and one 500 nanosecond
long trajectory explores a fifth (22%) of the area. This analysis suggests that
at least six replica simulations should be run to get 75% coverage of the
conformational space, at least for the Hsp90-NTD system under study.
Figure 4.6: The PC1 and PC2 of the combined trajectory data were plotted
to produce an area plot showing the space explored. The data was
then halved, again and again, to try to estimate how many simulations
would be enough to explore a similar area as the full dataset of fifty
replicas.
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4.3.2 What about the probability distributions?
The analysis of the conformational space exploration by replica simulations
suggested that six replica simulations provide a reasonable coverage (>75%)
of the total space. However, to get good data for entropy computations, it is
not enough just to explore as much of conformational space as possible. The
sampling of the explored space is also vital to get an accurate ensemble
distribution. A heatmap was produced showing the probability distribution of
the different areas of the conformational space visited by the simulations. The
heatmap is shown in Figure 4.7, where white areas correspond to the most
frequently sampled regions, followed by yellow, orange and purple, with the
darker areas only explored very rarely. Comparing the heatmap of
conformational space in Figure 4.7 to the total area plot shown in Figure 4.6,
it is very clear that not all areas are sampled extensively. There is a clear
tendency for the system to be found in a few ‘hot spots’. These ‘hot spots’
were visited around 2800 times during the simulation, compared to only a few
visits to the outer edges of the volume.
With the question still in mind; “How much simulation data are needed to
explore ‘enough’ conformational space?”, the combined replica dataset was
divided into smaller parts. These were used to produce heatmaps of the
conformational space explored, to see if the amount of data affected the
probability distribution. As can be seen from the bottom panel of Figure 4.7,
25 replicas produce a similar probability distribution to the total 50 replica
dataset. Some perturbations from the distribution are already seen when only
a quarter of the data are used. This corresponding to around 6 microseconds
of simulation data (12.5 replicas from the total dataset). These perturbations
become larger as the dataset is reduced further, as seen on the lower panel
of Figure 4.7. The heatmap analysis thus suggests that more than 12 replicas
should be run to get a similar statistical distributions of the microstates to the
full 50 replica dataset.
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Figure 4.7: Probability distributions of the sampling of the conformational
space by the 17-DMAG:Hsp90 replica trajectories. The large plot on the
top panel of the figure shows the distribution for the full dataset of 25
µs. When half of the data (25 replicas/12.5 µs) is used to obtain the
distribution, the shape of the data looks nearly identical to the full
dataset. However, the distribution starts to skew when only a quarter or
less of the data is used.
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4.3.3 Is the sampling of conformational space system dependent?
To look into how the molecular constraints effect the size and sampling of
conformational space, we also ran replica simulations of the GVK0153 bound
protein. As the GVK0153:Hsp90-NTD system was shown to have different
dynamics, and in particular larger entropy, compared to the 17-DMAG bound
protein analysed in the previous section, comparing these two systems would
allows us to examine the effect flexibility has on the sampling of
conformational space. For this, we ran 25 replicas of 200 nanosecond long
simulations of the Hsp90-NTD:GVK0153 complex.
The GVK0153 bound Hsp90-NTD replica dataset was concatenated with the
17-DMAG:Hsp90-NTD replica trajectories of the same amount (5 µs). The
concatenated dataset was used to generate a combined set of eigenvectors
to repeat the analysis described in Sections 4.3.1 and 4.3.2.
The resulting volume of space plots are shown in Figure 4.8. The area that
the systems collectively visit is shown in purple; and the area visited by the
GVK0153 bound protein correspond to the blue volume, and the red volume
is for the 17-DMAG:Hsp90-NTD space. From the plots it can be seen that the
more flexible Hsp90-NTD:GVK0153 system explores a much greater
percentage of the combined space (91%) compared to the 17-DMAG bound
protein, which visits only half of the combined space (55%).
The heatmaps shown in Figure 4.9 also demonstrate the differences in the
space exploration by the two systems, where the GVK0153 bound protein
clearly explores two different areas of space frequently, compared to the one
clear ‘hot spot’ seen by the 17-DMAG bound Hsp90.
The overall sampling of the space differs between GVK0153 bound Hsp90-
NTD compared to the protein in complex with 17-DMAG, as suggested by
both the entropy calculations and the principal component analysis. Both the
volume plots and heatmaps also reflect the more flexible nature of the
GVK0153 bound structure. This means that PC (using heatmaps and/or
volume plots) analysis could be used in conjunction with the entropy
calculations to explore differences in the dynamics.
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Figure 4.8: Two dimensional volume plots of the PC1 and PC2 projections
of the combined 17-DMAG and GVK0153 datasets are shown in
purple. The blue volume shows the area GVK0153 bound protein
explored, and the red volume that of 17-DMAG:Hsp90 complex.
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Figure 4.9: Probability distributions of the sampling of the conformational
space by the concatenated 17-DMAG:Hsp90 and GVK0153:Hsp90
trajectories.
4.3.4 Convergence of configurational entropy
As configurational entropy has a hidden dependency on the length of the
simulation dataset, the entropies were also calculated using the larger
datasets. These values were compared to those computed in Section 4.2 from
the 500 nanosecond more frequently sampled triplicate trajectories. The
difference here was that for the more frequently sampled trajectories, we
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calculated the entropy separately for each replica, in comparison for the larger
dataset, where concatenated trajectories were used. For the larger dataset,
the entropies were calculated from seven microseconds of data, as any larger
dataset caused the software to run out of memory.
The values for configurational entropy obtained from the 500 nanosecond long
trajectories were 4,040±45 kcal/mol/K for the GVK0153 bound structure and
3,810±45 kcal/mol/K for the 17-DMAG one (see section 4.2). In comparison,
the configurational entropies were significantly higher when seven
microseconds of data were used for the calculation and data fitting; 4,935
kcal/mol/K and 4,465 kcal/mol/K respectively (Figure 4.10). This difference in
the entropy values is likely to be caused by differences in fitting with more data
points available. The spread of the entropy values calculated for a 5
nanosecond window is very similar for the shorter 500 nanosecond and
concatenated 7 microsecond datasets. The difference between the largest
and smallest value calculated for the 5 nanosecond window was 130
kcal/mol/K with standard error of 15.3 kcal/mol/K for the concatenated dataset,
compared to 168 kcal/mol/K with standard error of 6.7 kcal/mol/K for the 500
nanosecond long more frequently sampled repeats. Despite the difference in
the configurational entropy values from the short and long trajectories, the
ranking of entropy values matches, and both datasets show the differences in
the flexibility between the two ligand bound proteins. The take home message
is that whilst the actual entropy values do not seem to converge, the ranking
of the configurational entropies does. Therefore, the entropy data should still
be useful from the drug design point of view.
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Figure 4.10: Configurational entropy values calculated by quasi-harmonic
approach for the larger (5 µs) concatenated datasets.
4.4 ‘Naïve entropy’ using the histogram based method
Since we have already calculated the probability distribution of states from the
2D energy landscape (in Section 4.3.2), we used these data to calculate the
‘naïve’ entropy using the histogram method. We call this ‘naïve’ because the
entropy calculated is not the total configurational entropy of the molecule; it
only takes the two largest movements of the system into account. One of the
issues with the histogram method is the selection of a suitable window width
for the bins. The above data allows to study this effect on overall
configurational entropy.
For the calculations, the two dimensional area obtained from the two largest
principal component projections of the 17-DMAG:Hsp90-NTD replica dataset
was divided into smaller bins. Here, a bin corresponds to a microstate. The
bins were then used to calculate the entropy using the ‘standard’ Boltzmann
formula, where entropy is related to a weighted sum of the logarithms of each
microstate:
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ܵ= −ߢ஻ ∑ ݌௜ln݌௜௦௧௔௧௘௦ (eq. 20)
Here the ߢ஻ is the Boltzmann constant and pi is the probability of finding the
system in microstate i [88]. The calculations were repeated using different bin
widths, and an example of the differing bin sizes is shown in Figure 4.11.
The number of bins used to calculate probability distribution ranged from ten
to ten thousand. The entropy values for the different bins are shown in Figure
4.12. The very coarse grain approach of using only 10 bins resulted in an
entropy value three times smaller compared to when 10,000 bins were used.
Figure 4.12 clearly shows that entropy value is increasing when smaller
sampling windows are used. This increase is more pronounced when a very
coarse sampling strategy is adopted. Whenever a decreasing window size is
used (total bin number of 5,000 or greater), the entropy values start to tend
towards a stable limit. This demonstrates the importance of selecting a
sufficiently small sampling window. In principle, how many bins are used to
calculate entropy, should not affect the comparison of differences in entropy
between complexes. However, the selection of the bins is crucial if the
absolute entropy is calculate as this value is dependent on the number of
possible states (i.e. bins). For protein configurational entropy calculations,
window widths ranging from 1 to 5 degree rotations around di-hedral angles
have been suggested [89]. The issue remains on how to choose a suitably bin
size; too large a bin results in coarse data that skews the entropy value, too
small a bin is computationally expensive and may be biologically irrelevant.
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Figure 4.11: Illustration of the effect of bin sizes on conformational space
sampling for the 17-DMAG:Hsp90-NTD dataset. The left hand image
presents data where each PC divided into 100 bins is and the image on
the right is divided into 25 bins.
Figure 4.12: The configurational entropy values calculated by the histogram
methods vary over three-fold for the same system when the bin size is
increased from 10 to 10,000. This illustrating how critical it is to select a
small enough sampling interval. It can be seen that as the number of
bins is increasing, the entropy value starts to reach a stable limit.
0
2
4
6
8
10
12
14
16
18
20
10 25 50 100 200 500 1000 5000 10000
En
tr
op
y
(J/
K)
x
10
-2
3
Number of bins
121
4.5 Configurational entropy of ligands – un-harmonicity at
play
Often the choice of the method used to calculate configurational entropies
depends on the system. This final section illustrates this using simulation data
for the two small ligand Hsp90 inhibitors, 17-DMAG and GVK0153. The ligand
entropies were first calculated using the quasi-harmonic approach, as was
done for the Hsp90-NTD protein in Section 4.2. The histogram method using
dihedral angle calculations were also attempted for the smaller GVK0153
ligand. The ligand only simulation data were analysed by two undergraduate
Physics students, Peter Adkins and Max Holme, for their final year project
under my supervision, and it is these results that are presented here.
4.5.1 Ligand entropies calculated with the quasi-harmonic
approach
MD trajectories were collected for one hundred nanosecond long simulations
of the two inhibitors 17-DMAG and GVK0153. Given the smaller size of the
molecules compared to the protein (44 atoms for GVK0153 and 92 for 17-
DMAG versus ~3500 for Hsp90-NTD), this trajectory length was thought to be
reasonable to obtain adequate sampling of conformational space.
The QHA was then used to calculate the configurational entropy as a function
of sampling window for both molecules. The resulting entropy plots are shown
in Figure 4.13. From the graphs it can be seen that the larger 17-DMAG
molecule entropy seems to have stabilized over the 100 nanosecond
simulations, as the entropy values have begun to reach a stable plateau over
the larger time frames. The entropy calculations for the smaller GVK0153
molecule did not produce the expected logarithmic curve approaching a stable
limit (right panel in Figure 4.13). Instead, the entropy seems to increase and
decrease randomly as the simulation progresses.
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Figure 4.13: The configurational entropy of the 17-DMAG and GVK0153
ligands as calculated using the quasi-harmonic approach, and plotted
against the sampling window length. The configurational entropy could
be estimated by fitting the data as described for the larger 17-DMAG
ligand, shown on the left. The data for the small GVK0153 molecule did
not produce the expected logarithmic curve, thus the configurational
entropy could not be estimated. (Graphs prepared by Peter Adkins)
For the 17-DMAG entropy, the spread of the entropy values over the smaller
time windows, which are shown by blue error bars, has stabilised after fifty
nanoseconds. For the GVK0153 on the other hand, the spread of points that
present the average entropies along the same amount of sampling is very
large as can be seen from the error bars. This suggests that the GVK0153
molecule is more flexible and the underlying energy landscape cannot be
described as a single energy well.
The 17-DMAG molecule has a smooth enough energy landscape for the
entropy to be calculated using the quasi harmonic approach. Therefore the
data were fitted using ܵൌ ஶܵ + ஺௧೙ , as was done for the protein data in Section
4.2. The entropy for free 17-DMAG ligand was estimated to be 114 kcal/mol.
In comparison, the configurational entropy of the protein bound 17-DMAG
ligand was calculated to be 92 kcal/mol, suggesting a small penalty in
configurational entropy upon binding.
To get an idea of the accuracy of the bound versus unbound 17-DMAG
entropy results, a literature search of molecular dynamics and NMR studies
was conducted on the 17-DMAG ligand. The 17-DMAG ligand is a derivative
of geldanamycin and they share an identical 19-membered ansamycin ring
(see Figure 2.1 in Chapter 2). This macroring has 14 single, and thus
17-DMAG GVK0153
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rotatable, bonds. As the two structures share the same ‘backbone’, the
published geldanamycin data was used as a model for 17-DMAG. The solid
state structure of geldanamycin has been solved, and early crystallography
work on the protein bound molecule suggested that the ‘free’ and ‘bound’
forms are remarkably different. The crystallography work suggested that the
‘free’ form was more open compared to the tight C-shape structure of the
bound ligand (see Figure 4.14). The geldanamycin thus required trans-cis
isomerisation upon binding to the Hsp90. Subsequently, the difference in the
free and bound forms has been calculated using MMPBSA methods, which
suggested that there is a -3.4 cal/mol/K to -5.4 cal/mol/K penalty upon binding
of geldanamycin to Hsp90 [115]. However, a few years later, the solution
structure of the inhibitor was solved. Here, the authors found that there are
twelve different conformations of geldanamycin in the equilibrium population,
each nearly equally likely to be occur. Hsp90 would simply selectively bind to
a pre-populated state of geldanamycin. This is in contrast to the earlier studies
suggesting that the inhibitor had to go through trans-cis isomerisation [166].
Studies on 17-DMAG also supported the view that the ansamycin ring does
not undergo isomerisation upon binding [136]. Given the results from the
literature, the difference we found in the configurational entropy between the
free and bound 17-DMAG forms seems to be of a reasonable magnitude.
Figure 4.14: The two different conformations of geldanamycin as predicted
from structural and simulation data (Figure from [115]).
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Given the atypical data for the GVK0153 molecule, both trajectories were
further analysed using root mean square deviation (RMSD) of the simulated
structures relative to the starting structure. The RMSD data over time is shown
in Figure 4.15. From the graphs it can be seen that the 17-DMAG molecule
fluctuates around an average position. GVK0153 seems to undergo larger
structural changes, as the graph of RMSD over time shows large ‘jumps’. This
RMSD plot of the GVK0153, showing large structural changes, explains the
atypical configurational entropy graph, where the entropy was not only
increasing over the duration of simulation, but also decreasing with large
errors between the window sizes. The main assumption of the quasi-harmonic
approximation for entropy calculation is that the molecule resides in a single
large energy well, with small fluctuation around the average structure. From
the RMSD data, the GVK0153 molecule clearly visits different states in
multiple energy wells, thus does not satisfy the QHA assumption.
Figure 4.15: RMSD graphs of the simulations of the two ligands. The 17-
DMAG ligand on the left fluctuations around similar average
conformation. Larger conformational changes are seen for the
GVK0153 ligand on the right. (Graphs prepared by Peter Adkins)
4.5.2 Dihedral angle analysis suggests three separate energy
wells for GVK0153
To investigate the changes in the GVK0153 structure suggested by the QHA
and RMSD data analysis, it was decided to analyse the data further by using
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the dihedral angle fluctuations. This approach is similar to that used in entropy
estimations by the histogram based method.
As can be seen from Figure 4.16, the GVK0153 molecule is made up of a
purine scaffold that is connected to an aryl moiety by a CH2 linker [167]. Both
ring structures of the GVK0153 are rigid due to the double bonds, but the CH2
linker as well as amide and methyl groups, highlighted in Figure 4.16, contain
rotatable bonds. These rotatable bonds were selected for the dihedral angle
fluctuation analysis.
The dihedral angle fluctuations over the simulation time were calculated using
the Amber ptraj tool [80]. The bin sizes, that define what contributes a different
conformation, was set to 10 degrees.
Based on the molecule structure, the methyl and the amide group dihedral
angle fluctuations were expected to exhibit small fluctuations around an
average position, rather than larger conformational re-arrangements. For the
methyl group attached to the purine scaffold of GVK0153, the dihedral angle
analysis showed three separate states around 60, 180 and 300 degrees, as
seen in Figure 4.16. The size of the each peak was roughly the same,
suggesting that the methyl group adopted three equal rotational states. A
methyl group is made up of three equal hydrogens connected to a carbon.
Given the bond geometry, these are expected to produce three
interchangeable states. The three different states that were observed matched
the expected distribution. The amide group dihedral angle analysis also
produced the expected distribution of a single state, based on the chemical
connectivity (data not shown).
In contrast to methyl and amide groups attached to the two different rings, any
changes in the dihedral angle of the CH2 linking the two rings, would result in
large conformational changes in the GVK0153 molecule. From the dihedral
angle analysis we observed three maxima centred around 65, 160 and 300
degrees. The probability distribution for the maxima was roughly 50%, 5% and
45% respectively. The least likely conformation is that of the two rings being
stacked, as seen in the Figure 4.16. These different conformations of the
molecule cause the underlying energy landscape to have multiple energy
minima, rather than the single harmonic one, as is assumed by the QHA. This
126
explains why the configurational entropy calculations by the quasi harmonic
approach did not converge.
Figure 4.16: To look further into the structural fluctuations of the GVK0153
molecule, three different dihedral angles were selected for analysis as
indicated on the left by the G1, G2 and G3 arrows. The right panel
shows the probability distribution of the G1 and the G3 dihedrals. The
resulting changes in the molecule conformations for the G3 dihedral is
shown in the bottom figure. (The histogram distribution were calculated
and plotted by Max Holmes)
4.6 Conclusions
In this chapter we explored the use of the quasi-harmonic approach method
to compute configurational entropies of Hsp90-NTD in complex with inhibitors.
We also explored the amount of simulation data required to get an accurate
description of the underlying conformational space.
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The results presented here show that the quasi-harmonic approach can be
adopted with relative ease for both smaller and more complex systems, as
long as the system does not undergo large conformational re-arrangements.
The quasi-harmonic approximation provided the expected ranking of the
configurational entropy values (Sconf) for the different Hsp90 systems.
However, the calculated values may not reflect the exact entropy; when more
simulation data were used for calculations, the entropy value increased.
Despite this, the calculations can be used to produce ‘entropy ranking’. This
reflects the dynamics of the system, and this information can still be of use for
drug design, if effects of molecule flexibility are of interest. Moreover, obtaining
a value (here Sconf) to compare flexibilities of different systems will provide a
more objective measure, rather than comparison of flexibilities of certain
regions of the protein of interest, as in Chapter 3 using RMSF analysis and
looking at PCA fluctuations in Chapter 3.
We also wanted to attempt to answer the question - how many simulations
are needed to provide a “good coverage” of the conformational space (75%
or greater)?. Here the results of the two largest eigenvector movements that
were used to describe the conformational space suggested that at least 6
replica simulations that collectively provide several microseconds of data are
needed. When the coverage of the underlying energy landscape is of interest,
these results highlight the potential issue with the common practice of running
three replica simulations. We have shown that data from three replica
simulations cover under two-thirds the total conformational space. However,
in Chapter 3, we found that the differences in the flexibility of the different
Hsp90 complexes could be seen from analysis of only three replica
simulations. The configurational entropies also provided the expected ranking
when only 3 simulations were used for calculations, but the value was
considerably larger when more replica data were used for the computations.
The larger dataset is likely to provide a more accurate configurational entropy
value and the question of how many replicas should be run will depend on
what the data is used for; ranking of complexes or trying to obtain an accurate
value for configurational entropy.
Finally, the method of choice for configurational entropy calculations does
depend on the flexibility of the system under study. QHA cannot be used for
128
very flexible molecules, which occupy multiple energy minima. There are
issues with the dihedral method relating to selection of the bin sizes and the
complexity of the system it can describe, due to collective motions. This
means that it may not be easy to compare the entropies of different systems,
especially if they have been calculated by different methods. Thus it is clear
that the currently used methods for entropy estimations still do not tell the
whole story. It remains to be seen whether simply correction terms could be
added to the existing methods to solve these issues, or whether a completely
new way of looking into quantifying the flexibility of soft biomolecules is
needed.
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Chapter 5
Overall summary and conclusions
Introducing a new drug to market is a lengthy and expensive process, typically
it takes 10-15 years and costs $1.7 billion [168]. The main problem is that only
around 3% of the new drug projects manage to produce a successful drug
molecule [169]. Whilst the majority of failures occur in the later stages of the
process, during clinical trials, there is still room for improvement in the initial
drug discovery stages. An overall success rate of ~35% is typical during the
drug discovery process, problems leading to failure may arise due to issues
with understanding the underlying biology, lack of lead molecules, poor
potency or selectivity to name but a few [169]. Given this very high failure rate,
are the methods used by the pharmaceutical industry to find new drugs
suitable for the task? The current process of initial high throughput screening,
followed by structural studies focuses on finding compounds that bind. These
steps are followed by lead optimisation, where efforts are made to modify any
promising lead compounds sometimes with help from structural data to further
improve the binding affinity. Binding affinity, although providing a tool with
which to rank the potential drug compounds, is a global value that includes
changes in the systems flexibility, structure as well as changes in solvation.
As proteins are dynamic rather than static structures, and dynamics plays an
important role in binding affinity (in terms of the entropy), a better
understanding of dynamics, and how they could be manipulated, could be one
way of improving the process. The details of any changes in flexibility of the
system cannot be readily accessed from the global affinity value, or the
structural data.
In this study we used the Hsp90 chaperone, which is also a cancer medication
target, to study the effects small molecules have on protein dynamics. We
demonstrated that the structure and binding affinities, do not tell the whole
story of what is happening to the protein upon complex formation. The X-ray
crystal structures of 17-DMAG and GVK0153 bound Hsp90-NTD are nearly
identical, and both ligands bind the protein with similar nanomolar affinity.
However, a more in depth study into the protein dynamics showed that the
larger 17-DMAG ligand suppressed the lid-region dynamics; this did not
happen in the apo and the GVK0153 ligand bound structures. These
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differences were seen both with NMR relaxation dispersion measurements
and from analysis of MD simulation data.
From this study we have learned that dynamics also play a role in protein and
ligand interactions. Further, the changes in dynamics may play a biologically
relevant role. Hsp90 is known to be a highly dynamic protein with a large
number of client proteins in whose maturation Hsp90 plays a role [39]. The
current view of the Hsp90 chaperoning action is that not all cellular Hsp90 are
the same, but the diverse client interactions are determined and regulated by
different co-chaperones [39]. The Hsp90 co-chaperome is complex. Some of
the co-chaperones are client specific (for example the Cdc37 is a kinase
specific co-chaperone), whereas others are not [32, 170]. The co-chaperones
play diverse roles ranging from client recruitment, regulating the Hsp90
ATPase activity or seem to ‘trap’ the Hsp90 complex in a certain conformation,
to name but a few. The diverse co-chaperones also interact with different parts
of Hsp90, some binding to the NTD, others to the CTD, and others contacting
all three domains [32]. It has also been shown that different co-chaperone
complexes are required for the client maturation. For example, the
glucocorticoid receptor maturation. only requires Hop as well as the
chaperones Hsp70 and Hsp90 for activity. However, a different steroid
receptor, the progesterone receptor also requires the p23 and Hsp40 co-
chaperones, in addition to Hsp70, Hsp90 and Hop for maturation [171, 172].
On top of the co-complex co-chaperone network, it has also been shown that
different Hsp90 inhibitors interact with different cellular pools of Hsp90. For
instance, geldanamycin and a purine analogue, will interact with different
cellular pools of Hsp90 [47, 173]. H/D exchange mass spectrometry studies
demonstrated that the binding of small molecule inhibitors and Cdc37 co-
chaperone to the Hsp90 N-terminal domain, change the orientations of the N-
, middle and C-terminal domains of the full length Hsp90, compared to the apo
protein [52]. Given the large number of diverse Hsp90 clients, and the fact that
there is no single co-chaperone, or client protein interactions site, it is likely
that the conformational dynamics do play a role in chaperone’s function.
Indeed, it has been shown that some clients, such as HSF1, interact with only
a single Hsp90 closed conformation, that is only present for a short time within
the Hsp90 open-closed cycle. Other clients, such as HIF1α, interact with 
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multiple conformations [48]. The natural ligands, ADP and ATP, also change
the N-terminal dynamics of Hsp90, suggesting that dynamics is likely to play
a functional role in the chaperone activity [50]. Further understanding of the
role that dynamics play in regulating Hsp90 activity is thus likely to be
important, both for the underlying biology, and with regards to how it can be
manipulated by small molecules. Here we have shown that 17-DMAG binding
can lock the Hsp90-NTD into a more rigid conformation. This could favour
interaction with a subset of client proteins, without affecting the interaction of
others. All together this provides specificity. Potentially, this allows one to
design an ‘ideal’ drug that only prevents the folding of ‘bad’ cancer related
proteins, without affecting Hsp90 functions in normal cells.
Whilst our results suggest that manipulating the conformational dynamics of
the Hsp90 chaperone by small molecules could help to select only a certain
subset of targets, further studies are needed. As it is known that some clients
interact only with a certain conformation of the Hsp90 using open and closed
form mutants, follow up studies are needed to understand what effects the
differing lid-region dynamics, that we found, play at cellular level [48]. The
differences in dynamics may play a role in client recruitment, or effect the co-
chaperone composition. Also, it would be interesting to study the effects of the
two inhibitors have in the dynamics of the full length Hsp90. This would be
particularly important as the changes in the N-terminal structure have been
shown to have an effect on the NTD and middle domain interface [39]. Thus
the full length chaperone may adopt different conformations when in complex
by the two different ligands.
We used both atomistic level techniques and global thermodynamic
measurements to study the dynamics of Hsp90. In contrast to the changes in
protein flexibility seen by NMR and MD methods, the global thermodynamic
parameters from ITC suggest that for Hsp90, protein dynamics provide only a
minor contribution to the binding free energy. The effects from water
molecules (i.e. solvation and desolvation of the ligand and protein upon
binding) overcome the protein dynamics contribution, and drive the binding
reaction. Although some studies have found good correlation between the ITC
data and changes in protein flexibility, as measured by NMR, the effect of
water has also been demonstrated to be the major driving force in the binding
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of other drug molecules [50, 146]. Our results thus suggests that whilst
understanding the underlying dynamics may be important to better manipulate
the different cellular pools of Hsp90, further understanding of the role that
water plays is also needed to optimise solvation energy. The end goal,
whether it is to optimise the binding free energy, or to further understand the
changes in flexibility of the molecule under study, will dictate the choice of
methods.
Whilst MD data did reproduce the differences in the protein dynamics seen by
NMR methods, the results obtained here were from a multi-disciplinary
approach. The global thermodynamic parameters with differing entropic
binding signatures suggested that there may be differences in the underlying
dynamics. However, it turned out that the dynamic changes are masked by
the effect of water in the binding signature. NMR studies on the protein-
inhibitor complexes highlighted differences in the micro- to millisecond
dynamics in the Hsp90-protein lid-area. This helped to pinpoint areas to focus
on in the MD data analysis. Interestingly, the differences in the lid-region
dynamics could be seen by PCA analysis, using 500 nanosecond long
trajectories. Finally, the differences in the lid-area dynamics could be
explained by analysing the ligand-protein contacts using X-ray crystal
structures. It is likely that a similar multi-disciplinary approach is needed, if the
study of differences in dynamics is to be incorporated into the drug discovery
process. The simulations can be used to predict the dynamic behaviour of
drug target. Crystal structures can then be used to pinpoint any residues or
regions which may drive, or stabilise, the dynamic regions. These results
could be used to decide, which compound should be taken for further testing
and development in the wet lab. However, one should remember that
optimising the target binding affinity is only one parameter that needs to be
considered in the drug discovery process. Other parameters that need to be
considered include oral bioavailability, the ADME/DMPK values (absorption,
distribution, metabolism, and excretion/drug metabolism and
pharmacokinetics), toxicology issues, patient demographics to name but a few
[174]. Interestingly, it has been noted that optimisation of the enthalpic
component of the drug-target binding by later generation statins and HIV-1
protease inhibitors lead to better pharmacokinetic and drug resistance profile
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[174]. This suggests that it may be beneficial to keep in mind multiple
parameters during each step optimisation to get a better end product.
Finally, we showed that calculations of the configurational entropies using MD
data can be used to quantify the differences in the dynamics. This provides a
‘value’, which can be used in ranking molecules; this is similar to the currently
used ranking based on binding affinity. However, it is difficult to understand
the underlying biology from numbers alone. Viewing the main motions during
the simulation is a far superior way to see what is happening, and to
understand the underlying biology. This would be a similar method to the
current use of visualising X-ray structures of the targets, for example to identify
additional areas where the drug molecules could be extended in fragment
based drug design in order to improve affinity. To investigate these protein
dynamics better, it is more efficient to run multiple replica simulations. For
replica simulations, based on our data, the commonly used three replica
simulations explore just over half of the underlying energy landscape. We
recommend that six or more replicas are run as this provides a much better
description. However, how much simulation data is needed will ultimately
depend on the question the simulation is seeking to answer, and of course, of
the system under study. The recent advances in computer technology have
speeded up the simulations considerably, The GPU technology has brought
down the potential setup costs for ‘faster’ simulations considerably. With the
continued improvements in the computing, it may be possible to run very large
systems routinely, which may give a better picture of what is happening in the
cell, rather than the reductionist approach that is currently used. Here, rather
than simulating a part of the Hsp90-chaperone, a simulation of the full length
protein, with the co-chaperone complex, may be possible in the future. This
would allow us to see in ‘real time’ what effect manipulating the lid-region
dynamics may have on the client protein selection.
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Appendix 1 - NMR samples and experiments
Samples and experiments:
Sample 1: Hsp90-NTD (D9-E246) (2H, 13C, 15N), 20 mM Na2HPO4, 20 mM
NaH2PO4, 1% AEBSF, 5% D2O
Sample 2 and 3: As sample 1 plus 750 µM ligands (either GVK0153 or 17-
DMAG)
Conditions: pH 7.5; temperature: 25°C
Experiments:
1H15N-TROSY
TROSY-HNCA
TROSY-HNCO
TROSY-HNcaCO
Hsp90-NTD FASTA:
DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYE
SLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTK
AFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSA
GGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPI
TLFVEKERDKEVSDDEAE
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Appendix 2 – MD parameter files
em.mdp (energy minimisation)
; VARIOUS PREPROCESSING OPTIONS =
title =
cpp = /lib/cpp -traditional
include =
define = -DPOSRES
; RUN CONTROL PARAMETERS =
integrator = steep
; start time and timestep in ps =
tinit = 0
dt = 0.001
nsteps = 10000
; ENERGY MINIMIZATION OPTIONS =
emtol = 0.00001
emstep = 0.1
nstcgsteep = 1000
; OPTIONS FOR ELECTROSTATICS AND VDW =
; Method for doing electrostatics =
coulombtype = PME
rcoulomb = 1.2
rlist = 1.2
; Method for doing Van der Waals =
vdw-type = Cut-off
rvdw = 1.2
; Spacing for the PME/PPPM FFT grid =
fourierspacing = 0.12
; FFT grid size, when a value is 0 fourierspacing will be used =
fourier_nx = 0
fourier_ny = 0
fourier_nz = 0
; EWALD/PME/PPPM parameters =
pme_order = 4
ewald_rtol = 1e-05
ewald_geometry = 3d
epsilon_surface = 0
optimize_fft = no
*************************************
md1.mdp (equilibration)
; VARIOUS PREPROCESSING OPTIONS =
title =
cpp = /lib/cpp -traditional
include =
define = -DPOSRES
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; RUN CONTROL PARAMETERS =
integrator = md ; leap-frog integrator
nsteps = 5000
dt = 0.002 ; 2 fs
; Output control
nstxout = 500 ; save coordinates every n ps
nstvout = 500 ; save velocities every n ps
nstxtcout = 500
nstfout = 0
nstenergy = 500 ; save energies every n ps
nstlog = 1000
nstcomm = 10
nstcalenergy = 10
xtc-grps = Protein
; Bond parameters
continuation = no ; Restarting after NVT
constraint_algorithm = lincs
constraints = all-bonds ; all bonds (even heavy atom-H bonds) constrained
lincs_iter = 1
lincs_order = 4 ;
; Neighborsearching
ns_type = grid ; search neighbouring grid cells
nstlist = 10
rlist = 1.2 ; short-range neighbour list cutoff (in nm)
rcoulomb = 1.2 ; short-range electrostatic cutoff (in nm)
vdw-type = Cut-off
rvdw = 1.2 ; short-range van der Waals cutoff (in nm)
; Electrostatics
coulombtype = PME
pme_order = 4
fourierspacing = 0.12
epsilon-rf = 1
tcoupl = V-rescale ; modified Berendsen thermostat
tc-grps = Protein Non-Protein
tau_t = 0.1 0.1
ref_t = 100 100
pcoupl = Berendsen
pcoupltype = isotropic
tau_p = 1.0
ref_p = 1.0
compressibility = 4.5e-5
refcoord_scaling = com
; Periodic boundary conditions
pbc = xyz ; 3-D PBC
; Dispersion correction
DispCorr = EnerPres
; Velocity generation
gen-vel = yes
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gen-temp = 100
gen-seed = 32926
***********************************
md2.mdp (equilibration)
; VARIOUS PREPROCESSING OPTIONS =
title =
cpp = /lib/cpp -traditional
include =
define = -DPOSRES
; RUN CONTROL PARAMETERS =
integrator = md ; leap-frog integrator
nsteps = 5000
dt = 0.002 ; 2 fs
; Output control
nstxout = 500 ; save coordinates every n ps
nstvout = 500 ; save velocities every n ps
nstxtcout = 500
nstfout = 0
nstenergy = 500 ; save energies every n ps
nstlog = 1000 ; update log file every n ps
nstcomm = 10
nstcalenergy = 10
xtc-grps = Protein
; Bond parameters
continuation = yes
constraint_algorithm = lincs
constraints = all-bonds ; all bonds (even heavy atom-H bonds) constrained
lincs_iter = 1
lincs_order = 4
; Neighborsearching
ns_type = grid ; search neighboring grid cells
nstlist = 10
rlist = 1.2 ; short-range neighborlist cutoff (in nm)
rcoulomb = 1.2 ; short-range electrostatic cutoff (in nm)
vdw-type = Cut-off
rvdw = 1.2 ; short-range van der Waals cutoff (in nm)
; Electrostatics
coulombtype = PME
pme_order = 4
fourierspacing = 0.12
epsilon-rf = 1
; Temperature coupling is on
tcoupl = V-rescale ; modified Berendsen thermostat
tc-grps = Protein Non-Protein
tau_t = 0.1 0.1
ref_t = 100 100
; Pressure coupling is on
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pcoupl = Berendsen
pcoupltype = isotropic
tau_p = 1.0
ref_p = 1.0
compressibility = 4.5e-5
refcoord_scaling = com
; Periodic boundary conditions
pbc = xyz ; 3-D PBC
; Dispersion correction
DispCorr = EnerPres ; account for cut-off vdW scheme
; Velocity generation
gen-vel = no ; Velocity generation is off
gen-temp = 100
***********************************************
md3.mdp (equilibration)
; VARIOUS PREPROCESSING OPTIONS =
title =
cpp = /lib/cpp -traditional
include =
define = -DPOSRES
; RUN CONTROL PARAMETERS =
integrator = md ; leap-frog integrator
nsteps = 5000
dt = 0.002 ; 2 fs
; Output control
nstxout = 500 ; save coordinates every n ps
nstvout = 500 ; save velocities every n ps
nstxtcout = 500
nstfout = 0
nstenergy = 500 ; save energies every n ps
nstlog = 1000 ; update log file every n ps
nstcomm = 10
nstcalenergy = 10
xtc-grps = Protein
; Bond parameters
continuation = yes
constraint_algorithm = lincs
constraints = all-bonds ; all bonds (even heavy atom-H bonds) constrained
lincs_iter = 1
lincs_order = 4
; Neighborsearching
ns_type = grid ; search neighboring grid cells
nstlist = 10
rlist = 1.2 ; short-range neighborlist cutoff (in nm)
rcoulomb = 1.2 ; short-range electrostatic cutoff (in nm)
vdw-type = Cut-off
rvdw = 1.2 ; short-range van der Waals cutoff (in nm)
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; Electrostatics
coulombtype = PME ; Particle Mesh Ewald for long-range electrostat
ics
pme_order = 4 ; cubic interpolation
fourierspacing = 0.12 ; grid spacing for FFT
epsilon-rf = 1
; Temperature coupling is on
tcoupl = V-rescale
tc-grps = Protein Non-Protein
tau_t = 0.1 0.1
ref_t = 300 300
; Pressure coupling is on
pcoupl = Berendsen
pcoupltype = isotropic
tau_p = 1.0
ref_p = 1.0
compressibility = 4.5e-5
refcoord_scaling = com
; Periodic boundary conditions
pbc = xyz ; 3-D PBC
; Dispersion correction
DispCorr = EnerPres ; account for cut-off vdW scheme
; Velocity generation
gen-vel = no
gen-temp = 100
********************************************
md9.mdp (production MD)
; VARIOUS PREPROCESSING OPTIONS =
title =
cpp = /lib/cpp -traditional
include =
define = -DPOSRES
; RUN CONTROL PARAMETERS =
integrator = md ; leap-frog integrator
nsteps = 25000000 ; 2 * 25000000 = 50ns
dt = 0.002 ; 2 fs
; Output control
nstxout = 500 ; save coordinates every 1 ps
nstvout = 500 ; save velocities every 1 ps
nstxtcout = 500
nstfout = 0
nstenergy = 500 ; save energies every 1 ps
nstlog = 1000 ; update log file every 2 ps
nstcomm = 10
nstcalcenergy = 10
xtc-grps = Protein
; Bond parameters
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continuation = yes
constraint_algorithm = lincs
constraints = all-bonds
lincs_iter = 1
lincs_order = 4
; Neighborsearching
ns_type = grid
nstlist = 10 ; 20 fs
rlist = 1.2 ; short-range neighborlist cutoff (in nm)
rcoulomb = 1.2 ; short-range electrostatic cutoff (in nm)
vdw-type = Cut-off
rvdw = 1.2 ; short-range van der Waals cutoff (in nm)
; Electrostatics
coulombtype = PME ; Particle Mesh Ewald for long-range
electrostatics
pme_order = 4 ; cubic interpolation
fourierspacing = 0.12 ; grid spacing for FFT
epsilon-rf = 1
; Temperature coupling is on
tcoupl = V-rescale ; modified Berendsen thermostat
tc-grps = Protein Non-Protein ; two coupling groups - more accurate
tau_t = 0.1 0.1
ref_t = 300 300 ; reference temperature, one for each group, in K
; Pressure coupling is on
pcoupl = Berendsen
pcoupltype = isotropic ; uniform scaling of box vectors
tau_p = 1.0 ; time constant, in ps
ref_p = 1.0 ; reference pressure, in bar
compressibility = 4.5e-5 ; isothermal compressibility of water, bar^-1
refcoord_scaling = com
; Periodic boundary conditions
pbc = xyz ; 3-D PBC
; Dispersion correction
DispCorr = EnerPres ; account for cut-off vdW scheme
; Velocity generation
gen_vel = no ; Velocity generation is off
gen-temp = 100
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Appendix 3 – CPMG data
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